<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003710.pub2" GROUP_ID="VASC" ID="131601082309533588" MERGED_FROM="" MODIFIED="2013-06-25 16:32:00 +0100" MODIFIED_BY="Diane Horsley" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;Copy edit update  was done in  February 2006 (issue 2 2006)&lt;/p&gt;" NOTES_MODIFIED="2013-06-25 16:27:21 +0100" NOTES_MODIFIED_BY="Diane Horsley" REVIEW_NO="0108" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-06-25 16:26:39 +0100" MODIFIED_BY="Diane Horsley">
<TITLE>Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block</TITLE>
<CONTACT>
<PERSON ID="13836" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Janine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dretzke</LAST_NAME>
<SUFFIX/>
<POSITION>Systematic Author</POSITION>
<EMAIL_1>j.dretzke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health &amp; Epidemiology</DEPARTMENT>
<ORGANISATION>University of Birmingham</ORGANISATION>
<ADDRESS_1>Edgbaston</ADDRESS_1>
<ADDRESS_2/>
<CITY>Birmingham</CITY>
<ZIP>B15 2TT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 12 1414 7850</PHONE_1>
<PHONE_2/>
<FAX_1>+44 12 1414 7878</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-06-25 16:26:39 +0100" MODIFIED_BY="Diane Horsley">
<PERSON ID="13836" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Janine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dretzke</LAST_NAME>
<SUFFIX/>
<POSITION>Systematic Author</POSITION>
<EMAIL_1>j.dretzke@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health &amp; Epidemiology</DEPARTMENT>
<ORGANISATION>University of Birmingham</ORGANISATION>
<ADDRESS_1>Edgbaston</ADDRESS_1>
<ADDRESS_2/>
<CITY>Birmingham</CITY>
<ZIP>B15 2TT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 12 1414 7850</PHONE_1>
<PHONE_2/>
<FAX_1>+44 12 1414 7878</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17029" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Toff</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Cardiology</POSITION>
<EMAIL_1>w.toff@le.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Sciences Wing</DEPARTMENT>
<ORGANISATION>University of Leicester</ORGANISATION>
<ADDRESS_1>Glenfield Hospital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leicester</CITY>
<ZIP>LE3 9QP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 11 6250 2500</PHONE_1>
<PHONE_2/>
<FAX_1>+44 11 6250 2501</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13880" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gregory</FIRST_NAME>
<MIDDLE_INITIALS>YH</MIDDLE_INITIALS>
<LAST_NAME>Lip</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Cardiovascular Medicine &amp; Director - HTVBU</POSITION>
<EMAIL_1>g.y.h.lip@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>www.swbh.nhs.uk</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Birmingham Centre for Cardiovascular Sciences, City Hospital</ORGANISATION>
<ADDRESS_1>Dudley Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Birmingham</CITY>
<ZIP>B18 7QH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 121 507 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+44 121 554 4083</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17026" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>James</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Raftery</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Health Technology Assessment, Chair NETSCC, Director Wessex Institute</POSITION>
<EMAIL_1>J.P.Raftery@soton.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Wessex Institute, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>University of Southampton</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Southampton</CITY>
<ZIP>SO16 7NS</ZIP>
<REGION>Hampshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17023" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fry-Smith</LAST_NAME>
<SUFFIX/>
<POSITION>Information Specialist</POSITION>
<EMAIL_1>a.s.fry-smith@bham.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health &amp; Epidemiology</DEPARTMENT>
<ORGANISATION>University of Birmingham</ORGANISATION>
<ADDRESS_1>Edgbaston</ADDRESS_1>
<ADDRESS_2/>
<CITY>Birmingham</CITY>
<ZIP>B15 2TT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 12 1414 6769</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13948" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Rod</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Taylor</LAST_NAME>
<SUFFIX/>
<POSITION>Professor in Health Services Research</POSITION>
<EMAIL_1>rod.taylor@pms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Peninsula College of Medicine and Dentistry, Universities of Exeter &amp; Plymouth</ORGANISATION>
<ADDRESS_1>Veysey Building</ADDRESS_1>
<ADDRESS_2>Salmon Pool Lane</ADDRESS_2>
<CITY>Exeter</CITY>
<ZIP>EX2 4SG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1392 726 056</PHONE_1>
<PHONE_2>+44 7968 152 537</PHONE_2>
<FAX_1>+44 1392 726 001</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-06-25 16:01:49 +0100" MODIFIED_BY="Karen Hovhannisyan">
<UP_TO_DATE>
<DATE DAY="25" MONTH="2" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="9" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2006"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2013-06-25 16:02:21 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-06-25 16:02:16 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>Query over analyses</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-25 16:02:21 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-25 16:02:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Dept of Public Health and Epidemiology, University of Birmingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>City Hospital, Brimingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Glenfield Hospital, Leicester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Health Services Management Centre, University of Birmingham</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Regional NHS Executive</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-06-25 16:27:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Compared to single chamber ventricular pacemakers, dual chamber pacemakers may reduce the incidence of complications in people with sick sinus syndrome and atrioventricular block</TITLE>
<SUMMARY_BODY>
<P>Sick sinus syndrome (SSS) and atrioventricular block (AV block) are the two most common reasons people have pacemakers implanted. Both involve the heart beating abnormally slowly. Pacemakers replace or control the heart's own electrical activity. Single chamber pacemakers work on one of the chambers (sections) of the heart, while dual chamber pacemakers, which are more expensive, work on two simultaneously. The review of trials found that dual chamber pacemakers tended to prevent more subsequent heart problems than single chamber ventricular pacemakers. The impact on people's overall quality of life is uncertain. The review did not investigate the relative benefits or risks of surgery to upgrade to a dual chamber pacemaker.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Dual chamber pacing or single chamber atrial pacing ('physiologic' pacing) is believed to have an advantage over single chamber ventricular pacing in that it resembles cardiac physiology more closely by maintaining atrioventricular (AV) synchrony and dominance of the sinus node, which in turn may reduce cardiovascular morbidity and mortality thus contributing to patient survival and quality of life. However, a significant proportion of pacemakers currently implanted are single chamber ventricular pacemakers.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the short- and long-term clinical effectiveness of dual chamber pacemakers compared to single chamber ventricular pacemakers in adults with AV block, sick sinus syndrome or both. An additional objective was to assess separately any potential differences in effectiveness between dual chamber pacing and single chamber atrial pacing. The clinical effectiveness of single chamber atrial pacing versus single chamber ventricular pacing was not examined.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Controlled Trials Register (The Cochrane Library Issue 3, 2002), MEDLINE (1966 to 2002), EMBASE (1980 to 2002) and the Science Citation Index (1980 to 2002) were searched on 19th August 2002. Citation lists and web sites were checked and researchers in the field contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Parallel group or crossover randomised controlled trials of at least 48 hours duration comparing dual chamber pacing and single chamber ventricular pacing, and investigating cardiovascular morbidity, mortality, patient related quality of life, exercise capacity and complication rates.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data was extracted onto pre-piloted data extraction forms. Quality assessment was undertaken using a checklist, with a sub-sample of quality data independently extracted by a second reviewer. Where appropriate data was available, meta-analysis was performed. Where meta-analysis was not possible, the number of studies showing a positive, neutral or negative direction of effect and statistical significance were simply counted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Five parallel and 26 crossover randomised controlled trials were identified. The quality of reporting was found to be poor. Pooled data from parallel studies shows a statistically non-significant preference for physiologic pacing (primarily dual chamber pacing) for the prevention of stroke, heart failure and mortality, and a statistically significant beneficial effect regarding the prevention of atrial fibrillation (odds ratio (OR) 0.79, 95% CI 0.68 to 0.93). Both parallel and crossover studies favour dual chamber pacing with regard to pacemaker syndrome (parallel: Peto OR 0.11, 95% CI 0.08 to 0.14; crossover: standardised mean difference (SMD) -0.74, 95% CI - 0.95 to -0.52). Pooled data from crossover studies shows a statistically significant trend towards dual chamber pacing being more favourable in terms of exercise capacity (SMD -0.24, 95% CI -0.03 to -0.45). No individual studies reported a significantly more favourable outcome with single chamber ventricular pacing.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>This review shows a trend towards greater effectiveness with dual chamber pacing compared to single chamber ventricular pacing, which supports the current British Pacing and Electrophysiology Group's Guidelines regarding atrioventricular block. Additional randomised controlled trial evidence from ongoing trials in this area will further inform the debate.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-06-25 16:27:21 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Cardiac bradyarrhythmia (slow heart rhythm) results from the disturbance of the generation or conduction of cardiac electrical activity. Sick sinus syndrome (SSS) refers to a spectrum of cardiac arrhythmias that includes sinus arrest, sinoatrial block, sinus bradycardia or alternating paroxysmal atrial tachyarrhythmias with bradycardia (tachy-brady syndrome). Patients can develop symptoms such as syncope, lightheadedness or dyspnoea during episodes of bradycardia, while patients with the tachy-brady syndrome may develop atrial fibrillation (<LINK REF="REF-Gregoratos-1999" TYPE="REFERENCE">Gregoratos 1999</LINK>). Atrioventricular block (AV block) refers to abnormalities in AV conduction and is classified as first, second (type I or II) or third degree (complete) block. Complete heart block is defined as the absence of all atrioventricular conduction. Patients may be asymptomatic or they may experience symptoms due to bradycardia and/or ventricular arrhythmia. (<LINK REF="REF-Gregoratos-1998" TYPE="REFERENCE">Gregoratos 1998</LINK>; <LINK REF="REF-Julian-1992" TYPE="REFERENCE">Julian 1992</LINK>). </P>
<P>SSS and AV block are the major indications for pacemaker implantation in the US and other parts of the world (<LINK REF="REF-Tang-2000" TYPE="REFERENCE">Tang 2000</LINK>). Sick sinus syndrome accounts for approximately half of all pacemaker implants in industrialised countries and atrioventricular block for the majority of the remaining cases (<LINK REF="REF-Lamas-1997" TYPE="REFERENCE">Lamas 1997</LINK>). These two indications accounted for around 70% of UK pacemaker implants in 1999 (<LINK REF="REF-NPD-2000" TYPE="REFERENCE">NPD 2000</LINK>).</P>
<P>Single chamber pacemakers sense and pace either in the atrium or the ventricle, while dual chamber pacemakers can sense/pace in both chambers. The atrial or ventricular output can be either inhibited or triggered in response to a sensed signal. Rate responsive pacemakers have one or more sensors that detect physical activity and adjust the pacing rate accordingly, which is necessary in patients with chronotropic incompetence (<LINK REF="REF-Bush-1994" TYPE="REFERENCE">Bush 1994</LINK>; <LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>). The North American Society of Pacing and Electrophysiology (NASPE) and the British Pacing and Electrophysiology Group (BPEG) set up the NBG code (<B>N</B>ASPE/<B>B</B>PEG <B>G</B>eneric Code) in 1987 to describe different pacing modes (<LINK REF="REF-Bernstein-1987" TYPE="REFERENCE">Bernstein 1987</LINK>). In view of evolving technology this code has recently been updated (<LINK REF="REF-Bernstein-2002" TYPE="REFERENCE">Bernstein 2002</LINK>). See Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for a Glossary of Terms and See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for details of the revised NBG code.</P>
<P>The normal sequence of atrial depolarisation and contraction followed by ventricular depolarisation and contraction is termed atrioventricular (AV) synchrony. Maintenance of this sequence results in optimal ventricular filling and cardiac output (<LINK REF="REF-Connolly-1996" TYPE="REFERENCE">Connolly 1996</LINK>). Atrioventricular asynchrony and retrograde atrial activation occur more frequently with ventricular ('non-physiological') pacing modes and are prevented by single chamber atrial or dual chamber ('physiological') pacing modes, which allow dominance of the sinus node (when intact) and more closely mimic normal cardiac physiology (<LINK REF="REF-Ausubel-1985" TYPE="REFERENCE">Ausubel 1985</LINK>; <LINK REF="REF-Bush-1994" TYPE="REFERENCE">Bush 1994</LINK>; <LINK REF="REF-Connolly-1996" TYPE="REFERENCE">Connolly 1996</LINK>; <LINK REF="REF-Heldman-1990" TYPE="REFERENCE">Heldman 1990</LINK>; <LINK REF="REF-Kusumoto-1996" TYPE="REFERENCE">Kusumoto 1996</LINK>; <LINK REF="REF-Tang-2000" TYPE="REFERENCE">Tang 2000</LINK>). </P>
<P>'Pacemaker syndrome' refers to a spectrum of symptoms such as (pre-) syncope, dyspnoea, chest pain, palpitations and lethargy associated with loss of AV synchrony (<LINK REF="REF-Ausubel-1985" TYPE="REFERENCE">Ausubel 1985</LINK>; <LINK REF="REF-Travill-1992" TYPE="REFERENCE">Travill 1992</LINK>). The incidence of reported pacemaker syndrome in VVI(R) pacemaker recipients varies widely in the literature, with estimates ranging from 7 to 10 % up to 83% (<LINK REF="REF-Heldman-1990" TYPE="REFERENCE">Heldman 1990</LINK>; <LINK REF="REF-Kusumoto-1996" TYPE="REFERENCE">Kusumoto 1996</LINK>). Reasons for this variation include the lack of a standard definition for pacemaker syndrome and the fact that these types of symptoms are common in cardiac patients with or without pacemakers (<LINK REF="REF-Connolly-1996" TYPE="REFERENCE">Connolly 1996</LINK>). In addition to preventing pacemaker syndrome, it has also been suggested that dual chamber pacemakers reduce the risk of atrial fibrillation, stroke and death, and that they enhance exercise capacity and quality of life compared to single chamber pacemakers (<LINK REF="REF-Connolly-1996" TYPE="REFERENCE">Connolly 1996</LINK>; <LINK REF="REF-Gregoratos-1998" TYPE="REFERENCE">Gregoratos 1998</LINK>).</P>
<P>The choice of pacing mode depends to some extent on the underlying indication for pacing. The British Pacing and Electrophysiology Group's 1991 guidelines (<LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>) stipulate that patients with intact AV conduction should be paced in the atrium only, whilst the ventricle should be paced if there is actual or threatened AV block. A contraindication for dual chamber pacing is AV block with chronic atrial fibrillation. </P>
<P>An ageing UK population and an increasing survival rate after surgical correction of paediatric congenital heart disease are likely to increase the pacemaker implantation rate. In recent years, pacemaker therapy has been advocated for conditions such as hypertrophic cardiomyopathy, idiopathic dilated cardiomyopathy, the long QT syndrome and after cardiac transplantation. In addition to an overall increase of implants there has been a clear trend over the last 20 years in favour of more complex rate-responsive and/or dual chamber systems (<LINK REF="REF-NPD-2000" TYPE="REFERENCE">NPD 2000</LINK>). More complex models of pacemaker can be up to twice the cost of simple models due to more expensive hardware, a longer implantation time and potentially additional follow-up due to complications or reprogramming requirements (<LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>; <LINK REF="REF-Gregoratos-1998" TYPE="REFERENCE">Gregoratos 1998</LINK>).</P>
<P>World-wide surveys performed in 1997 showed an increase in the pacemaker implantation rate since 1993 in the USA, with an increasing proportion of dual chamber pacemakers being implanted (<LINK REF="REF-Bernstein-2001" TYPE="REFERENCE">Bernstein 2001</LINK>); the survey of Asian Pacific, Middle Eastern, South American countries and Canada (<LINK REF="REF-Mond-2001" TYPE="REFERENCE">Mond 2001</LINK>) revealed large variations in the implantation rates of dual chamber and single chamber pacemakers, with more developed countries generally implanting a higher proportion of dual chamber pacemakers than developing countries. European implantation rates have increased between 1994 and 1999 (<LINK REF="REF-NPD-2000" TYPE="REFERENCE">NPD 2000</LINK>), with an increasing proportion of dual chamber pacemakers being implanted.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the short and long-term effects (benefits and harm) of permanent dual chamber pacemakers compared separately to single chamber ventricular pacemakers and single chamber atrial pacemakers in adults with sick sinus syndrome, atrioventricular block, or both, on cardiovascular morbidity and mortality, quality of life, exercise capacity and complication rate. Although of clinical relevance, the review did not assess the evidence regarding the potential clinical benefit of single chamber atrial based pacing compared to single chamber ventricular pacing.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-06-25 16:27:21 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-06-25 16:27:15 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials of either parallel group or crossover design comparing single chamber ventricular pacing with dual chamber pacing, or single chamber atrial pacing with dual chamber pacing. In the case of a crossover study, all patients have a dual chamber pacing system implanted which is subsequently programmed to a single chamber ventricular or dual chamber pacing mode. In a parallel group study, patients are randomised to receive either a single chamber or a dual chamber pacing system.</P>
<P>Only studies in which patients are paced for a minimum duration of 48 hours in one pacing mode were included as the review is concerned with clinical outcomes rather than acute haemodynamics. After running the search strategies outlined below, the shortest pacing time in one pacing mode amongst the included studies was found to be one week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>A patient population aged 18 or over, where greater than 50% in one single trial have sick sinus syndrome, AV block or both.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Rate-adaptive or non rate-adaptive pacemakers capable of sensing and/or pacing in both the atrium and ventricle, i.e. dual chamber pacemakers (eg DDD, DDDR, DDI, DDIR, VDD, VDDR).</P>
<P>
<B>Comparisons</B>
<BR/>Rate-adaptive or non rate-adaptive pacemakers capable of sensing and/or pacing in the ventricle i.e. single chamber ventricular pacemakers (eg VVI, VVIR), or single-chamber atrial pacemakers (eg AAI, AAIR). Studies that compare more than one type of dual chamber or single chamber pacemaker have been included, provided that a single chamber ventricular mode is compared to a dual chamber mode as part of the study.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-06-25 16:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-25 16:03:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cardiovascular mortality or all-cause mortality.</LI>
<LI>Cardiovascular morbidity: symptoms of pacemaker syndrome (as defined by the trialists), onset of atrial fibrillation, stroke or other thromboembolic events, heart failure.</LI>
</UL>
<P>As there is no standard definition of pacemaker syndrome, the assessment criteria defined by the authors have been listed for each study (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for crossover studies and Additional <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> for parallel studies). Where several studies have included the same criteria the results for these have been summarised and compared directly (see meta-analyses).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-06-25 16:04:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Quality of life (assessment to include: measurement of psychological/mental functioning, social functioning, physical status including ability to undertake everyday activities, symptoms caused by disease or treatment).</LI>
<LI>Exercise assessment (a measurement of exercise duration and/or walking distance).</LI>
<LI>Complication rate (including device complications severe enough to warrant an additional visit to hospital, prolongation of a hospital stay, re-implantation of the pacemaker or other surgical procedure).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-06-25 16:27:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-06-25 16:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>A formal search strategy was developed using validated search filters for identifying randomised controlled trials combined with MeSH and text words relating to the intervention and comparator. Electronic searches of the Cochrane Library Controlled Clinical Trials Register (The Cochrane Library Issue 3, 2002) see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, MEDLINE (1966 to 2002) see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, EMBASE (1980 to 2002) see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, SCIENCE CITATION INDEX (1980 to 2002) were undertaken on 19th August 2002, see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. </P>
<P>No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-25 16:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>Citation lists of included studies and reviews were searched and the trial co-ordinators of identified ongoing trials were contacted. The web sites of professional associations (e.g. the British Pacing and Electrophysiology Group, the North American Society of Pacing and Electrophysiology, the American College of Cardiology and the American Heart Association), patient groups and manufacturers were searched using appropriate search terms.</P>
<P>In order to identify ongoing research, the following data sources were searched: National Research Registry, MRC funded projects, UK Department of Health Research, British Heart Foundation, <A HREF="http://clinicaltrials.gov/ct/gui/c/b">clinicaltrials.gov/ct/gui/c/b</A>, www.controlled-trials.com, www.CentreWatch.com.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-06-25 16:16:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment strategy</HEADING>
<P>A modified Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) was used for quality assessment of both parallel and crossover studies. Items assessed were method of randomisation, concealment, blinding (of participants and outcome assessors), completeness and evidence of intention to treat analysis. Additional quality items assessed for parallel studies were mode or device randomisation, comparability of study arms at the beginning of the trial and comparability of treatment of both study arms throughout the trial (e.g. in terms of care received, length of follow-up etc.). For crossover studies, the presence of a washout period between treatments and a period effect test were thought to be important additional quality issues, as treatment received in the first crossover period can influence the effect of treatment in the second period and vice versa. (Hills 1979)</P>
<P>Studies were ranked according to quality in order to assess the feasibility of performing sensitivity analyses of the clinical effectiveness results. A study was judged to be of inadequate quality if there was evidence of failure to meet two or more quality criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction strategy</HEADING>
<P>All identified studies were assessed against the inclusion and exclusion criteria (JD). A random sample of identified studies was independently assessed (AFS) and any disagreement resolved through discussion with a third reviewer (RT).</P>
<P>A data extraction proforma was used to extract data on study characteristics, study quality and results (JD). The proforma was piloted on a sample of primary studies and modified before use. A subsample of quality data was independently extracted by a second reviewer (RT). Where data was available only in abstract form, or it was not evident from the full publication whether the inclusion criteria applied, the authors were contacted. Authors were also contacted for additional information on planned or ongoing trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>For crossover trials, data was generally presented in aggregate form for both crossover periods. We initially used a vote counting approach to quantify the results across all studies. In addition, we used MetaView 4.1 to perform meta-analyses where appropriate outcome data were available. Fixed effects pooling was used throughout as there was no evidence of statistical heterogeneity. Odds ratios (with 95% confidence intervals) were calculated for binary data and standardised mean differences (SMD, with 95% confidence intervals) for continuous data. Funnel plots were generated, where possible to assess heterogeneity and possible publication bias (<LINK REF="REF-Egger-1998" TYPE="REFERENCE">Egger 1998</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-06-25 16:17:50 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>A total of 1170 citations were originally retrieved of which 944 were judged to be clearly not relevant. The remaining 226 studies appeared to be comparisons of dual chamber pacing versus single chamber ventricular pacing. Of these, a further 194 studies were excluded as they did not meet one or more of the inclusion criteria. Of the remaining 32 studies, two reported different outcome measures of the same trial (<LINK REF="STD-Linde_x002d_Edelstam-1992" TYPE="STUDY">Linde-Edelstam 1992</LINK>). </P>
<P>Of the 31 included randomised controlled trials, five were of parallel design and 26 of crossover design. There were differences between studies regarding modes compared, type of randomisation (mode or device) and population characteristics. All crossover studies necessarily used mode randomisation whilst three of the parallel studies used mode and two used device randomisation. In the parallel group studies, implantation occurred immediately before the study, whilst in crossover studies, patients were found to have been paced for varying time periods before the reprogramming of pacemakers for the study. Additional <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> and <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> list the main study characteristics of all included parallel and crossover studies. </P>
<P>All identified studies were comparisons of dual chamber pacing and single chamber ventricular pacing, or, in the case of two parallel studies, a combination of dual chamber and single chamber atrial pacing compared to single chamber ventricular pacing. No studies were identified that compared dual chamber pacing with single chamber atrial pacing. </P>
<P>The parallel studies had mean follow-up times of 18.3 to 36 months and investigated pacemaker syndrome (three studies), atrial fibrillation (five studies), heart failure (four studies) and quality of life (three studies). Patient numbers varied between 198 and 2568. Crossover studies had smaller patient numbers (between 8 and 44) although with patients acting as their own controls numbers were effectively doubled. The study durations were shorter (between seven days and three months), and the outcomes investigated were subsequently restricted to short-term ones (symptoms of pacemaker syndrome and/or exercise tests). Outcomes from parallel studies were reported as binary measures (e.g. presence or absence of pacemaker syndrome), whilst crossover studies used continuous measures (e.g. mean score from a questionnaire on symptom severity). The mean age of the patients taking part in the crossover studies (67.3 years) was lower than that of the patients in the parallel studies (73.7 years). There were differences between studies in the assessment of pacemaker syndrome (e.g. number and type of symptoms assessed and scoring scales). </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All studies failed to meet two or more quality criteria. There was a lack of details on: the process of randomisation (26/31 studies, 83.9%), concealment of allocation (29/31 studies, 93.5%), blinding of patients and/or outcome assessors (18/31 studies, 58.1%), withdrawals or crossovers (7/31 studies, 22.6%) and clear intention to treat analysis (23/31 studies, 74.2%). Details of the quality assessment are shown in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> and <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>. A period effect test was performed in only one of the crossover trials (<LINK REF="STD-Hargreaves" TYPE="STUDY">Hargreaves</LINK> 1995), and a washout period (two weeks) between treatments before symptom assessment was also only present in one crossover trial (<LINK REF="STD-Kristensson-1985" TYPE="STUDY">Kristensson 1985</LINK>). As the quality assessment was based solely on the published report, the lack of evidence of high quality may be a reflection of inadequate reporting rather than poor trial quality. As the checklist included items not contained within the Jadad checklist, particularly with regard to the crossover studies, a Jadad score was not calculated. As there were no clear differences in quality between studies, sensitivity analyses according to study quality were not performed.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-06-25 16:17:50 +0100" MODIFIED_BY="[Empty name]">
<P>Results from individual trials were pooled where the same outcome was measured and where the means and standard deviations were stated or calculable (for continuous outcomes) or the event rate for all patients stated (binary outcomes).</P>
<SUBSECTION>
<HEADING LEVEL="3">Cardiovascular mortality and morbidity - parallel studies</HEADING>
<P>For all cause mortality, stroke and heart failure, there was a trend towards a benefit from dual chamber pacing (all cause mortality, based on four studies: OR 0.94, 95% CI 0.80 to 1.12; stroke, based on four studies: OR 0.75, 95% CI 0.54 to 1.04; heart failure, based on three studies: OR 0.80, 95% CI 0.64 to 1.00). None of these differences were statistically significant.</P>
<P>The <LINK REF="STD-MOST" TYPE="STUDY">MOST</LINK> (2002) trial only reported cardiovascular mortality. There was no significant difference between dual chamber pacing and single chamber ventricular pacing (unadjusted hazard ratio of 0.93, 95% CI 0.69 to 1.24; adjusted hazard ratio of 0.87, 95% CI 0.65 to 1.18).</P>
<P>The incidence of pacemaker syndrome was higher for patients paced in a ventricular mode compared to patients paced in a dual chamber mode. The pooled Peto odds ratio for symptoms of pacemaker syndrome, based on three studies, was OR 0.11 (95% CI 0.08 to 0.14). Based on four studies, the incidence of atrial fibrillation was also significantly higher in single chamber ventricular versus dual chamber pacemaker users (OR 0.79, 95% CI 0.68 to 0.93). Atrial fibrillation was measured as an outcome in one additional study, however, as no data was provided, these results could not be included in the meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis (SSS and AV block) of cardiovascular mortality and morbidity - parallel studies</HEADING>
<P>The composite outcome of stroke or death due to a cardiovascular cause was investigated in <LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> (2000) where a statistically non-significant trend for patients with SSS to benefit less from physiologic pacing compared to those with AV block was found.</P>
<P>For stroke, heart failure and mortality, the <LINK REF="STD-PASE" TYPE="STUDY">PASE</LINK> (1998) trial found no significant differences between SSS and AV groups according to pacing mode. The incidence of atrial fibrillation in this trial was higher in a single chamber mode for SSS and higher in a dual chamber mode for AV block, however, these differences were not significant.</P>
<P>
<LINK REF="STD-Mattioli" TYPE="STUDY">Mattioli</LINK> (1998) found a significantly higher incidence of atrial fibrillation in a single chamber ventricular mode for the SSS group, however, data for the AV group was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cardiovascular morbidity - crossover studies</HEADING>
<P>Due to the shorter duration of these studies, the only outcome relating to morbidity was incidence and frequency of symptoms of pacemaker syndrome, which was reported in 25 studies. In nine studies there were significantly fewer symptoms in a dual chamber mode and in four studies there were no significant differences between dual chamber or single chamber ventricular modes. In 12 studies, some of the symptoms measured appeared significantly less frequently in a dual chamber mode, whilst there were no significant differences for others. Pooling across nine studies, we found a statistically significant reduction in total pacemaker syndrome symptoms in dual chamber pacing compared to single chamber ventricular pacing of -0.74 SD units (95% CI -0.95 to -0.52). Means and standard deviations (SDs) were not available across all studies to allow their results to be included in this pooling. However, the direction of effect was consistent across all studies with either fewer symptoms in a dual chamber mode or no difference in symptoms between dual chamber and single chamber ventricular pacing.</P>
<P>We also found a statistically significant reduction in individual symptoms with dual chamber pacing, particularly with regard to dizziness, based on seven studies (SMD -0.89, 95% CI -1.13 to -0.64); fatigue, based on five studies (SMD -0.77, 95% CI -1.05 to -0.49); breathlessness, based on seven studies (SMD -0.92, 95% CI -1.18 to -0.66); palpitation, based on seven studies (SMD -0.69, 95% CI -0.93 to -0.45); and chest pain, based on five studies (SMD -0.33, 95% CI -0.60 to -0.05).</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis (SSS and AV block) of cardiovascular morbidity - crossover studies</HEADING>
<P>There were 12 crossover studies with an AV block population only and one study with an SSS population only, therefore, there was insufficient information to compare the results of these studies. Of the remaining studies, all but two reported data in an aggregate form for the subgroups. The remaining two studies (based on 8 and 21 patients in the SSS groups and 8 and 14 patients in the AV block groups respectively) showed little difference in effect between the two groups (<LINK REF="STD-Heldman" TYPE="STUDY">Heldman</LINK>; <LINK REF="STD-Mitsuoka" TYPE="STUDY">Mitsuoka</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life data</HEADING>
<P>The <LINK REF="STD-PASE" TYPE="STUDY">PASE</LINK> (1998) and <LINK REF="STD-MOST" TYPE="STUDY">MOST</LINK> (2002) trials assessed quality of life using the SF-36 index and the Specific Activity Scale respectively. No statistically significant difference in quality of life between single chamber ventricular and dual chamber modes was observed in the earlier study with the exception of mental health at 9 months and cardiovascular functional status at 18 months (benefit from dual chamber pacing). The 2002 study reported a statistically significant improvement in six out of eight SF-36 subscales over a four year period with dual chamber pacing when last measurements were carried forward in those patients that crossed over. No significant differences were identified if the health status was carried over.</P>
<P>The <LINK REF="STD-PASE" TYPE="STUDY">PASE</LINK> trial (1998) compared quality of life according to indication and pacing mode. There were no significant differences for any of the SF-36 subscale scores in the AV block group, whilst in the SSS group there were significant differences favouring dual chamber pacing at three months in scores on the physical role, social function and emotional role subscales.</P>
<P>Five crossover studies investigated quality of life. The study by <LINK REF="STD-H_x00f6_ijer" TYPE="STUDY">Höijer</LINK> (2002) found an overall non-significant preference for dual chamber pacing in 11 out of 17 quality of life functions measured, no difference between the two modes for four functions and a non-significant preference for single chamber ventricular pacing for two functions. The other four crossover studies found either no significant difference between quality of life in a single chamber ventricular or dual chamber mode or a significantly higher quality of life in a dual chamber mode. No study found a statistically significant improvement in quality of life for patients paced with a single chamber ventricular mode regardless of which assessment tool was used. Given the range of measures used it was not possible to pool quality of life outcome across studies. Details of quality of life measurements can be found in the Additional <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>. Results for studies investigating quality of life in different patient populations could not be compared as different assessment scales were used (<LINK REF="STD-Lau-_x0028_1_x0029_" TYPE="STUDY">Lau (1)</LINK>; <LINK REF="STD-Linde_x002d_Edelstam-1992" TYPE="STUDY">Linde-Edelstam 1992</LINK>). One study (<LINK REF="STD-Lukl-1994" TYPE="STUDY">Lukl 1994</LINK>) lists results for SSS (7 patients) and AV block (14 patients) groups separately, with little difference in quality of life between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exercise capacity</HEADING>
<P>A total of 14 crossover studies reported exercise capacity. Six studies reported exercise capacity to be significantly higher for dual chamber pacing and five reported it to be similar in both dual chamber and single chamber ventricular pacing. Three studies, which compared more than two pacing modes, reported either higher exercise capacity or no difference depending on which dual chamber and single chamber modes were compared. No studies showed significantly increased exercise capacity with single chamber ventricular pacing.</P>
<P>Pooled study data based on 10 of these studies revealed a statistically significant increase in exercise capacity of 0.24 SD units (95% CI 0.03 to 0.45) with dual chamber pacing compared to single chamber ventricular pacing. A comparison of data according to SSS and AV block subgroups was not possible as data was presented only in an aggregate form.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Complication rates</HEADING>
<P>We found no studies that assessed long-term complications in the two pacing modes over the whole length of the trial period. The <LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> trial (2000) reported a higher incidence of peri-operative complications during dual chamber pacemaker implantation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>There was little evidence of funnel plot asymmetry for either total pacemaker symptoms (based on 8 crossover studies) or exercise capacity results (based on 10 crossover studies). This was confirmed with a non-significant Egger test (p = 0.45 and p = 0.133 respectively).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>We identified a total of 5 parallel and 26 crossover randomised controlled trials that compared dual chamber pacing with single chamber ventricular pacing for AV block and SSS. Despite marked differences across studies in terms of pacing mode, population and outcome assessment, we observed a consistent trend towards benefit with dual chamber pacing compared to single chamber ventricular pacing across all studies and all outcomes. This benefit included a reduction in symptoms of pacemaker syndrome, atrial fibrillation and improvement in exercise capacity. This finding provides evidential support for the current British Pacing and Physiology Group guidelines (<LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>), which recommend dual chamber pacing (DDD mode) as optimal therapy for atrioventricular (AV) block. In sick sinus syndrome the guidelines recommend single chamber atrial pacing. Whilst single chamber atrial pacing was not compared to single chamber ventricular pacing in this review, the review does support atrial based pacing for sick sinus syndrome.</P>
<P>It is recognised that there are additional complex variables which are likely to vary both between patients and studies. These include differences in AV delay in DDD/VDD mode, percentage of time paced and the presence of ventricular-atrial asynchrony or retrograde conduction in VVI mode, all of which can impact on cardiac haemodynamics. A discussion of the likely impact of these factors is beyond the scope of this review.</P>
<P>The review did not assess the evidence for potential benefits of atrial versus ventricular pacing, nor was the potential difference in effectiveness between rate-adaptive and non-rate adaptive pacemakers investigated. At the time of completing the review, evidence had not been identified on the effectiveness of single chamber atrial compared to dual chamber pacing. One relevant trial has since been identified (see <LINK REF="STD-Nielsen" TYPE="STUDY">Nielsen</LINK>, 2003, Studies Awaiting Assessment). The currently ongoing <LINK REF="STD-DANPACE" TYPE="STUDY">DANPACE</LINK> study compares dual chamber pacing with single chamber atrial pacing in sick sinus syndrome and may provide further evidence. In order to inform the choice of the type of pacemaker for a given indication, the results of this review need to be considered in conjunction with these other pacing issues.</P>
<P>Although only randomised controlled trials were included in this review, poor quality trials may introduce bias and potentially overestimate the benefit of treatment. Given the consistent poor reporting of trial quality in this review we were unable to undertake a sensitivity analysis to examine the impact of quality on the conclusions of the review. Inevitably, any systematic review can be subject to publication bias, i.e., positive results and benefits are more likely to be published whilst side effects or treatment failures are under-reported. To limit such bias we undertook extensive searching, moreover, we found no objective evidence of publication bias.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>On the basis of 5 parallel and 26 crossover randomised controlled trials, we observed some clinical benefit for dual chamber pacing compared to single chamber ventricular pacing. Pooled analysis demonstrated a significant reduction in atrial fibrillation and pacemaker syndrome with dual pacing.</P>
<P>There are a number of issues that impact on the applicability of the findings of this review to routine practice. Firstly, the mean age of the patients taking part in crossover studies (mean age 67.3 years) is lower than the mean age of those taking part in the parallel studies (mean age 73.7 years). It could be argued that younger patients, particularly those selected on the basis of their ability to take part in studies assessing exercise capacity, may be fitter or healthier than the general pacemaker population and, therefore, not representative. Second, the exercise tests undertaken in the trial setting may not necessarily be representative of the type of activities undertaken as part of daily life, and an improvement in an exercise test cannot necessarily be extrapolated to an improved ability to function in everyday life.</P>
<P>Randomisation by device (i.e. hardware) or mode (i.e. software) may have an influence on treatment effect. Mode randomisation is artificial in that patients randomised to a single chamber mode have a dual chamber device with an additional, unused lead implanted, which is then programmed to a single chamber mode. Any potential differences in complication rate or type between a single chamber and a dual chamber device would not manifest themselves in a trial using mode randomisation. There is also an argument that mode randomisation can lead to bias as the decision to upgrade from a single chamber to a dual chamber mode may be influenced by the ease with which this can be achieved. It can be seen from the included parallel studies that there was a trend for crossover rates to be higher in the mode randomised studies (<LINK REF="STD-MOST" TYPE="STUDY">MOST</LINK> 2002 crossover rate: single to dual 26%, dual to single 2%; <LINK REF="STD-PASE" TYPE="STUDY">PASE</LINK> 1998 crossover rate: single to dual: 31%, dual to single: not stated; <LINK REF="STD-Wharton" TYPE="STUDY">Wharton</LINK> 1998: crossover rate: single to dual 44%, dual to single 9%) than in the device randomised studies (<LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> crossover rate: single to dual 2.1%, 2.7% and 4.3% at 1, 3 and 5 years; dual to single: 10.8%, 12.8% and 17.1% at 1, 3 and 5 years).</P>
<P>In contrast, device randomisation reflects everyday practice as patients receive the most appropriate device according to their condition. Here, the incidence of pacemaker syndrome may be underestimated as comparatively minor symptoms may not be thought worth the risk of upgrade. In summary, regardless of whether device or mode randomisation was undertaken, there are potential biases that need to be considered when interpreting the results of these trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further clinical evidence is needed particularly for the effect of dual chamber and single chamber ventricular pacing on patient related quality of life, long-term adverse outcomes, mortality and the effect on patients with AV block and SSS respectively or other relevant indications. This is reflected by the four large randomised controlled trials that are currently ongoing or due to report in the UK (<LINK REF="STD-UKPACE" TYPE="STUDY">UKPACE</LINK>, <LINK REF="STD-STOP_x002d_AF" TYPE="STUDY">STOP-AF</LINK>), Denmark (<LINK REF="STD-DANPACE" TYPE="STUDY">DANPACE</LINK>) and Canada (the extended <LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> study). The Canadian trial referred to is a 3-year extension of the <LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> trial included in this review (Connolly 2000). The populations in these trials have AV block, SSS, or both, and physiologic pacemakers (dual chamber or single chamber atrial) are being compared to ventricular pacemakers, with the exception of the <LINK REF="STD-DANPACE" TYPE="STUDY">DANPACE</LINK> study, which compares dual chamber pacing to single chamber atrial modes. Details of these trials are in the Table of Characteristics of Ongoing Studies. The design of any future trials should take into account the methodological issues raised in this report in order to avoid potentially biased results. Additionally, future trials should ensure that follow-up is sufficient to identify long-term effects of the different pacing modes. In the <LINK REF="STD-CTOPP" TYPE="STUDY">CTOPP</LINK> trial, for example, the difference in effect on atrial fibrillation did not become apparent until after two years. Finally, there is newer evidence suggesting that right ventricular apical pacing, even in DDD pacing, may lead to interventricular desynchrony and subsequent haemodynamic deterioration (<LINK REF="REF-Tse-2002" TYPE="REFERENCE">Tse 2002</LINK>), which may explain a lack of strong evidence in favour of DDD pacing. This area is likely to become a focus of future research. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Chris Leonard and Rebecca Mason for administrative support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>J Dretzke - None <BR/>WD Toff - Joint principal investigator for the UKPACE trial; received fees for speaking, support for research and expenses for attending meetings from pacemaker manufacturers and suppliers including ELA Medical, Guidant, St Jude Medical and Medtronic <BR/>GYH Lip - None <BR/>J Raftery - None <BR/>A Fry-Smith - None <BR/>R Taylor - Consultancy work for Medtronic (Europe) in a therapeutic area not closely associated with pacemakers.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Janine Dretzke was the main author. She designed the protocol; undertook the searches; assessed studies for eligibility; extracted all data; performed the quality assessment; liaised with experts and wrote and collated the review.</P>
<P>Rod Taylor was the project manager and takes overall responsibility for the report. He advised on protocol development; undertook quality assessment of a subset of studies; provided statistical advice; liaised with experts and assisted in the writing of the review.</P>
<P>William Toff provided clinical guidance; advised on the protocol and assisted in the writing of the review.</P>
<P>Gregory YH Lip assisted in the protocol development; provided clinical guidance and commented on the draft review.</P>
<P>James Raftery advised on the protocol and assisted in the writing of the review.</P>
<P>Anne Fry-Smith advised on the search strategies and assessed a subset of studies for eligibility.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Avery" NAME="Avery" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avery B, Banning A, Lawson T, McGurk L, Buchalter M</AU>
<TI>Physiological pacing improves symptoms and increases exercise capacity in the elderly patient</TI>
<SO>International Journal of Cardiology</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>2</NO>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boon" NAME="Boon" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boon NA, Frew AJ, Cobbe SM</AU>
<TI>An intra-patient comparison of ambulatory blood-pressure during chronic DDD and VVI pacing</TI>
<SO>British Heart Journal</SO>
<YR>1986</YR>
<VL>55</VL>
<NO>5</NO>
<PG>508</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Boon NA, Frew AJ, Johnston JA, Cobbe SM</AU>
<TI>A comparison of symptoms and intra-arterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous (DDD) and ventricular demand (VVI) pacing</TI>
<SO>British Heart Journal</SO>
<YR>1987</YR>
<VL>58</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capucci" NAME="Capucci" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cappuci A, Cazzin R, Zardo F, Boriani G, Zanuttini D, Piccolo E</AU>
<TI>DDDR versus DDD and VVIR pacing: A single blind randomised evaluation of symptoms and effort performance</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>3</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Channon" NAME="Channon" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Channon KM, Hargreaves MR, Cripps TR, Gardner M, Ormerod OJ</AU>
<TI>DDD versus. VVI pacing in patients aged over 75 years with complete heart block: a double-blind crossover comparison</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>1994</YR>
<VL>87</VL>
<NO>4</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CTOPP" NAME="CTOPP" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM et al</AU>
<TI>Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>1385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR et al</AU>
<TI>Progression to chronic atrial fibrillation after pacing: The Canadian Trial of Physiologic Pacing</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>1</NO>
<PG>167-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang AS, Roberts RS, Kerr C, Gillis AM, Green MS, Talajic M et al</AU>
<TI>Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>25</NO>
<PG>3081-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis" NAME="Davis" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis MJE, Mundin HA, Mews GC, Cope GD</AU>
<TI>Functional benefits of physiologic compared with ventricular pacing in complete heart block</TI>
<SO>Clinical Progress in Electrophysiology &amp; Pacing</SO>
<YR>1985</YR>
<VL>3</VL>
<NO>6</NO>
<PG>457-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deharo" NAME="Deharo" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deharo JC, Badier M, Thirion X, Ritter P, Provenier F, Graux P et al</AU>
<TI>A randomized, single-blind crossover comparison of the effects of chronic DDD and dual sensor VVIR pacing mode on quality-of-life and cardiopulmonary performance in complete heart block</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>9</NO>
<PG>1320-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hargreaves" NAME="Hargreaves" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hargreaves MR, Channon KM, Cripps T, Gardner M, Ormerod OJ</AU>
<TI>Comparison of dual chamber and ventricular rate responsive pacing in patients over 75 with complete heart block</TI>
<SO>British Heart Journal</SO>
<YR>1995</YR>
<VL>74</VL>
<NO>4</NO>
<PG>397-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heldman" NAME="Heldman" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heldman D, Mulvihill D, Nguyen H, Messenger JC, Rylaarsdam A, Evans K et al</AU>
<TI>True incidence of pacemaker syndrome</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 Pt 2</NO>
<PG>1742-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-H_x00f6_ijer" NAME="Höijer" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Höijer CJ, Brandt J, Willenheimer R, Juul-Moller S, Bostrom PA</AU>
<TI>Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation</TI>
<SO>European Heart Journal</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>490-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamalvand" NAME="Kamalvand" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamalvand K, Tan K, Kotsakis A, Bucknall C, Sulke N</AU>
<TI>Is mode switiching beneficial? A randomized study in patients with paroxysmal atrial tachyarrhythmias</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>2</NO>
<PG>496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenny" NAME="Kenny" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenny RA, Ingram A, Mitsuoka T, Walsh K, Sutton R</AU>
<TI>Optimum pacing mode for patients with angina pectoris</TI>
<SO>British Heart Journal</SO>
<YR>1986</YR>
<VL>56</VL>
<NO>5</NO>
<PG>463-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensson" NAME="Kristensson" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensson BE, Arnman K, Smedgard P, Ryden L</AU>
<TI>Physiological versus single-rate ventricular pacing: a double-blind crossover study</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>1</NO>
<PG>73-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-_x0028_1_x0029_" NAME="Lau (1)" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau CP, Tai YT, Leung WH, Wong CK, Lee P, Chung FL</AU>
<TI>Rate-adaptive pacing in sick sinus syndrome: effects of pacing modes and intrinsic conduction on physiological responses, arrhythmias, symptomatology and quality of life</TI>
<SO>European Heart Journal</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1445-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-_x0028_2_x0029_" NAME="Lau (2)" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau CP, Tai YT, Lee PW, Cheung B, Tang MO, Lam WK</AU>
<TI>Quality-of-life in DDDR pacing: atrioventricular synchrony or rate adaptation?</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11 pt 2</NO>
<PG>1838-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linde_x002d_Edelstam" NAME="Linde-Edelstam" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linde-Edelstam C, Nordlander R, Pehrsson SK, Ryden L</AU>
<TI>A double-blind study of submaximal exercise tolerance and variation in paced rate in atrial synchronous compared to activity sensor modulated ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>6</NO>
<PG>905-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linde-Edelstam C, Nordlander R, Unden AL, Orth-Gomer K, Ryden L</AU>
<TI>Quality-of-life in patients treated with atrioventricular synchronous pacing compared to rate modulated ventricular pacing: a long-term, double-blind, crossover study</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>10 Pt 1</NO>
<PG>1467-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukl" NAME="Lukl" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukl J, Doupal V, Heinc P</AU>
<TI>Quality-of-life during DDD and dual sensor VVIR pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11 Pt 2</NO>
<PG>1844-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattioli" NAME="Mattioli" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattioli AV, Castellani ET, Vivoli D, Sgura FA, Mattioli G</AU>
<TI>Prevalence of atrial fibrillation and stroke in paced patients without prior atrial fibrillation: a prospective study</TI>
<SO>Clinical Cardiology</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>2</NO>
<PG>117-122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menozzi" NAME="Menozzi" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menozzi C, Brignole M, Morachini PV, Lolli G, Bacchi M, Tesorieri MC, et al</AU>
<TI>Intrapatient comparison between chronic VVIR and DDD pacing in patients affected by high degree AV block without heart failure</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 Pt 2</NO>
<PG>1816-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitsuoka" NAME="Mitsuoka" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitsuoka T, Kenny RA, Yeung TA, Chan SL, Perrins JE, Sutton R</AU>
<TI>Benefits of dual chamber pacing in sick sinus syndrome</TI>
<SO>British Heart Journal</SO>
<YR>1988</YR>
<VL>60</VL>
<NO>4</NO>
<PG>338-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MOST" NAME="MOST" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R et al</AU>
<TI>Ventricular pacing or dual-chamber pacing for sinus-node dysfunction</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>1854-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldroyd" NAME="Oldroyd" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldroyd KG, Rae AP, Carter R, Wingate C, Cobbe SM</AU>
<TI>Double blind crossover comparison of the effects of dual chamber pacing (DDD) and ventricular rate-adaptive (VVIR) pacing on neuroendocrine variables, exercise performance, and symptoms in complete heart block</TI>
<SO>British Heart Journal</SO>
<YR>1991</YR>
<VL>65</VL>
<NO>4</NO>
<PG>188-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PASE" NAME="PASE" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK, et al</AU>
<TI>Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<NO>16</NO>
<PG>1097-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrins" NAME="Perrins" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrins EJ, Morley CA, Chan SL, Sutton R</AU>
<TI>Randomised controlled trial of physiological and ventricular pacing</TI>
<SO>British Heart Journal</SO>
<YR>1983</YR>
<VL>50</VL>
<NO>2</NO>
<PG>112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rediker" NAME="Rediker" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rediker DE, Eagle KA, Homma S, Gillam LD, Harthorne JW</AU>
<TI>Clinical and hemodynamic comparison of VVI versus DDD pacing in patients with DDD pacemakers</TI>
<SO>American Journal of Cardiology</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>4</NO>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saner-and-Fricker" NAME="Saner and Fricker" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saner H, Fricker U</AU>
<TI>Haemodynamic benefits and quality of life with DDD versus VVIR pacing: Evaluation by exercise Doppler echocardiography and quality-of-life score</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>3</NO>
<PG>125-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulke-1991" NAME="Sulke 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulke N, Chambers J, Dritsas A, Sowton E</AU>
<TI>A randomized double-blind crossover comparison of four rate-responsive pacing modes</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>3</NO>
<PG>696-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulke-1992" NAME="Sulke 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulke N, Dritsas A, Bostock J, Wells A, Morris R, Sowton E</AU>
<TI>"Subclinical" pacemaker syndrome: a randomised study of symptom free patients with ventricular demand (VVI) pacemakers upgraded to dual chamber devices</TI>
<SO>British Heart Journal</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>1</NO>
<PG>57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulke-1994" NAME="Sulke 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulke N, Chambers J, Sowton E</AU>
<TI>Variability of left atrial bloodflow predicts intolerance of ventricular demand pacing and may cause pacemaker syndrome</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>6</NO>
<PG>1149-1159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wharton" NAME="Wharton" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wharton JM, Sorrentino RA, Campbell P, Gonzalez-Zuelgaray J, Keating E, Curtis A et al</AU>
<TI>Effect of pacing modality on atrial tachyarrhythmia recurrence in the tachycardia-bradycardia syndrome: preliminary results of the Pacemaker Atrial Tachycardia Trial</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>98</VL>
<NO>18</NO>
<PG>Suppl (I): I-494, abstract</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yee" NAME="Yee" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yee R, Benditt DG, Kostuk WJ, Ko PT, Purves P, Klein GJ</AU>
<TI>Comparative functional effects of chronic ventricular demand and atrial synchronous ventricular inhibited pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1992" NAME="Abe 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93347120&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe Y, Kadowaki K, Sato T, Nakagomi A, Kumagai T</AU>
<TI>[Secretion of atrial natriuretic peptide during artificial pacing: assessments including the influence of ventriculoatrial conduction]. [Japanese]</TI>
<SO>Journal of Cardiology</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>1</NO>
<PG>265-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="739"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adinolfi-1985" NAME="Adinolfi 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adinolfi E, Devita S, Genova L, Raganelli L, Scaccia A, Carbonardi L et al</AU>
<TI>Radionuclide evaluation of DDD versus VVI pacing with a nonimaging probe - nuclear stethoscope</TI>
<SO>Pace-Pacing And Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3</NO>
<PG>A98</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aggarwal-1995" NAME="Aggarwal 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95352353&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aggarwal RK, Connelly DT, Ray SG, Ball J, Charles RG</AU>
<TI>Early complications of permanent pacemaker implantation: no difference between dual and single chamber systems</TI>
<SO>British Heart Journal</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>6</NO>
<PG>571-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="742"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahern-1992" NAME="Ahern 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;92409439&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahern T, Nydegger C, McCormick DJ, Maquilan M, Schuster M, Kutalek SP</AU>
<TI>Incidence and timing of activity parameter changes in activity responsive pacing systems</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>5</NO>
<PG>762-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="744"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpert-1986" NAME="Alpert 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;86169320&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpert MA, Curtis JJ, Sanfelippo JF, Flaker GC, Walls JT, Mukerji V et al</AU>
<TI>Comparative survival after permanent ventricular and dual chamber pacing for patients with chronic high degree atrioventricular block with and without preexistent congestive heart failure</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>4</NO>
<PG>925-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="745"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpert-1987" NAME="Alpert 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;87181457&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpert MA, Curtis JJ, Sanfelippo JF, Flaker GC, Walls JT, Mukerji V et al</AU>
<TI>Comparative survival following permanent ventricular and dual-chamber pacing for patients with chronic symptomatic sinus node dysfunction with and without congestive heart failure</TI>
<SO>American Heart Journal</SO>
<YR>1987</YR>
<VL>113</VL>
<NO>4</NO>
<PG>958-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="746"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amici-1996" NAME="Amici 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;1996065047&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amici E, Neri R, Donati R, Gambelli G</AU>
<TI>Transesophageal echocardiographic color Doppler evaluation of pulmonary vein flow during ventricular pacing</TI>
<SO>American Journal of Cardiac Imaging</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azam-1998" NAME="Azam 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;1998296202&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azam N, Chapman M, Roberts DH</AU>
<TI>'Subclinical' pacemaker syndrome - Further evidence using ambulatory blood pressure measurement to compare VVI and DDD pacing in asymptomatic patients</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>1</NO>
<PG>8-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="162"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baldo-1996" NAME="Baldo 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;1996246601&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldo V, Biscione F, Battista M, Baldo E, Lombardi D</AU>
<TI>Right ventricular echo-pacing test in the diagnosis of ischemic cardiopathy in patients with VVI</TI>
<SO>Cardiovascular Imaging</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>2</NO>
<PG>349-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="283"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrington-1995" NAME="Barrington 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95288184&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barrington WW, Windle JR, Easley AA, Rundlett R, Eisenger G</AU>
<TI>Clinical comparison of acute single to dual chamber pacing in chronotropically incompetent patients with left ventricular dysfunction</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3 Pt 1</NO>
<PG>433-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="757"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batey-1990" NAME="Batey 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;90265720&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batey RL, Sweesy MW, Scala G, Forney RC</AU>
<TI>Comparison of low rate dual chamber pacing to activity responsive rate variable ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>5</NO>
<PG>646-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="758"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Been-1984" NAME="Been 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984089639&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Been M, De Bono DP, Miller HC, Hillis WS</AU>
<TI>Effect of afterload reduction in patients with ventricular and physiological pacing</TI>
<SO>British Heart Journal</SO>
<YR>1984</YR>
<VL>51</VL>
<NO>3</NO>
<PG>292-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="705"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanc-1992" NAME="Blanc 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1992175859&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanc J.J, Mansourati J, Ritter P, Nitzsche R, Pages Y, Genet L et al</AU>
<TI>Atrial natriuretic factor release during exercise in patients successively paced in DDD and rate matched ventricular pacing</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>4 I</NO>
<PG>397-402</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="522"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosch-1990" NAME="Bosch 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91047104&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosch R, Aguade S, Candell J, Ortega D, Murtra M</AU>
<TI>[Evaluation of DDD and VVIR pacemakers with gated radionuclide ventriculography]. [Spanish]</TI>
<SO>Revista Espanola de Cardiologia</SO>
<YR>1990</YR>
<VL>43 Suppl (2)</VL>
<PG>20-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="772"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bren-1986" NAME="Bren 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bren GB, Wasserman AG, Elbayoumi J, Ross AM</AU>
<TI>Comparison of DDD end rate responsive-VVI pacing during exercise</TI>
<SO>Circulation</SO>
<YR>1986</YR>
<VL>74</VL>
<NO>4</NO>
<PG>388</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1289"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignole-1988" NAME="Brignole 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;89098542&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brignole M, Sartore B, Barra M, Menozzi C, Lolli G</AU>
<TI>Is DDD superior to VVI pacing in mixed carotid sinus syndrome? An acute and medium-term study</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>11 Pt 2</NO>
<PG>1902-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="778"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignole-1989a" NAME="Brignole 1989a" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;89240153&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brignole M, Sartore B, Barra M, Menozzi C, Lolli G</AU>
<TI>Ventricular and dual chamber pacing for treatment of carotid sinus syndrome</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>4 Pt 1</NO>
<PG>582-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="780"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignole-1989b" NAME="Brignole 1989b" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;89306304&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brignole M, Menozzi C, Lolli G, Sartore B, Bertulla A</AU>
<TI>[The choice of stimulation mode in patients with cardioinhibitory or mixed carotid sinus hypersensitivity, with or without associated sinus dysfunction]. [Italian]</TI>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1989</YR>
<VL>19</VL>
<NO>1</NO>
<PG>28-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="781"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignole-1991" NAME="Brignole 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;91172635&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brignole M, Menozzi C, Lolli G, Oddone D, Gianfranchi L, Bertulla A</AU>
<TI>Validation of a method for choice of pacing mode in carotid sinus syndrome with or without sinus bradycardia</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>2 Pt 1</NO>
<PG>196-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brignole-1992" NAME="Brignole 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;92221934&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brignole M, Menozzi C, Lolli G, Bottoni N, Gaggioli G</AU>
<TI>Long-term outcome of paced and nonpaced patients with severe carotid sinus syndrome</TI>
<SO>American Journal of Cardiology</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>12</NO>
<PG>1039-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="783"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunner_x002d_La-2000" NAME="Brunner-La 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20131403&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunner-La Rocca HP, Rickli H, Weilenmann D, Duru F, Candinas R</AU>
<TI>Importance of ventricular rate after mode switching during low intensity exercise as assessed by clinical symptoms and ventilatory gas exchange</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>1</NO>
<PG>32-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="785"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabello-1990" NAME="Cabello 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91047103&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabello JB, Bordes P, Mauri M, Lozano MV, Herrero A</AU>
<TI>[Long-term effects of cardiac pacing on natriuretic atrial peptide levels in patients with AV</TI>
<SO>Revista Espanola de Cardiologia</SO>
<YR>1990</YR>
<VL>43 Suppl 2</VL>
<PG>13-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="791"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabello-1996" NAME="Cabello 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;96321264&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabello JB, Bordes P, Mauri M, Valle M, Quiles JA</AU>
<TI>Acute and chronic changes in atrial natriuretic factor induced by ventricular pacing: a self controlled clinical trial</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>5</NO>
<PG>815-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="792"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Candinas-1994" NAME="Candinas 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;1994192675&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Candinas R, Eugster W, MacCarter D, Schonbeck M, Amann FW, Turina M</AU>
<TI>Does rate modulation with a minute ventilation pacemaker simulate the intrinsic heart rate response observed during representative patient daily activities?</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>2</NO>
<PG>89-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="412"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chabernaud-1993" NAME="Chabernaud 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;93332474&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chabernaud JM, Gueret P, Blanc P, Bavoux O, Bensaid J</AU>
<TI>[Comparison of VVI and DDD cardiac stimulation during exercise test evaluated by respiratory gas exchange measurement. Study of patients with normal systolic function and complete atrioventricular block unchanged during exercise test]. [French]</TI>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1993</YR>
<VL>86</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="799"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Channon-1997" NAME="Channon 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97181431&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Channon KM, Hargreaves MR, Gardner M, Ormerod OJ</AU>
<TI>Noninvasive beat-to-beat arterial blood pressure measurement during VVI and DDD pacing: relationship to symptomatic benefit from DDD pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>1 Pt 1</NO>
<PG>25-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="802"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chauhan-1994" NAME="Chauhan 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;95148357&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chauhan A, Grace AA, Newell SA, Stone DL, Shapiro LM, Schofield PM et al</AU>
<TI>Early complications after dual chamber versus single chamber pacemaker implantation. [see comments]</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11 Pt 2</NO>
<PG>2012-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chida-1993" NAME="Chida 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;94133460&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chida K, Ohkawa S, Imai T, Suzuki Y, Ishikawa K, Watanabe C et al</AU>
<TI>[Long-term follow-up study after permanent pacemaker implantation in patients aged 60 years or over with sick sinus syndrome]. [Japanese]</TI>
<SO>Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics</SO>
<YR>1993</YR>
<VL>30</VL>
<NO>10</NO>
<PG>869-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="805"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Copperman-1993" NAME="Copperman 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;1994003356&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Copperman Y, Bornstein NM, Nissel T, Laniado S</AU>
<TI>The use of transcranial Doppler in the hemodynamic assessment of implanted pacemakers</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>12</NO>
<PG>2217-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="434"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daubert-1984" NAME="Daubert 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984105447&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daubert JC, Roussel A, Langella B</AU>
<TI>Haemodynamic and M mode echocardiographic study of the consequences of ventriculo-atrial conduction in man</TI>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>4</NO>
<PG>413-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="708"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1985" NAME="Davies 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies R, Willis J, Akyurekli Y, Ascroft F, Beanlands D</AU>
<TI>Non-invasive comparison of ventricular-function with atrioventricular sequential versus ventricular pacing in complete heart-block</TI>
<SO>Pace-Pacing And Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3</NO>
<PG>A37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1558"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeFilippi-1981" NAME="DeFilippi 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Defilippi R, Bramucci E, Gavazzi A, Scuri PM, Mussini A, Zawaideh Z et al</AU>
<TI>Acute and chronic hemodynamic aspects at rest and during exertion of patients using physiologic pacemakers (Funke Mod 5999) - comparison with synchronous ventricular pacing</TI>
<SO>Pace-Pacing And Clinical Electrophysiology</SO>
<YR>1981</YR>
<VL>4</VL>
<NO>3</NO>
<PG>A41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="287"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Douard-1995" NAME="Douard 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95335541&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Douard H, Blaquiere-Roche C, Tourtoulou V, Bordier P, Broustet JP</AU>
<TI>Effect of atrioventricular synchronous pacing on cardiac output determined by CO2 rebreathing at constant submaximal exercise</TI>
<SO>American Journal of Cardiology</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>3</NO>
<PG>189-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="839"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dritsas-1993" NAME="Dritsas 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;1993239383&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dritsas A, Joshi J, Webb SC, Athanassopoulos G, Oakley CM, Nihoyannopoulos P</AU>
<TI>Beat-to-Beat variability in stroke volume during VVI pacing as predictor of hemodynamic benefit from DDD pacing</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>8</NO>
<PG>1713-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duan-2001" NAME="Duan 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;2002041411&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duan D-C, Tai H-C, Lee K-H, Ding PYA, Kong C-W</AU>
<TI>Incidence of atrial fibrillation in Chinese patients with different modes of pacing</TI>
<SO>Acta Cardiologica Sinica</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>4</NO>
<PG>223-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="107"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eagle-1988" NAME="Eagle 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;1988278367&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eagle KA, Harthorne JW</AU>
<TI>Single chamber and dual chamber pacing compared</TI>
<SO>Cardiology Board Review</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>11</NO>
<PG>89-99</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebagosti-1988" NAME="Ebagosti 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;89098545&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebagosti A, Gueunoun M, Saadjian A, Dolla E, Gabriel M, Levy S et al</AU>
<TI>Long-term follow-up of patients treated with VVI pacing and sequential pacing with special reference to VA retrograde conduction</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>11 Pt 2</NO>
<PG>1929-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faerestrand-1985" NAME="Faerestrand 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;1986019522&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faerestrand S, Ohm OJ</AU>
<TI>A time-related study of the hemodynamic benefit of atrioventricular synchronous pacing evaluated by Doppler echocardiography</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>6</NO>
<PG>834-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="662"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fananapazir-1983a" NAME="Fananapazir 1983a" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;83194405&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fananapazir L, Srinivas V, Bennett DH</AU>
<TI>Comparison of resting hemodynamic indices and exercise performance during atrial synchronized and asynchronous ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>2 Pt 1</NO>
<PG>202-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="866"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fananapazir-1983b" NAME="Fananapazir 1983b" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;83246727&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fananapazir L, Bennett DH, Monks P</AU>
<TI>Atrial synchronized ventricular pacing: contribution of the chronotropic response to improved exercise performance</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>3 Pt 1</NO>
<PG>601-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="865"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faria-1991" NAME="Faria 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;91283216&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faria H, Providencia LA, Andrade C, Paisana F, Monteiro V, Lucete M et al</AU>
<TI>[Assessment of the left ventricular function in patients with pacemakers VVI and DDD, using</TI>
<SO>Revista Portuguesa de Cardiologia</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fishberger-1996" NAME="Fishberger 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;96200229&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishberger SB, Wernovsky G, Gentles TL, Gamble WJ, Gauvreau K, Burnett et al</AU>
<TI>Long-term outcome in patients with pacemakers following the Fontan operation</TI>
<SO>American Journal of Cardiology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>10</NO>
<PG>887-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="870"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-French-1988" NAME="French 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;89098533&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>French WJ, Haskell RJ, Wesley GW, Florio J</AU>
<TI>Physiological benefits of a pacemaker with dual chamber pacing at low heart rates and single chamber rate responsive pacing during exercise</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>11 Pt 2</NO>
<PG>1840-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frielingsdorf-1995" NAME="Frielingsdorf 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95377865&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frielingsdorf J, Dur P, Gerber AE, Vuilliomenet A, Bertel O</AU>
<TI>Physical work capacity with rate responsive ventricular pacing (VVIR) versus dual chamber pacing (DDD) in patients with normal and diminished left ventricular function</TI>
<SO>International Journal of Cardiology</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>3</NO>
<PG>239-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="877"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fromer-1987" NAME="Fromer 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;1988213145&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fromer M, Kappenberger L, Babotai I</AU>
<TI>Subjective and objective response to single- versus dual-chamber pacing</TI>
<SO>Journal of Electrophysiology</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>4</NO>
<PG>343-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukumoto-1986" NAME="Fukumoto 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;1986124908&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukumoto H, Koike R, Sato H</AU>
<TI>Myocardial metabolism and hemodynamics during exercise in patients with cardiac pacemaker for complete A-V block. A comparison of DDD mode and VVI mode</TI>
<SO>Japanese Journal of Artificial Organs</SO>
<YR>1986</YR>
<VL>15</VL>
<NO>2</NO>
<PG>829-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuoka-2000" NAME="Fukuoka 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20280838&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuoka S, Nakagawa S, Fukunaga T, Yamada H</AU>
<TI>Effect of long-term atrial-demand ventricular pacing on cardiac sympathetic activity</TI>
<SO>Nuclear Medicine Communications</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>3</NO>
<PG>291-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="880"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallik-1994" NAME="Gallik 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;94224613&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallik DM, Guidry GW, Mahmarian JJ, Verani MS, Spencer WH</AU>
<TI>Comparison of ventricular function in atrial rate adaptive versus dual chamber rate adaptive pacing during exercise</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>2</NO>
<PG>179-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="886"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghio-1991" NAME="Ghio 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;92164920&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghio S, Marinoni G, Broglia P, Eleuteri E, Barba F, Bargiggia G et al</AU>
<TI>[Hemodynamic benefits of sequential atrioventricular pacing]. [Italian]</TI>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>9</NO>
<PG>957-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="892"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-1995" NAME="Gold 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;96007340&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold MR, Feliciano Z, Gottlieb SS, Fisher ML</AU>
<TI>Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. [see comments]</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>4</NO>
<PG>967-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="902"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-2000" NAME="Gold 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20245069&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold MR, Brockman R, Peters RW, Olsovsky MR, Shorofsky SR</AU>
<TI>Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy</TI>
<SO>American Journal of Cardiology</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>9</NO>
<PG>1106-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griebenow-1984" NAME="Griebenow 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1985036969&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griebenow R, Saborowski F, Hossmann V, Grotz J</AU>
<TI>Vasodepression in carotid sinus syndrome: Effect of ventricular and bifocal stimulation on arterial blood pressure in the supine position and during orthostasis</TI>
<SO>Herz Kreislauf</SO>
<YR>1984</YR>
<VL>16</VL>
<NO>11</NO>
<PG>576-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="686"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griebenow-1989" NAME="Griebenow 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;90065476&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griebenow R, Kramer L, Steffen HM, Schafer HJ</AU>
<TI>Quantification of the heart rate-independent vasodepressor component in carotid sinus syndrome</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>22</NO>
<PG>1132-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedman-1985" NAME="Hedman 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;86067355&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedman A, Nordlander R, Pehrsson SK</AU>
<TI>Changes in Q-T and Q-aT intervals at rest and during exercise with different modes of cardiac pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>6</NO>
<PG>825-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedman-1988" NAME="Hedman 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;1988251071&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedman A, Nordlander R</AU>
<TI>Changes in QT and Q-aT intervals induced by mental and physical stress with fixed rate and atrial triggered ventricular inhibited cardiac pacing</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1426-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="625"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoeschen-1991" NAME="Hoeschen 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;1991179445&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoeschen RJ, Reimold SC, Lee RT, Plappert TJ, Lamas GA</AU>
<TI>The effect of posture on the response to atrioventricular synchronous pacing in patients with underlying cardiovascular disease</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>5 I</NO>
<PG>756-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horie-1999" NAME="Horie 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;1999084589&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horie H, Tsutamoto T, Ishimoto N, Minai K, Yokohama H, Nozawa M et al</AU>
<TI>Plasma brain natriuretic peptide as a biochemical marker for atrioventricular sequence in</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>2</NO>
<PG>282-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="129"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ijiri-2000" NAME="Ijiri 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20478211&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ijiri H, Komori S, Kohno I, Sano S, Yin D, Takusagawa M et al</AU>
<TI>Improvement of exercise tolerance by single lead VDD pacemaker: evaluation using cardiopulmonary exercise test</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1336-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="938"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iliev-2000" NAME="Iliev 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20131408&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iliev II, Yamachika S, Muta K, Hayano M, Ishimatsu T, Nakao K, et al</AU>
<TI>Preserving normal ventricular activation versus atrioventricular delay optimization during pacing: the role of intrinsic atrioventricular conduction and pacing rate</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>1</NO>
<PG>74-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="939"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishikawa-1994" NAME="Ishikawa 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;1994182933&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishikawa T, Kimura K, Sumita S, Kuji N, Miyazaki N, Tochikubo O et al</AU>
<TI>Left atrial and left ventricular diameters in patients treated with pacemakers</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>46-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="413"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishikawa-1995" NAME="Ishikawa 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;1995160635&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishikawa T, Sumita S, Kimura K, Kuji N, Nakayama R, Nemoto T et al</AU>
<TI>Diastolic mitral regurgitation observed in patients with complete atrioventricular block during</TI>
<SO>Japanese Journal of Artificial Organs</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>2</NO>
<PG>503-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="350"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishikawa-1996" NAME="Ishikawa 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;1996213744&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishikawa T, Sumita S, Kikuchi M, Satoh T, Terada K, Kuji N et al</AU>
<TI>Diastolic mitral regurgitation when the heart rate is normalised by ventricular pacing</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="290"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwase-1986" NAME="Iwase 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;1986219181&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwase M, Sotobata I, Yokoto M</AU>
<TI>Evaluation by pulsed Doppler echocardiography of the atrial contribution to left ventricular</TI>
<SO>American Journal of Cardiology</SO>
<YR>1986</YR>
<VL>58</VL>
<NO>1</NO>
<PG>104-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="680"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwase-1991" NAME="Iwase 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;93148100&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwase M, Miyaguchi K, Aoki T, Kato K, Hatano K, Hayashi H et al</AU>
<TI>[Evaluation of maintenance of cardiac output during DDD and VVI pacing by exercise Doppler echocardiography]. [Japanese]</TI>
<SO>Journal of Cardiology</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>3</NO>
<PG>727-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="948"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jordaens-1988" NAME="Jordaens 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;88287031&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jordaens L, De Backer G, Clement DL</AU>
<TI>Physiologic pacing in the elderly. Effects on exercise capacity and exercise-induced arrhythmias</TI>
<SO>Japanese Heart Journal</SO>
<YR>1988</YR>
<VL>29</VL>
<NO>1</NO>
<PG>35-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="958"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1990" NAME="Jutzy 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91133918&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Florio J, Isaeff DM, Marsa RJ, Bansal RC, Jutzy KR et al</AU>
<TI>Comparative evaluation of rate modulated dual chamber and VVIR pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 Pt 2</NO>
<PG>1838-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="962"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1991" NAME="Jutzy 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;92081678&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Florio J, Isaeff DM, Feenstra L, Briggs B, Levine PA</AU>
<TI>Limitations of testing methods for evaluation of dual chamber versus single chamber adaptive rate pacing</TI>
<SO>American Journal of Cardiology</SO>
<YR>1991</YR>
<VL>68</VL>
<NO>17</NO>
<PG>1715-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="963"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1992a" NAME="Jutzy 1992a" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1993041225&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Feenstra L, Florio J, Levine P</AU>
<TI>Evaluation of DDDR vs VVIR pacing in patients with associated cardiac and pulmonary disease</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1992</YR>
<VL>2</VL>
<NO>2</NO>
<PG>101-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="475"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1992b" NAME="Jutzy 1992b" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1992263876&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Feenstra L, Florio J, Hodgkin JE, Levine PA</AU>
<TI>Advantages of dual chamber rate adaptive pacing compared with ventricular rate adaptive pacing in patients with pulmonary disease</TI>
<SO>Journal of Cardiopulmonary Rehabilitation</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>4</NO>
<PG>270-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="513"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1992c" NAME="Jutzy 1992c" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93065472&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Feenstra L, Pai R, Florio J, Bansal R, Aybar R et al</AU>
<TI>Comparison of intrinsic versus paced ventricular function</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>11 Pt 2</NO>
<PG>1919-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="964"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jutzy-1994" NAME="Jutzy 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;94101971&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jutzy RV, Houston-Feenstra L, Levine PA</AU>
<TI>Comparison of cardiac pacing modes in patients with chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<NO>1</NO>
<PG>83-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamalvand-1996" NAME="Kamalvand 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;97100469&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamalvand K, Kotsakis A, Tan K, Bucknall C, Sulke N</AU>
<TI>Evaluation of a new pacing algorithm to prevent rapid tracking of atrial tachyarrhythmias</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>11 Pt 2</NO>
<PG>1714-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kano-1992" NAME="Kano 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;92232980&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kano K, Okada M, Tanahashi Y, Hayashi H, Yokota M, Saito H et al</AU>
<TI>Left ventricular performance at rest and during exercise in patients with dual-chamber pacemakers</TI>
<SO>Internal Medicine</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="971"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kargul-1996" NAME="Kargul 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kargul W, Wilczek J, Kowalik J, Szydlo K, Grzegorzewski B, Zajac T et al</AU>
<TI>Simultaneous using of ECG and blood pressure holter registration in patients with pacemaker</TI>
<SO>Heartweb</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>1</NO>
<PG>U209-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1351"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kikis-1983" NAME="Kikis 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;83182130&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kikis D, Esser H</AU>
<TI>[Hemodynamics in ventricular and atrioventricular sequential stimulation in patients with</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1983</YR>
<VL>108</VL>
<NO>14</NO>
<PG>532-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="982"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolettis-1995" NAME="Kolettis 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;96081419&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolettis TM, Kremastinos DT, Kyriakides ZS, Tsirakos A, Toutouzas PK</AU>
<TI>Effects of atrial, ventricular, and atrioventricular sequential pacing on coronary flow reserve</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>9 Pt 1</NO>
<PG>1628-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="986"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolettis-1998" NAME="Kolettis 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;99044801&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolettis TM, Kyriakides ZS, Kremastinos DT</AU>
<TI>Coronary blood flow velocity during apical versus septal pacing</TI>
<SO>International Journal of Cardiology</SO>
<YR>1998</YR>
<VL>66</VL>
<NO>2</NO>
<PG>203-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="987"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolettis-2000" NAME="Kolettis 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20098420&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolettis TM, Kyriakides ZS, Tsiapras D, Popov T, Paraskevaides IA, Kremastinos DT</AU>
<TI>Improved left ventricular relaxation during short-term right ventricular outflow tract compared to apical pacing</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>1</NO>
<PG>60-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1996a" NAME="Koller 1996a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller B, Pache J, Hofmann M, GoedelMeinen L</AU>
<TI>Atrial arrhythmias in pacemaker therapy: A randomized DDD vs VVI crossover trial in 50 patients</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>8</NO>
<PG>388</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1996-b" NAME="Koller 1996 b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller B, Pache J, Hofmann M, GoedelMeinen L</AU>
<TI>Atrial arrhythmias in pacemaker therapy: A randomized DDD vs VVI crossover trial in 50 patients</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>8</NO>
<PG>388</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensson-1983" NAME="Kristensson 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;84057868&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensson BE, Arnman K, Ryden L</AU>
<TI>Atrial synchronous ventricular pacing in ischaemic heart disease</TI>
<SO>European Heart Journal</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>9</NO>
<PG>668-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="993"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensson-1985" NAME="Kristensson 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;1986059426&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensson B-E, Arnman K, Ryden L</AU>
<TI>The haemodynamic importance of atrioventricular synchrony and rate increase at rest and during exercise</TI>
<SO>European Heart Journal</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>9</NO>
<PG>773-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensson-1986" NAME="Kristensson 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;86286745&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensson BE, Karlsson O, Ryden L</AU>
<TI>Holter-monitored heart rhythm during atrioventricular synchronous and fixed-rate ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>4</NO>
<PG>511-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="995"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kruse-1982" NAME="Kruse 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;82184619&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kruse I, Arnman K, Conradson TB, Ryden L</AU>
<TI>A comparison of the acute and long-term hemodynamic effects of ventricular inhibited and atrial synchronous ventricular inhibited pacing</TI>
<SO>Circulation</SO>
<YR>1982</YR>
<VL>65</VL>
<NO>5</NO>
<PG>846-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="998"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kyriakides-1994" NAME="Kyriakides 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;94318356&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kyriakides ZS, Antoniadis A, Iliodromitis E, Michelakakis N, Kremastinos, DT</AU>
<TI>Short-term effects of right atrial, right ventricular apical, and atrioventricular sequential pacing</TI>
<SO>British Heart Journal</SO>
<YR>1994</YR>
<VL>71</VL>
<NO>6</NO>
<PG>536-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1003"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labovitz-1985" NAME="Labovitz 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;85235261&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labovitz AJ, Williams GA, Redd RM, Kennedy HL</AU>
<TI>Noninvasive assessment of pacemaker hemodynamics by Doppler echocardiography</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1985</YR>
<VL>6</VL>
<NO>1</NO>
<PG>196-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamaison-1993" NAME="Lamaison 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;1993351284&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamaison D, Page E, Aupetit JF, Defaye P, Rozand JY, Mouton E et al</AU>
<TI>A comparison between single atrial and dual chamber rate adaptive (AAIR and DDDR) and non adaptive AAI and DDD cardiac pacing using cardiopulmonary exercise testing in patients with atrial chronotropic incompetence</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>3</NO>
<PG>197-204</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="438"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lascault-1989" NAME="Lascault 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;1989183832&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lascault G, Bigonzi F, Frank R, Abergel E, Klimczak K, Fontaine G et al</AU>
<TI>Non-invasive study of dual chamber pacing by pulsed Doppler.</TI>
<SO>European Heart Journal</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>6</NO>
<PG>525-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="593"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-1990" NAME="Lau 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91133917&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau CP, Wong CK, Leung WH, Liu WX</AU>
<TI>Superior cardiac hemodynamics of atrioventricular synchrony over rate responsive pacing at submaximal exercise: observations in activity sensing DDDR pacemakers</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 Pt 2</NO>
<PG>1832-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1020"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-1992" NAME="Lau 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1992342487&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau C-P, Tai Y-T, Li JPS, Chung FLW, Sung S, Yamamoto A</AU>
<TI>Initial clinical experience with a single pass VDDR pacing system</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>11 II</NO>
<PG>1894-1900</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="497"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lau-1997" NAME="Lau 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;98068062&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lau CP, Tse HF, Cheng G</AU>
<TI>Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients. [see comments]</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>4</NO>
<PG>358-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1025"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LaVilla-1994" NAME="LaVilla 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;1994144416&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Villa G, Padeletti L, Lazzeri C, Salvi S, Michelucci A, Fronzaroli C et al</AU>
<TI>Plasma levels of natriuretic peptides during ventricular pacing in patients with a dual chamber</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>5 I</NO>
<PG>953-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leclercq-1995" NAME="Leclercq 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95274568&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leclercq C, Gras D, Le Helloco A, Nicol L, Mabo P, Daubert C</AU>
<TI>Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing</TI>
<SO>American Heart Journal</SO>
<YR>1995</YR>
<VL>129</VL>
<NO>6</NO>
<PG>1133-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leclercq-1998" NAME="Leclercq 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;1999007683&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D et al</AU>
<TI>Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1825-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="144"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leman-1985" NAME="Leman 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;85215920&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leman RB, Kratz JM</AU>
<TI>Radionuclide evaluation of dual chamber pacing: comparison between variable AV intervals and ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3 Pt 1</NO>
<PG>408-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1031"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemke-1990" NAME="Lemke 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91021407&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemke B, Gude J, von Dryander S, Barmeyer J, Braun BE, Krieg M</AU>
<TI>[Effect of AV synchronization and rate increase on hemodynamics and on atrial natriuretic peptide in patients with total AV block]. [German]</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1990</YR>
<VL>79</VL>
<NO>8</NO>
<PG>547-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1032"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linde_x002d_Edelstam-1992" NAME="Linde-Edelstam 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1992175862&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linde-Edelstam C, Hjemdahl P, Pehrsson SK, Astrom H, Nordlander R</AU>
<TI>Is DDD pacing superior to VVI,R? A study on cardiac sympathetic nerve activity and myocardial oxygen consumption at rest and during exercise</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>4 I</NO>
<PG>425-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="521"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-1993" NAME="Lo 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;1994339836&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo BF, Bianconi L, Altamura G, Mennuni M, Castro A, Magliocca M et al</AU>
<TI>Atrial natriuretic factor levels during DDD and VVI pacing</TI>
<SO>New Trends in Arrhythmias</SO>
<YR>1993</YR>
<VL>9</VL>
<NO>3</NO>
<PG>651-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="397"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lo-1997" NAME="Lo 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;98023975&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lo BF, Altamura G, Bianconi L, Toscano S, Pandozi C, Castro A et al</AU>
<TI>[Acute effects of ventricular and bicameral stimulation on plasma levels of natriuretic hormone]. [Italian]</TI>
<SO>Giornale Italiano di Cardiologia</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1019-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotto-1985" NAME="Lotto 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotto A, Valentini R, Greco EM, Sernesi L, Arlotti M, Eriano G et al</AU>
<TI>DDD and rate incremental VVI pacing - hemodynamic evaluation during exercise</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3</NO>
<PG>A12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Love-1984" NAME="Love 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984162908&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Love JC, Haffajee CI, Gore JM, Alpert JS</AU>
<TI>Reversibility of hypotension and shock by atrial or atrioventricular sequential pacing in patients with right ventricular infarction</TI>
<SO>American Heart Journal</SO>
<YR>1984</YR>
<VL>108</VL>
<NO>1</NO>
<PG>5-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="710"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukl-1991" NAME="Lukl 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;93114006&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukl J, Heinc P</AU>
<TI>The effect of heart rate on the working capacity of patients with complete heart block and physiological pacemaker</TI>
<SO>Cor et Vasa</SO>
<YR>1991</YR>
<VL>33</VL>
<NO>6</NO>
<PG>506-513</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukl-1992a" NAME="Lukl 1992a" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;92280160&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukl J, Heinc P</AU>
<TI>[Relative contribution of standard and physiologic stimulation for maximal work capacity in patients with complete atrioventricular block]. [Czech]</TI>
<SO>Vnitrni Lekarstvi</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>2</NO>
<PG>105-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1055"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukl-1992b" NAME="Lukl 1992b" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;92280178&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukl J, Doupal V, Heinc P, Hyzak A</AU>
<TI>[Permanent variable frequency cardiac pacing: which patients with chronic complete atrioventricular block profit most?]. [Czech]</TI>
<SO>Vnitrni Lekarstvi</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>3</NO>
<PG>234-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukl-1994" NAME="Lukl 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;1994157736&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukl J, Doupal V, Heinc P</AU>
<TI>Which patients are indicated for replacement of ventricular pacing for dual chamber pacing?</TI>
<SO>Cor et Vasa</SO>
<YR>1994</YR>
<VL>36</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="415"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madigan-1984" NAME="Madigan 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984099195&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madigan NP, Flaker GC, Curtis JJ</AU>
<TI>Carotid sinus hypersensitivity: Beneficial effects of dual-chamber pacing</TI>
<SO>American Journal of Cardiology</SO>
<YR>1984</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1034-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="704"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmud-1983" NAME="Mahmud 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;1983183049&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmud R, Lehmann M, Denker S</AU>
<TI>Atrioventricular sequential pacing: Differential effect on retrograde conduction related to level of impulse collision</TI>
<SO>Circulation</SO>
<YR>1983</YR>
<VL>68</VL>
<NO>1</NO>
<PG>23-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="726"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahy-1996" NAME="Mahy 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;1996175087&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahy IR, Lewis DM, Shore AC, Penney MD, Smith LDR, Tooke JE</AU>
<TI>Disturbance of peripheral microvascular fluid permeability by the onset of atrioventricular asynchrony in patients with programmable pacemakers</TI>
<SO>Heart</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>5</NO>
<PG>509-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="293"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maity-1987" NAME="Maity 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;88226692&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maity AK, Ganguly K, Chatterjee SS, Banerjee A, Sinha T, Kar CC</AU>
<TI>Haemodynamic advantage of AV sequential pacing--a comparison with ventricular pacing</TI>
<SO>Indian Heart Journal</SO>
<YR>1987</YR>
<VL>39</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1060"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maity-1992" NAME="Maity 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93170826&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maity AK, Ghosh SP, Dasbiswas A, Chatterjee SS, Chaudhury D, Das MK</AU>
<TI>Haemodynamic advantage with single chamber rate responsive pacemakers over dual chamber pacemakers during exercise in chronotropic incompetence</TI>
<SO>Indian Heart Journal</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>4</NO>
<PG>231-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1061"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manolis-1998" NAME="Manolis 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manolis AG, Katsivas A, Vassilopoulos C, Dragios D, Louvros N</AU>
<TI>Efficacy of different pacing modes in patients with intact sinus node function who underwent RF AV junction ablation due to drug refractory paroxysmal atrial fibrillation</TI>
<SO>Heartweb</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>2</NO>
<PG>U16-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1386"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manolis-2000" NAME="Manolis 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;2000429561&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manolis AG, Vassilopoulos CV, Katsivas AG, Koutsogeorgis DH, Louvros NE</AU>
<TI>Diurnal dynamics of ventricular repolarization in paced patients with heart failure: The potential role of pacing mode</TI>
<SO>Experimental &amp; Clinical Cardiology</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>2</NO>
<PG>90-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="29"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markewitz-1991" NAME="Markewitz 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;92086525&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markewitz A, Hemmer W</AU>
<TI>What's the price to be paid for rate response: AV sequential versus ventricular pacing?</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>11 Pt 2</NO>
<PG>1782-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1068"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maron-1999" NAME="Maron 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;99289698&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS</AU>
<TI>Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>22</NO>
<PG>2927-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinelli-2000" NAME="Martinelli 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;21021436&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinelli FM, Nishioka SA, Lopes H, Oliveira JC, Pedrosa AA, Siqueira SF et al</AU>
<TI>Neurohumoral behavior in recipients of cardiac pacemakers controlled by a closed-loop autonomic nervous system-driven sensor</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>11 Pt 2</NO>
<PG>1778-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1071"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maseki-1985" NAME="Maseki 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;1985222684&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maseki T, Ishihara T, Ohmiya T</AU>
<TI>Evaluation of left ventricular function by multi-gated RI cardiac pool imaging in patients with VDD and DVI versus VVI pacemakers, at rest and at exercise</TI>
<SO>Japanese Journal of Artificial Organs</SO>
<YR>1985</YR>
<VL>14</VL>
<NO>3</NO>
<PG>1411-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="695"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattioli-1997" NAME="Mattioli 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97276095&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattioli AV, Castellani ET, Fusco A, Paolillo C, Mattioli G</AU>
<TI>Stroke in paced patients with sick sinus syndrome: relevance of atrial mechanical function, pacing mode and clinical characteristics</TI>
<SO>Cardiology</SO>
<YR>1997</YR>
<VL>88</VL>
<NO>3</NO>
<PG>264-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1075"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattioli-1998" NAME="Mattioli 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;98179848&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattioli AV, Vivoli D, Mattioli G</AU>
<TI>Influence of pacing modalities on the incidence of atrial fibrillation in patients without prior atrial fibrillation. A prospective study</TI>
<SO>European Heart Journal</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>2</NO>
<PG>282-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattioli-1999" NAME="Mattioli 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;99447578&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattioli AV, Tarabini CE, Mattioli G</AU>
<TI>Stroke in paced patients with sick sinus syndrome: influence of left atrial function and size</TI>
<SO>Cardiology</SO>
<YR>1999</YR>
<VL>91</VL>
<NO>3</NO>
<PG>150-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIntosh-1997" NAME="McIntosh 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97371076&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh SJ, Lawson J, Bexton RS, Gold RG, Tynan MM, Kenny RA</AU>
<TI>A study comparing VVI and DDI pacing in elderly patients with carotid sinus syndrome</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>77</VL>
<NO>6</NO>
<PG>553-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1085"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McMeekin-1990" NAME="McMeekin 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;90138282&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McMeekin JD, Lautner D, Hanson S, Gulamhusein SS</AU>
<TI>Importance of heart rate response during exercise in patients using atrioventricular synchronous and ventricular pacemakers</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>1</NO>
<PG>59-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1087"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meisel-2000" NAME="Meisel 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20404583&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meisel E, Rauwolf T, Burghardt M, Kappenberger L</AU>
<TI>[Pacemaker therapy of hypertrophic obstructive cardiomyopathy. PIC (Pacing in Cardiomyopathy) Study Group]. [German]</TI>
<SO>Herz</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>4</NO>
<PG>461-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1089"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mizutani-1997" NAME="Mizutani 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;1997123207&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizutani N, Kobayashi T, Kato I</AU>
<TI>Optimal pacing mode for sick sinus syndrome</TI>
<SO>Japanese Journal of Artificial Organs</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>2</NO>
<PG>369-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="247"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1997" NAME="Murphy 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;1998048503&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy CF, Bulbeck VJ, Chase BD, Lawson CS, Dawkins KD, Morgan JM</AU>
<TI>Comparison of mode switching DDDR pacing versus VVIR pacing following atrioventricular node ablation for refractory atrial fibrillation and flutter</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>2</NO>
<PG>68-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="204"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-2000" NAME="Nielsen 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;20265727&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen JC, Bottcher M, Nielsen TT, Pedersen AK, Andersen HR</AU>
<TI>Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing - effect of pacing mode and rate</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1453-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1114"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielson-1985" NAME="Nielson 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen AP, Rokey R, Kuo LC, Verani MS, Quinones MA, Spencer WR et al</AU>
<TI>A prospective comparison of DDD and VVI pacing in patients with non-fixed heart-rates at rest and during exercise</TI>
<SO>Pace-Pacing And Clinical Electrophysiology</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>2</NO>
<PG>292</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1404"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1982" NAME="Nishimura 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;83090557&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura RA, Gersh BJ, Vlietstra RE, Osborn MJ, Ilstrup DM, Holmes DR</AU>
<TI>Hemodynamic and symptomatic consequences of ventricular pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1982</YR>
<VL>5</VL>
<NO>6</NO>
<PG>903-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1116"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1997" NAME="Nishimura 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97167312&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN et al</AU>
<TI>Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>2</NO>
<PG>435-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1117"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nitsch-1983" NAME="Nitsch 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;84123384&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nitsch J, Seiderer M, Bull U, Luderitz B</AU>
<TI>Effect of varied pacemaker stimulation on left ventricular volume data</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1983</YR>
<VL>72</VL>
<NO>12</NO>
<PG>718-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1118"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nitsch-1984a" NAME="Nitsch 1984a" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1985012847&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nitsch J, Seiderer M, Bull U, Luderitz B</AU>
<TI>Cardiac activation patterns in patients with physiological and ventricular pacing</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1984</YR>
<VL>62</VL>
<NO>23</NO>
<PG>1132-1135</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nitsch-1984b" NAME="Nitsch 1984b" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;84199875&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nitsch J, Seiderer M, Bull U, Luderitz B</AU>
<TI>Evaluation of left ventricular performance by radionuclide ventriculography in patients with</TI>
<SO>American Heart Journal</SO>
<YR>1984</YR>
<VL>107</VL>
<NO>5 Pt 1</NO>
<PG>906-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1119"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noll-1990" NAME="Noll 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;1990300136&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noll B, Krappe J, Goke B, Maisch B</AU>
<TI>Atrial natriuretic peptide levels reflect hemodynamic changes under pacemaker stimulation</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>8</NO>
<PG>970-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="570"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nordlander-1987" NAME="Nordlander 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;1987232963&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordlander R, Pehrsson SK, Astrom H, Karlsson J</AU>
<TI>Myocardial demands of atrial-triggered versus fixed-rate ventricular pacing in patients with complete heart block</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>5</NO>
<PG>1154-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1559"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nowak-1995" NAME="Nowak 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;95250666&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nowak B, Voigtlander T, Himmrich E, Liebrich A, Poschmann G, Epperlein et al</AU>
<TI>Cardiac output in single-lead VDD pacing versus rate-matched VVIR pacing</TI>
<SO>American Journal of Cardiology</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>14</NO>
<PG>904-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Occhetta-1997" NAME="Occhetta 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97231743&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Occhetta E, Perucca A, Fazzari M, Pistis G, Baduini G, Trevi G</AU>
<TI>[An intrapatient comparison of adaptation to aerobic and anaerobic exertion during 3 types of physiological cardiac stimulation in chronotropic failure of the sinus node: DDD, VVIR and DDDR]. [Italian]</TI>
<SO>Cardiologia</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1124"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Occhetta-1998" NAME="Occhetta 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;99143486&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Occhetta E, Bortnik M, Francalacci G, Sarasso G, Piccinino C, Pistono M et al</AU>
<TI>[Dual-chamber DDD pacing in NYHA III-IV functional class dilated cardiomyopathy: short and middle-term evaluation]. [Italian]</TI>
<SO>Cardiologia</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1327-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1125"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oldroyd-1990" NAME="Oldroyd 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oldroyd KG, Carter R, Wingate C, Rae AP, Cobbe SM</AU>
<TI>Double-blind crossover comparison of the effects of DDD vs VVIR pacing on neuroendocrine parameters, symptoms and exercise performance in complete heart-block</TI>
<SO>Circulation</SO>
<YR>1990</YR>
<VL>82</VL>
<NO>4</NO>
<PG>180</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1409"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ovsyshcher-1992" NAME="Ovsyshcher 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93065473&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ovsyshcher I, Gross JN, Blumberg S, Furman S</AU>
<TI>Precision of impedance cardiography measurements of cardiac output in pacemaker patients</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>11 Pt 2</NO>
<PG>1923-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ovsyshcher-1993" NAME="Ovsyshcher 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;93171482&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ovsyshcher I, Zimlichman R, Katz A, Bondy C, Furman S</AU>
<TI>Measurements of cardiac output by impedance cardiography in pacemaker patients at rest: effects of various atrioventricular delays</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>3</NO>
<PG>761-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1133"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papadopoulos-1997" NAME="Papadopoulos 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;1997104041&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papadopoulos CL, Kokkas BA, Sakadamis GC, Kanonidis IE, Kotridis PS, Karamouzis MI et al</AU>
<TI>ANP concentrations during interchanging DDD-VVI pacing modes in patients with retrograde ventriculoatrial conduction</TI>
<SO>Acta Cardiologica</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>1</NO>
<PG>37-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="249"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payne-1995" NAME="Payne 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;96117338&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payne GE, Williams H, Skehan JD</AU>
<TI>An approach in the assessment of pacing hemodynamics: a comparison of VVI and DDD</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>10</NO>
<PG>1861-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payne-1996" NAME="Payne 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;96255939&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payne GE, Skehan JD</AU>
<TI>Shuttle walking test: a new approach for evaluating patients with pacemakers</TI>
<SO>Heart</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>4</NO>
<PG>414-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1140"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Payne-1997" NAME="Payne 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97272684&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Payne G, Spinelli J, Garratt CJ, Skehan JD</AU>
<TI>The optimal pacing rate: an unpredictable parameter</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>4 Pt 1</NO>
<PG>866-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1138"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearson-1989" NAME="Pearson 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;1989145603&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearson AC, Janosik DL, Redd RM, Buckingham TA, Labovitz AJ</AU>
<TI>Hemodynamic benefit of atrioventricular synchrony: Prediction from baseline Doppler-echocardiographic variables</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>7</NO>
<PG>1613-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="596"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pehrsson-1983" NAME="Pehrsson 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;1984023734&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pehrsson SK</AU>
<TI>Influence of heart rate and atrioventricular synchronization on maximal work tolerance in</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1983</YR>
<VL>214</VL>
<NO>4</NO>
<PG>311-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="697"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pehrsson-1988" NAME="Pehrsson 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;89026492&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pehrsson SK, Hjemdahl P, Nordlander R, Astrom H</AU>
<TI>A comparison of sympathoadrenal activity and cardiac performance at rest and during exercise in patients with ventricular demand or atrial synchronous pacing</TI>
<SO>British Heart Journal</SO>
<YR>1988</YR>
<VL>60</VL>
<NO>3</NO>
<PG>212-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1141"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perrins-1984" NAME="Perrins 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perrins EJ, Hudson WM, Lahiri A, Raftery EB, Sutton R</AU>
<TI>A randomized controlled trial ofand incremental VVI-rate responsive pacing</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1984</YR>
<VL>3</VL>
<NO>2</NO>
<PG>507</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Proctor-1991" NAME="Proctor 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;91344824&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Proctor EE, Leman RB, Mann DL, Kaiser J, Kratz J, Gillette P</AU>
<TI>Single- versus dual-chamber sensor-driven pacing: comparison of cardiac outputs</TI>
<SO>American Heart Journal</SO>
<YR>1991</YR>
<VL>122</VL>
<NO>3 Pt 1</NO>
<PG>728-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1148"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Providencia-1988" NAME="Providencia 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;90212122&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Providencia LA, Paisana FM, Cristovao JL, Silva AM, Vinagre R, Faria H et al</AU>
<TI>"Physiological pacing": comparison of DDD and VVI programming by three different non-invasive methods</TI>
<SO>Revista Portuguesa de Cardiologia</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>299-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reynolds-1983" NAME="Reynolds 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds DW, Wilson MF, Burow RD, Schaefer CF, Lazzara R, Thadani U</AU>
<TI>Hemodynamic evaluation of atrioventricular sequential versus ventricular pacing in patients with normal and poor ventricular-function at variable heart-rates and posture</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>2</NO>
<PG>636</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="404"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rickli-2000" NAME="Rickli 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;2000073350&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rickli H, Rocca HPB, MacCarter DJ, Duru F, Candinas R</AU>
<TI>Importance of AV synchronous pacing during low intensity exercise evaluated by oxygen kinetics</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>2</NO>
<PG>174-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritter-1994" NAME="Ritter 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;1994182931&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritter P, Vai F, Pioger G</AU>
<TI>Comparison between DDD and VVIR pacing modes: Importance of atrioventricular delay programming. Implications for study protocols</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="414"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roelke-1994" NAME="Roelke 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;95148364&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roelke M, McNamara D, Osswald S, Semigran M, Dec W, Harthorne JW</AU>
<TI>A comparison of VVIR and DDDR pacing following cardiac transplantation</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11 Pt 2</NO>
<PG>2047-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1158"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero-1981" NAME="Romero 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romero LR, Haffajee CI, Doherty P, Levin W, Benotti JR, Vandersalm T et al</AU>
<TI>Comparison of ventricular-function and volume with AV sequential and ventricular pacing</TI>
<SO>Chest</SO>
<YR>1981</YR>
<VL>80</VL>
<NO>3</NO>
<PG>346</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero-1984" NAME="Romero 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;84144418&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romero LR, Haffajee CI, Levin W, Doherty PW, Berkovits BV, Alpert JS</AU>
<TI>Non-invasive evaluation of ventricular function and volumes during atrioventricular sequential</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>1</NO>
<PG>10-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenqvist-1991" NAME="Rosenqvist 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;91103165&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenqvist M, Isaaz K, Botvinick EH, Dae MW, Cockrell J, Abbott JA et al</AU>
<TI>Relative importance of activation sequence compared to atrioventricular synchrony in left ventricular function</TI>
<SO>American Journal of Cardiology</SO>
<YR>1991</YR>
<VL>67</VL>
<NO>2</NO>
<PG>148-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1164"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saccomamo-1995" NAME="Saccomamo 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;1995061549&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saccomamo G, Marini M, Amadio L, Paciaroni E</AU>
<TI>Permanent cardiac pacing and thromboembolic risk in elderly patients</TI>
<SO>Archives of Gerontology &amp; Geriatrics</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="365"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saccomanno-1989" NAME="Saccomanno 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;1989253103&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saccomanno G, Antonicelli R, Campanari G, Paciaroni E</AU>
<TI>Effects of mode and rate of pacing on atrial natriuretic peptide release in patients with permanent pacemakers</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>4</NO>
<PG>762-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="589"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sack-1999" NAME="Sack 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;1999097013&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sack S, Franz R, Dagres N, Oldenburg O, Herrmann J, Golles A et al</AU>
<TI>Can right-sided atrioventricular sequential pacing provide benefit for selected patients with severe congestive heart failure</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>5 B</NO>
<PG>124D-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="127"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samoil-1993" NAME="Samoil 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;1993179939&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samoil D, Grubb BP, Brewster P, Moore J, Temesy-Armos P</AU>
<TI>Comparison of single and dual chamber pacing techniques in prevention of upright tilt induced vasovagal syncope</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>1</NO>
<PG>36-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="456"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santini-1990" NAME="Santini 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;90195893&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santini M, Alexidou G, Ansalone G, Cacciatore G, Cini R, Turitto G</AU>
<TI>Relation of prognosis in sick sinus syndrome to age, conduction defects and modes of permanent cardiac pacing</TI>
<SO>American Journal of Cardiology</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>11</NO>
<PG>729-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schofield-1986" NAME="Schofield 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;87026371&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schofield PM, Bowes RJ, Brooks N, Bennett DH</AU>
<TI>Exercise capacity and spontaneous heart rhythm after transvenous fulguration of atrioventricular conduction</TI>
<SO>British Heart Journal</SO>
<YR>1986</YR>
<VL>56</VL>
<NO>4</NO>
<PG>358-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1180"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwaab-1998" NAME="Schwaab 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;1998099967&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwaab B, Schatzer-Klotz D, Berg M, Frohlig G, Franow H, Schwerdt H et al</AU>
<TI>AAIR versus DDDR stimulation in patients with bradycardia-tachycardia syndrome and chronotropic incompetence: Prospective, randomized, double- blind, cross-over study regarding quality of life, incidence of atrial tachyarrhythmias and cardiopulmonary capacity</TI>
<SO>Herzschrittmachertherapie und Elektrophysiologie</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Suppl (1)</NO>
<PG>11-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1365"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sedney-1989" NAME="Sedney 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;90098963&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sedney MI, Weijers E, van der Wall EE, Adipranoto JD, Camps J, Blokland JA et al</AU>
<TI>Short-term and long-term changes of left ventricular volumes during rate-adaptive and single-rate pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>12</NO>
<PG>1863-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1194"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shigemura-1990" NAME="Shigemura 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;91088828&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shigemura M, Sawada K, Hasegawa H, Kobayashi F, Izumi S, Suzuki T et al</AU>
<TI>[Comparison of cardiac output between in DDD and in VVI by pulsed Doppler echocardiographic method (correction with Swan-Ganz catheter method)]. [Japanese]</TI>
<SO>Kokyu to Junkan - Respiration &amp; Circulation</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1091-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simantirakis-1997" NAME="Simantirakis 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97339858&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simantirakis EN, Parthenakis FI, Chrysostomakis SI, Zuridakis EG, Igoumenidis NE, Vardas PE</AU>
<TI>Left atrial appendage function during DDD and VVI pacing</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>77</VL>
<NO>5</NO>
<PG>428-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snoeck-1992" NAME="Snoeck 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93213190&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snoeck J, Decoster H, Marchand X, Kahn JC, Baron B, Zannier D et al</AU>
<TI>[P wave changes and atrial fibrillation after implantation of VVI type pacemaker]. [French]</TI>
<SO>Archives des Maladies du Coeur et des Vaisseaux</SO>
<YR>1992</YR>
<VL>85</VL>
<NO>10</NO>
<PG>1419-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparks-1999" NAME="Sparks 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;99456763&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparks PB, Mond HG, Vohra JK, Yapanis AG, Grigg LE, Kalman JM</AU>
<TI>Mechanical remodeling of the left atrium after loss of atrioventricular synchrony. A long-term study in humans</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>16</NO>
<PG>1714-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparks-PB_x002c_-Mond2" NAME="Sparks PB, Mond2" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;20014795&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparks PB, Mond HG, Vohra JK, Jayaprakash S, Kalman JM</AU>
<TI>Electrical remodeling of the atria following loss of atrioventricular synchrony: a long-term study in humans</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>18</NO>
<PG>1894-1900</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1214"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stangl-1988" NAME="Stangl 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;89016693&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stangl K, Weil J, Seitz K, Laule M, Gerzer R</AU>
<TI>Influence of AV synchrony on the plasma levels of atrial natriuretic peptide (ANP) in patients with total AV block</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>8</NO>
<PG>1176-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1219"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-1984" NAME="Stewart 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984180701&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart WJ, Dicola VC, Harthorne JW</AU>
<TI>Doppler ultrasound measurement of cardiac output in patients with physiologic pacemakers.</TI>
<SO>American Journal of Cardiology</SO>
<YR>1984</YR>
<VL>54</VL>
<NO>3</NO>
<PG>308-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stierle-1995" NAME="Stierle 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;96139915&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stierle U, Kruger D, Mitusch R, Potratz J, Taubert G, Sheikhzadeh A</AU>
<TI>Adverse pacemaker hemodynamics evaluated by pulmonary venous flow monitoring</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>11</NO>
<PG>2028-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stojnic-1996" NAME="Stojnic 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;96370930&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stojnic BB, Stojanov PL, Angelkov L, Pavlovic SU, Radjen GS, Velimirovic, DB</AU>
<TI>Evaluation of asynchronous left ventricular relaxation by Doppler echocardiography during</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>6</NO>
<PG>940-944</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1222"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stone-1982" NAME="Stone 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;83071529&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stone JM, Bhakta RD, Lutgen J</AU>
<TI>Dual chamber sequential pacing management of sinus node dysfunction: advantages over single-chamber pacing</TI>
<SO>American Heart Journal</SO>
<YR>1982</YR>
<VL>104</VL>
<NO>6</NO>
<PG>1319-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1223"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sulke-1990" NAME="Sulke 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;90359361&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sulke AN, Pipilis A, Henderson RA, Bucknall CA, Sowton E</AU>
<TI>Comparison of the normal sinus node with seven types of rate responsive pacemaker during everyday activity</TI>
<SO>British Heart Journal</SO>
<YR>1990</YR>
<VL>64</VL>
<NO>1</NO>
<PG>25-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1224"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takeuchi-1990" NAME="Takeuchi 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;1990168033&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takeuchi A, Sasaki S, Ohzeki M, Nishimoto Y</AU>
<TI>Comparative studies of long term results on VVI and DDD type pacemaker</TI>
<SO>Japanese Journal of Artificial Organs</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>3</NO>
<PG>1011-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="582"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tani-1992" NAME="Tani 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93027569&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tani M, Fujiki A, Asanoi H, Yoshida S, Tsuji H, Mizumaki K et al</AU>
<TI>Effects of chronotropic responsive cardiac pacing on ventilatory response to exercise in patients with complete AV block</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>10 Pt 1</NO>
<PG>1482-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1236"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1996" NAME="Taylor 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;97122219&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor JA, Morillo CA, Eckberg DL, Ellenbogen KA</AU>
<TI>Higher sympathetic nerve activity during ventricular (VVI) than during dual-chamber (DDD) pacing</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>7</NO>
<PG>1753-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1238"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theodorakis-1990" NAME="Theodorakis 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;1991053842&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theodorakis G, Kremastinos D, Livanis MME, Archontakis C, Karavolias G, Toutouzas P</AU>
<TI>C-AMP and ANP levels in VVI and DDD pacing with different AV delays during daily activity and exercise</TI>
<SO>Pace-Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 II</NO>
<PG>1773-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="563"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theodorakis-1992a" NAME="Theodorakis 1992a" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;1993041214&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theodorakis G, Fitzpatrick A, Vardas P, Sutton R</AU>
<TI>Resting echo-Doppler estimation of cardiac output during AAI and DDD pacing, with varying AV delay, at different pacing rates</TI>
<SO>European Journal of Cardiac Pacing &amp; Electrophysiology</SO>
<YR>1992</YR>
<VL>2</VL>
<NO>1</NO>
<PG>22-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Theodorakis-1992b" NAME="Theodorakis 1992b" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93099895&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Theodorakis GN, Kremastinos DT, Markianos M, Livanis E, Karavolias G, Toutouzas PK</AU>
<TI>Total sympathetic activity and atrial natriuretic factor levels in VVI and DDD pacing with different atrioventricular delays during daily activity and exercise</TI>
<SO>European Heart Journal</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>11</NO>
<PG>1477-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1239"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vardas-1996" NAME="Vardas 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;96273640&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vardas PE, Markianos M, Skalidis E, Simantirakis E, Manios E, Papavasiliou E</AU>
<TI>Twenty four hour variation in plasma atrial natriuretic factor during VVI and DDD pacing</TI>
<SO>Heart</SO>
<YR>1996</YR>
<VL>75</VL>
<NO>6</NO>
<PG>620-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1250"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vardas-1997a" NAME="Vardas 1997a" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Journal&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vardas PE, Simantirakis EN, Parthenakis FI, Zuridakis EG, Chrysostomakis SI</AU>
<TI>Transoesophageal echocardiographic evaluation of left atrial appendage function during DDD and VVI pacing</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>2</NO>
<PG>93574</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vardas-1997b" NAME="Vardas 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;97393312&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vardas PE, Simantirakis EN, Parthenakis FI, Chrysostomakis SI, Skalidis, EI, Zuridakis EG</AU>
<TI>AAIR versus DDDR pacing in patients with impaired sinus node chronotropy: an echocardiographic and cardiopulmonary study</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>7</NO>
<PG>1762-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Videen-1986" NAME="Videen 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;86239041&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Videen JS, Huang SK, Bazgan ID, Mechling E, Patton DD</AU>
<TI>Hemodynamic comparison of ventricular pacing, atrioventricular sequential pacing, and atrial synchronous ventricular pacing using radionuclide ventriculography</TI>
<SO>American Journal of Cardiology</SO>
<YR>1986</YR>
<VL>57</VL>
<NO>15</NO>
<PG>1305-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-1984" NAME="Von 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;1984178414&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Bibra H, Ebner U, Busch U</AU>
<TI>Echocardiographic analysis of physiological pacemakers with respect to mitral valve movement</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1984</YR>
<VL>73</VL>
<NO>7</NO>
<PG>460-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="716"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakakura-1992" NAME="Wakakura 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;93060359&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wakakura M</AU>
<TI>[Radionuclide study of left ventricular function and regional myocardial perfusion in patients with a DDD pacemaker]. [Japanese]</TI>
<SO>Kaku Igaku - Japanese Journal of Nuclear Medicine</SO>
<YR>1992</YR>
<VL>29</VL>
<NO>5</NO>
<PG>561-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whiting-1983" NAME="Whiting 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;83194410&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whiting RB, Madigan NP, Heinemann FM, Curtis JJ, Reid J</AU>
<TI>Atrioventricular sequential pacing: comparison with ventricular pacing using systolic time</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>2 Pt 1</NO>
<PG>242-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshida-1999" NAME="Yoshida 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;1999086957&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshida H, Shirotani M, Mochizuki M, Sakata K</AU>
<TI>Assessment of myocardial fatty acid metabolism in atrioventricular synchronous pacing:</TI>
<SO>Journal of Nuclear Cardiology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>1 I</NO>
<PG>33-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="130"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshitomi-1998" NAME="Yoshitomi 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;1998238762&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshitomi H, Tanabe K, Asanuma T, Shimizu H, Kobayashi K, Ono M et al</AU>
<TI>Influence of cardiac pacing mode on left atrial appendage flow velocity: Implication to systemic</TI>
<SO>Echocardiography</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>5</NO>
<PG>473-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen" NAME="Nielsen" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pedersen AK</AU>
<TI>A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>4</NO>
<PG>614-623</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-CTOPP-extended" NAME="CTOPP extended" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DANPACE" NAME="DANPACE" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen HR, Svendson JH</AU>
<TI>The Danish multicentre randomized study on atrial inhibited versus dual-chamber pacing in sick sinus syndrome (the DANPACE study): Purpose and design of the study</TI>
<SO>Heartdrug</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>2</NO>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-STOP_x002d_AF" NAME="STOP-AF" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charles RG, McComb JM</AU>
<TI>Systematic trial of pacing to prevent atrial fibrillation</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>78</VL>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-UKPACE" NAME="UKPACE" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toff WD, Skehan JD, De Bono DP, Camm AJ</AU>
<TI>The United Kingdom pacing and cardiovascular events (UKPACE) trial</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>3</NO>
<PG>221-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan">
<REFERENCE ID="REF-Ausubel-1985" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Ausubel 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ausubel K, Furman S</AU>
<TI>The pacemaker syndrome</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1985</YR>
<VL>103</VL>
<NO>3</NO>
<PG>420-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-1987" MODIFIED="2008-09-08 22:37:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bernstein 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein AD, Camm AJ, Fletcher RD</AU>
<TI>The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>4 I</NO>
<PG>794-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-2001" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bernstein 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein AD &amp; Parsonnet V</AU>
<TI>Survey of cardiac pacing and implanted defibrillator practice patterns in the United States in 1997</TI>
<SO>Pacing and Clinical Electrophysiology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>5</NO>
<PG>842-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-2002" MODIFIED="2008-09-08 22:37:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bernstein 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein AD, Daubert JC, Fletcher RD, Hayes DL, Lüderitz B, Reynolds DW et al</AU>
<TI>The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>2</NO>
<PG>260-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bush-1994" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Bush 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bush DE, Finucane TE</AU>
<TI>Permanent cardiac pacemakers in the elderly</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>3</NO>
<PG>326-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1991" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Clarke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Clarke M, Sutton R, Ward D, Camm AJ, Rickards A, Ingram A et al</AU>
<TI>Recommendations for pacemaker prescription for symptomatic bradycardia</TI>
<SO>British Heart Journal</SO>
<YR>1991</YR>
<VL>66</VL>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connolly-1996" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Connolly 1996" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Kerr C, Gent M, Yusuf S</AU>
<TI>Dual-chamber versus ventricular pacing. Critical appraisal of current data</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>578-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1998" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Egger 1998" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD</AU>
<TI>Bias in location and selection of studies</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregoratos-1998" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Gregoratos 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Bruce Ferguson T et al.</AU>
<TI>ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation)</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>5</NO>
<PG>1175-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregoratos-1999" MODIFIED="2008-09-08 22:37:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Gregoratos 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gregoratos G</AU>
<TI>Permanent pacemakers in older persons</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1999</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1125-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heldman-1990" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Heldman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Heldman D, Mulvihill D, Nguyen H, Messenger JC, Rylaarsdam A et al</AU>
<TI>True incidence of pacemaker syndrome</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>12 Pt 2</NO>
<PG>1742-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hills--1979" NAME="Hills  1979" TYPE="JOURNAL_ARTICLE">
<AU>Hills M , Armitage P</AU>
<TI>The two-period cross-over clinical trial</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1979</YR>
<VL>8</VL>
<PG>7-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Julian-1992" MODIFIED="2008-09-08 22:37:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Julian 1992" TYPE="BOOK">
<AU>Julian GD, Campbell Cowan J</AU>
<SO>Cardiology</SO>
<YR>1992</YR>
<EN>6th</EN>
<PB>Bailliere Tindall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kusumoto-1996" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Kusumoto 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kusumoto FM, Goldschlager N</AU>
<TI>Cardiac pacing</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>2</NO>
<PG>89-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lamas-1997" MODIFIED="2008-09-08 22:37:57 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Lamas 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lamas GA</AU>
<TI>Pacemaker mode selection and survival: a plea to apply the principles of evidence based medicine to cardiac pacing practice</TI>
<SO>Heart</SO>
<YR>1997</YR>
<VL>78</VL>
<PG>218-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mond-2001" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Mond 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mond HG</AU>
<TI>The world survey of cardiac pacing and cardioverter defibrillators: calendar year 1997-Asian Pacific, Middle East, South America and Canada</TI>
<SO>Pacing &amp; Clinical Electrophysiology</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>5</NO>
<PG>856-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morley_x002d_Davis-1997" NAME="Morley-Davis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Morley-Davis A, Cobbe SM</AU>
<TI>Cardiac Pacing</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NPD-2000" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="NPD 2000" NOTES="&lt;p&gt;Cunningham D, Rickards T, Cunningham M. National Pacemaker Database. Annual Report 2000.  http://www.ccad.org.uk&lt;/p&gt;" NOTES_MODIFIED="2008-09-08 22:37:58 +0100" NOTES_MODIFIED_BY="Karen Hovhannisyan" TYPE="OTHER">
<AU>Cunningham D, Rickards T, Cunningham M</AU>
<TI>National Pacemaker Database. Annual Report 2000</TI>
<SO>http://www.ccad.org.uk</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2000" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Tang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tang CY, Kerr CR, Connolly SJ</AU>
<TI>Clinical trials of pacing mode selection</TI>
<SO>Cardiology Clinics</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>1-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Travill-1992" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Travill 1992" TYPE="JOURNAL_ARTICLE">
<AU>Travill CM, Sutton R</AU>
<TI>Pacemaker syndrome: an iatrogenic condition</TI>
<SO>British Heart Journal</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>2</NO>
<PG>163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tse-2002" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NAME="Tse 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hung-Fat Tse, Cannas Yu, Kwong-Kuen Wong, Vella Tsang, Yim-Lung Leung et al</AU>
<TI>Functional abnormalities in patients with permanent right ventricular pacing: The effect of sites of electrical stimulation</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>40</VL>
<PG>1451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Avery">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>13 patients (7 male, 6 female) with AV block, mean age 79.4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Boon">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 patients (13 male, 2 female) with AV block or SSS, mean age 69 (range 54-81)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Capucci">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 patients (12 male, 2 female) with AV block or SSS or both, <BR/>mean age 66.5 (+/-5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD, DDDR versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Channon">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 patients (8 male, 8 female) with AV block, mean age 81.25 (range 77-88)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-CTOPP">
<CHAR_METHODS>
<P>Parallel randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2568 patients (60% male, 40% female) with SSS or AV block or both, mean age 73 (+/-10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Physiological' pacemaker (dual or atrial, some rate-adaptive) versus single chamber ventricular pacemakers (some rate-adaptive)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Atrial fibrillation, stroke, heart failure, mortality, complication rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Device randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davis">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 patients (8 male, 8 female) with AV block, mean age 65 (range 23-84)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>VDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Deharo">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 patients (14 male, 4 female) with AV block, <BR/>mean age 70 (+/-6.5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hargreaves">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 patients (14 male, 6 female) with AV block, <BR/>mean age 80.5 (+/-1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heldman">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 patients (23 male, 17 female) with AV block or SSS or both, <BR/>mean age 68 (+/-10, range 47-86)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD, DDI versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-H_x00f6_ijer">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>19 patients (13 male, 6 female) with AV block or SSS, <BR/>mean age 75.5 (+/-7.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR, DDIR versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kamalvand">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 patients (28 male, 20 female) with AV block or SSS or both, <BR/>mean age 64 (+/-13)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR, DDDR with mode switching versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kenny">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 patients (4 male, 6 female) with AV block or SSS or both, <BR/>mean age 69.7 (+/-10.4, range 52-83)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD(100), DDD(150) versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kristensson">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>44 patients (22 male, 22 female) with AV block, <BR/>mean age 68 (+/-13, range 18-84)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>VDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lau-_x0028_1_x0029_">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 patients (male/female not specified) with SSS, mean age 66 (+/-2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR versus VVIR, AAIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lau-_x0028_2_x0029_">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>33 patients (male/female not specified) with AV block or SSS, mean age 66 (+/-1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD, DDDR versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Linde_x002d_Edelstam">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 patients (13 male, 4 female) with AV block, <BR/>mean age 64 (+/-11)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lukl">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 patients (male/female not specified) with AV block or SSS, mean age 68 (+/-8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mattioli">
<CHAR_METHODS>
<P>Parallel randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>210 patients (113 male, 97 female) with SSS or AV block, mean age 79 (+/-9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Physiological' pacemaker (DDD, VDD, AAI) versus VVI, VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Atrial fibrillation, stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Device randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Menozzi">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 patients (4 male, 10 female) with AV block, <BR/>mean age 72 (+/-6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mitsuoka">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 patients (14 male, 2 female) with AV block or SSS, mean age 64.1 (+/-12.2) AV block, 63.3 (+/-13.1) SSS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-MOST">
<CHAR_METHODS>
<P>Parallel randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>2010 patients (1045 male, 965 female) with SSS (21% also AV block), median age 74</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life, complication rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Oldroyd">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 patients (7 male, 3 female) with AV block, <BR/>mean age 56 (range 32-87)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PASE">
<CHAR_METHODS>
<P>Parallel randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>407 patients (60% male, 40% female) with SSS or AV block, mean age 76 (+/-7)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Perrins">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>13 patients (9 male, 4 female) with AV block, <BR/>mean age 65 (range 32-87)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>VDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rediker">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>19 patients (15 male, 4 female) with AV block or SSS, mean age 69.5 (35-83)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saner-and-Fricker">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 patients (7 male, 5 female) with AV block or SSS, mean age 68 (range 36-80)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sulke-1991">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 patients (9 male, 13 female) with AV block or AV block with SSS, mean age 51.9 (range 18-81)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD, DDIR, DDDR versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sulke-1992">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 patients (11 male, 5 female) with AV block or AV block with SSS, mean age 66.6 (range 41-84)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sulke-1994">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 patients (6 male, 4 female) with AV block or AV block with SSS, mean age 53 (+/-9.4, range 42-67)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR verus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wharton">
<CHAR_METHODS>
<P>Parallel randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>198 patients (109 male, 89 female) with SSS (with tachybrady syndrome), median age 72</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDDR versus VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yee">
<CHAR_METHODS>
<P>Crossover randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 patients (4 male, 4 female) with AV block , mean age 58.9 (+/-18.4)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>VDD versus VVI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pacemaker syndrome, exercise capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mode randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abe-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Adinolfi-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aggarwal-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ahern-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alpert-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alpert-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Amici-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azam-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baldo-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barrington-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Batey-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Been-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blanc-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bosch-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bren-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brignole-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brignole-1989a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brignole-1989b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brignole-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, indication for pacing other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brignole-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brunner_x002d_La-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabello-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabello-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Candinas-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chabernaud-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Channon-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>1st part of study less than 48 hours duration, 2nd part of study also reported in study included in this review (Channon et al., 1994)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chauhan-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chida-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Copperman-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daubert-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davies-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeFilippi-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Douard-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dritsas-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eagle-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ebagosti-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faerestrand-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fananapazir-1983a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fananapazir-1983b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faria-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fishberger-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block. Pacing following surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-French-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frielingsdorf-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fromer-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fukumoto-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fukuoka-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallik-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ghio-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gold-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gold-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Griebenow-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Griebenow-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hedman-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hedman-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoeschen-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horie-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ijiri-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iliev-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishikawa-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishikawa-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishikawa-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwase-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iwase-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jordaens-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if inclusion criteria met, author contacted but no reply received</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1992a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1992b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1992c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jutzy-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kamalvand-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication for pacing other than SSS or AV block.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kano-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kargul-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kikis-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolettis-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolettis-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolettis-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koller-1996-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if inclusion criteria met (regarding underlying indication), author contacted, no reply received</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koller-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if inclusion criteria met (regarding underlying indication), author contacted, no reply received</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kristensson-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kristensson-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kristensson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kruse-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kyriakides-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant. Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Labovitz-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamaison-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lascault-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lau-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-LaVilla-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant. Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leclercq-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leclercq-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leman-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lemke-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linde_x002d_Edelstam-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lo-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lo-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lotto-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Love-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lukl-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lukl-1992a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lukl-1992b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lukl-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madigan-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block, outcome assessed not relevant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmud-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahy-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maity-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maity-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manolis-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manolis-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Markewitz-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maron-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martinelli-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maseki-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattioli-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattioli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattioli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McIntosh-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McMeekin-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meisel-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mizutani-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielsen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielson-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishimura-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishimura-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nitsch-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nitsch-1984a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nitsch-1984b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noll-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nordlander-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>VVI versus VAT modes compared, duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nowak-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Occhetta-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Occhetta-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oldroyd-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplication (abstract only) of Oldroyd 1991 included in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ovsyshcher-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ovsyshcher-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papadopoulos-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payne-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payne-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Payne-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pearson-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pehrsson-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pehrsson-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perrins-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Proctor-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Providencia-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reynolds-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rickli-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ritter-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roelke-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romero-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romero-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosenqvist-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saccomamo-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saccomanno-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sack-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samoil-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indication other than SSS or AV block, outcome asssessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Santini-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schofield-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwaab-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Paper unobtainable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sedney-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shigemura-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simantirakis-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Snoeck-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sparks-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sparks-PB_x002c_-Mond2">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stangl-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stewart-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stierle-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stojnic-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stone-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sulke-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takeuchi-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tani-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taylor-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theodorakis-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theodorakis-1992a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Theodorakis-1992b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vardas-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vardas-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vardas-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of study less than 48 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Videen-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Von-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wakakura-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whiting-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yoshida-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yoshitomi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, outcome assessed not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Nielsen">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-CTOPP-extended">
<CHAR_STUDY_NAME>
<P>Canadian Trial of Physiologic Pacing Investigators</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>2568 patients with SSS, AV block or both</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Physiological versus ventricular pacemakers</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>mortality and stroke; atrial fibrillation, heart failure, complication rate</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>First part of trial completed; included in this review (Connolly 2000)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>S Connolly, Department of Medicine, McMaster University, Hamilton, Ontario, Canada</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Follow-up extended from 3-6 years; additional data expected 2003</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-DANPACE">
<CHAR_STUDY_NAME>
<P>Danish multicentre study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>1900 patients with SSS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>AAI versus dual chamber pacing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Total mortality</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>350 patients randomised February 2001 (active recruitment ongoing)</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>HR Anderson, Department of Cardiology, Skejby Sygehus, Arhus, Denmark</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Recruitment expected to last 6 years; follow-up of 5.5 years planned</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-STOP_x002d_AF">
<CHAR_STUDY_NAME>
<P>Systematic trial of pacing to prevent atrial fibrillation</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>235 patients with SSS (mean age 73)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>AAI(R) or DDD(R) versus VVI(R)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Atrial fibrillation, pacemaker syndrome, worsening congestive heart failure</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Trial ongoing in 2001; no data identified at time of completion of the report</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>RG Charles, Cardiothoracic Centre, Liverpool NHS Trust, Thomas Drive, Liverpool, UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-UKPACE">
<CHAR_STUDY_NAME>
<P>The UK pacing and cardiovascular events trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>2000 patients &gt;/= 70 years with AV block</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>DDD versus VVI or VVIR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All cause mortality, quality of life, exercise capacity, cardiovascular events, cost-utility</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Study completed; data expected to become available 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>WD Toff, Department of Cardiology, Glenfield Hospital, Leicester, UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Avery">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boon">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-CTOPP">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Capucci">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Channon">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davis">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deharo">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hargreaves">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heldman">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-H_x00f6_ijer">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kamalvand">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kenny">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kristensson">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lau-_x0028_1_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lau-_x0028_2_x0029_">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Linde_x002d_Edelstam">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lukl">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-MOST">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mattioli">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menozzi">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mitsuoka">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Oldroyd">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-PASE">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Perrins">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rediker">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saner-and-Fricker">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sulke-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sulke-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sulke-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wharton">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yee">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="1">
<TITLE>Glossary</TITLE>
<TABLE COLS="2" ROWS="23">
<TR>
<TH>
<P>Term or abbreviation</P>
</TH>
<TH>
<P>Description</P>
</TH>
</TR>
<TR>
<TD>
<P>A</P>
</TD>
<TD>
<P>Atrium</P>
</TD>
</TR>
<TR>
<TD>
<P>V</P>
</TD>
<TD>
<P>Ventricle</P>
</TD>
</TR>
<TR>
<TD>
<P>D</P>
</TD>
<TD>
<P>Dual (atrium and ventricle)</P>
</TD>
</TR>
<TR>
<TD>
<P>I</P>
</TD>
<TD>
<P>Inhibited: a type of pacemaker response in which the output pulse is suppressed (or inhibited) when an intrinsic event is sensed</P>
</TD>
</TR>
<TR>
<TD>
<P>R</P>
</TD>
<TD>
<P>Rate modulation: the ability of pacemakers to increase the pacing rate in response to physical activity or metabolic demand</P>
</TD>
</TR>
<TR>
<TD>
<P>Sensing</P>
</TD>
<TD>
<P>Refers to the detection of spontaneous cardiac depolarisations</P>
</TD>
</TR>
<TR>
<TD>
<P>Tracking</P>
</TD>
<TD>
<P>A dual-chamber pacing function in which atrial activity is sensed and results in a paced ventricular response after a predefined delay (the AV interval)</P>
</TD>
</TR>
<TR>
<TD>
<P>Physiological mode</P>
</TD>
<TD>
<P>Single chamber atrial pacing and dual chamber pacing are often referred to as 'physiological modes' as they more closely mimic normal cardiac physiology (including AV synchrony)</P>
</TD>
</TR>
<TR>
<TD>
<P>AAI</P>
</TD>
<TD>
<P>Single chamber atrial pacing; one lead is positioned in the atrium; pacing and sensing occurs in the atrium; atrial pacing is inhibited by sensed spontaneous atrial depolarisations; no rate modulation or multi-site pacing</P>
</TD>
</TR>
<TR>
<TD>
<P>AAIR</P>
</TD>
<TD>
<P>Single chamber atrial pacing as above but with rate modulation</P>
</TD>
</TR>
<TR>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Single chamber ventricular pacing; one lead is positioned in the ventricle; pacing and sensing occurs in the ventricle; ventricular pacing is inhibited by sensed spontaneous ventricular depolarisations; no rate modulation or multi-site pacing; loss of AV synchrony may occur with this pacing mode; may be referred to as 'non-physiological' pacing</P>
</TD>
</TR>
<TR>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Single-chamber ventricular pacing as above but with rate response</P>
</TD>
</TR>
<TR>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>Dual chamber pacing; use of two leads, one in the atrium and one in the ventricle; pacing and sensing occurs in both the atrium and the ventricle; in the absence of intrinsic activity, both chambers are paced at the programmed base rate; normally inhibited by atrial or ventricular sensing, and with ventricular pacing triggered by atrial sensing; no rate modulation or multi-site pacing</P>
</TD>
</TR>
<TR>
<TD>
<P>DDDR</P>
</TD>
<TD>
<P>Dual chamber as above but with rate modulation</P>
</TD>
</TR>
<TR>
<TD>
<P>DDI</P>
</TD>
<TD>
<P>Dual chamber pacing without atrial tracking</P>
</TD>
</TR>
<TR>
<TD>
<P>DDIR</P>
</TD>
<TD>
<P>Dual chamber pacing without atrial tracking, but with rate modulation</P>
</TD>
</TR>
<TR>
<TD>
<P>VDD</P>
</TD>
<TD>
<P>Ventricular pacing, triggered by atrial sensing, inhibited by ventricular sensing, no atrial pacing</P>
</TD>
</TR>
<TR>
<TD>
<P>AV synchrony</P>
</TD>
<TD>
<P>Normal sequence of atrial depolarisation and contraction followed by ventricular depolarisation and contraction; maintenance of this sequence results in optimal ventricular filling and cardiac output</P>
</TD>
</TR>
<TR>
<TD>
<P>Multi-site pacing</P>
</TD>
<TD>
<P>Refers to additional stimulation sites:A: stimulation sites in each atrium, more than one stimulation site in either atrium, or any combination of the two; V: stimulation sites in each ventricle, more than one stimulation site in either ventricle, or any combination of the two;D: any combination of V and A</P>
</TD>
</TR>
<TR>
<TD>
<P>BPEG</P>
</TD>
<TD>
<P>British Pacing and Electrophysiology Group</P>
</TD>
</TR>
<TR>
<TD>
<P>NASPE</P>
</TD>
<TD>
<P>North American Society of Pacing and Electrophysiology</P>
</TD>
</TR>
<TR>
<TD>
<P>NBG</P>
</TD>
<TD>
<P>NASPE/BPEG Generic Code</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="2">
<TITLE>Revised NBG Code for Pacing Modes</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TH>
<P>Chamber being paced</P>
</TH>
<TH>
<P>Chamber being sensed</P>
</TH>
<TH>
<P>Response to sensing</P>
</TH>
<TH>
<P>Rate modulation</P>
</TH>
<TH>
<P>Multisite pacing</P>
</TH>
</TR>
<TR>
<TD>
<P>O=none</P>
</TD>
<TD>
<P>O=none</P>
</TD>
<TD>
<P>O=none</P>
</TD>
<TD>
<P>O=none</P>
</TD>
<TD>
<P>O=none</P>
</TD>
</TR>
<TR>
<TD>
<P>A=atrium</P>
</TD>
<TD>
<P>A=atrium</P>
</TD>
<TD>
<P>I=inhibited</P>
</TD>
<TD>
<P>R=rate modulation</P>
</TD>
<TD>
<P>A=atrium</P>
</TD>
</TR>
<TR>
<TD>
<P>V=ventricle</P>
</TD>
<TD>
<P>V=ventricle</P>
</TD>
<TD>
<P>T=triggered</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>V=ventricle</P>
</TD>
</TR>
<TR>
<TD>
<P>D=dual (A + V)</P>
</TD>
<TD>
<P>D=dual (A + V)</P>
</TD>
<TD>
<P>D=dual (T + I)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>D=dual (A + V)</P>
</TD>
</TR>
<TR>
<TD>
<P>Manufacturers' designation only: S=single (A or V)</P>
</TD>
<TD>
<P>Manufacturers' designation only: S=single (A or V)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Foot note: "Multi site pacing" Refers to additional stimulation sites:A: stimulation sites in each atrium, more than one stimulation site in either atrium, or any combination of the two; V: stimulation sites in each ventricle, more than one stimulation site in either ventricle, or any combination of the two;</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="3">
<TITLE>Pacemaker syndrome results crossover studies</TITLE>
<TABLE COLS="8" ROWS="26">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Assessment tool</P>
</TH>
<TH>
<P>Outcome measure</P>
</TH>
<TH>
<P>Single chamber</P>
</TH>
<TH>
<P>Dual chamber</P>
</TH>
<TH>
<P>Stat significance</P>
</TH>
<TH>
<P>Direction of effect</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>Avery et al., 1994</P>
</TD>
<TD>
<P>Questionnaire on 11 symptoms based on Minnesota 'Living with heart failure' questionnaire re symptoms and ability to carry out daily tasks (0-5 score), max score 55. Low score = good sense of well-being.</P>
</TD>
<TD>
<P>Group mean (SD) for total symptom score</P>
</TD>
<TD>
<P>VVI<BR/>
<BR/>28 (10)</P>
</TD>
<TD>
<P>DDD/VDD<BR/>
<BR/>19 (5)</P>
</TD>
<TD>
<P>p&lt;0.05</P>
</TD>
<TD>
<P>Fewer symptoms of pacemaker syndrome and better ability to carry out daily tasks in DDD/VDD mode compared to VVI mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Boon et al., 1987</P>
</TD>
<TD>
<P>Questionnaire on 4 symptoms (shortness of breath, dizziness, fatigue, general well-being) scored from 0-10 on visual analogue scale. High score = good sense of well-being; more severe symptoms.</P>
</TD>
<TD>
<P>Group median, interquartile range (IR) and full range (FR) for individual symptoms <BR/>
<BR/>Shortness of breath<BR/>
<BR/>Dizziness<BR/>
<BR/>Fatigue<BR/>
<BR/>General well-being</P>
</TD>
<TD>
<P>VVI<BR/>
<BR/>
<BR/>
<BR/>
<BR/>2.21 IR 1.0-4.10 <BR/>FR 0-9.62 <BR/>0.32 IR 0-1.0 <BR/>FR 0-9.87 <BR/>0.28 IR 0.13-4.77 <BR/>FR 0-9.74 <BR/>9.52 IR 5.45-9.81 <BR/>FR 3.37-9.74</P>
</TD>
<TD>
<P>DDD<BR/>
<BR/>
<BR/>
<BR/>
<BR/>1.15 IR 0-2.18 <BR/>FR 0-6 <BR/>0.06 IR 0-0.29 <BR/>FR 0-4.49 <BR/>0.13 IR 0-1.99 <BR/>FR 0-7.95 <BR/>7.21 IR 8.65-9.93 <BR/>FR 5.38-9.93 <BR/>
</P>
</TD>
<TD>
<P>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>p&lt;0.05<BR/>
<BR/>p&lt;0.05<BR/>
<BR/>p&lt;0.05<BR/>
<BR/>p&lt;0.05</P>
</TD>
<TD>
<P>Fewer symptoms of pacemaker syndrome and higher level of well-being in DDD mode compared to VVI mode.</P>
</TD>
<TD>
<P>Data estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Capucci et al., 1993</P>
</TD>
<TD>
<P>Questionnaire on 8 symptoms (shortness of breath at rest, shortness of breath on exercise, neck pulsation, palpitation, chest pain at rest, chest pain on exercises, fainting, dizziness) scored 1-5 for frequency or degree of discomfort. 1=least discomfort.</P>
</TD>
<TD>
<P>Group mean (?) for total symptoms.NB: not clear whether SD calculated. No individual patient data.</P>
</TD>
<TD>
<P>VVIR<BR/>
<BR/>25.5 (5.4)</P>
</TD>
<TD>
<P>DDD<BR/>
<BR/>19.0 (3.1)<BR/>
<BR/>DDDR<BR/>
<BR/>17.8 (1.8)</P>
</TD>
<TD>
<P>DDD versus VVIR p&lt;0.01<BR/>
<BR/>DDDR versus VVIR<BR/>p&lt;0.01<BR/>
</P>
</TD>
<TD>
<P>Fewer symptoms of pacemaker syndrome in DDD and DDDR mode compared to VVIR mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Channon et al.,1994</P>
</TD>
<TD>
<P>Questionnaire on 7 symptoms (breathlessness, pulsation in neck, dizziness, blackout, wheeze, fatigue, palpitation) scored from 0-5 on visual analogue scale. (0=not at all, 5=very severe)</P>
</TD>
<TD>
<P>Group mean (SD) for total symptoms<BR/>group means (SD) for dizziness <BR/>fatigue <BR/>breathlessness</P>
</TD>
<TD>
<P>VVI<BR/>9.4 (5.67)<BR/>
<BR/>1.73 (1.71)<BR/>2.13 (1.69)<BR/>3.00 (1.89)</P>
</TD>
<TD>
<P>DDD<BR/>4.73 (4.40)<BR/>
<BR/>0.47 (0.92)<BR/>1.20 (1.42)<BR/>1.80 (1.66)</P>
</TD>
<TD>
<P>
<BR/>p&lt;0.006<BR/>
<BR/>p&lt;0.007<BR/>p=0.01<BR/>p&lt;0.03</P>
</TD>
<TD>
<P>Fewer symptoms of pacemaker syndrome in DDD mode compared to VVI mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Davis et al., 1985</P>
</TD>
<TD>
<P>Davis et al., 1985 Daily symptom diaries on 10 symptoms (chest pain, chest discomfort, dizziness, blurred vision, palpitation, dyspnoea at rest, dyspnoea on exertion, disturbed sleep, pulsating sensation in neck, pulsating sensation in abdomen)</P>
</TD>
<TD>
<P>Group mean episodes per week <BR/>chest pain and/or discomfort<BR/>dizziness<BR/>palpitation<BR/>dyspnoea at rest<BR/>dyspnoea on exertion<BR/>
<BR/>no SD or SE stated</P>
</TD>
<TD>
<P>VVI<BR/>
<BR/>1.7<BR/>2.2<BR/>1.0<BR/>1.5<BR/>7.3</P>
</TD>
<TD>
<P>VDD<BR/>
<BR/>1.5<BR/>0.8<BR/>1.0<BR/>0.2<BR/>2.2</P>
</TD>
<TD>
<P>
<BR/>
<BR/>NS<BR/>NS<BR/>NS<BR/>NS<BR/>NS</P>
</TD>
<TD>
<P>Fewer episodes per week of 4 symptoms of pacemaker syndrome in VDD mode compared to VVI mode. One symptom of pacemaker syndrome occurred at equal frequency in both modes.Results not listed for all symptoms.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Deharo et al., 1996</P>
</TD>
<TD>
<P>5 symptoms (sleep disturbance, chest pain, palpitation, dizziness, neck pulsations) scored 0-3. 0=no symptoms, 3=very frequent symptoms</P>
</TD>
<TD>
<P>Group mean (SD) forSleep disturbanceChest painPalpitationDizzinessNeck pulsations</P>
</TD>
<TD>
<P>VVIR1.13 (1.46)0.5 (0.91)0.6 (1.3)0.53 (0.91)0.33 (0.72)</P>
</TD>
<TD>
<P>DDD1.3 (1.44)0.2 (0.56)0.33 (0.72)0.14 (0.52)0.2 (0.56)</P>
</TD>
<TD>
<P>NSNSNSNSNS</P>
</TD>
<TD>
<P>Lower overall symptom score for 4 symptoms (chest pain, palpitation, dizziness, neck pulsations) in DDD mode compared to VVIR mode. One higher overall symptom score in DDD mode compared to VVI mode (sleep disturbance). No statistical significance for any differences.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hargreaves et al., 1995</P>
</TD>
<TD>
<P>Questionnaire on frequency and severity of 8 symptoms (breathlessness pulsation, dizziness, blackout, wheeze, fatigue, palpitation, cough) scored 0-5 each on analogue scale. (0=none, 5=very severe) </P>
</TD>
<TD>
<P>Group mean (SE) Means (SE) for groups according to pacing order: DDD/VVIRMeans (SE) for groups according to pacing order: VVIR/DDD</P>
</TD>
<TD>
<P>VVIR5.2 (0.8) 6.3 (1.0)2.7 (2.0)</P>
</TD>
<TD>
<P>DDD2.9 (0.8) 2.9 (1.0)3.9 (1.0)</P>
</TD>
<TD>
<P>p&lt;0.05p&lt;0.05NS</P>
</TD>
<TD>
<P>Overall significantly lower score for 8 symptoms of pacemaker syndrome in DDD mode compared to VVIR mode.Difference not significant if paced in VVIR mode first.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Heldman et al., 1990</P>
</TD>
<TD>
<P>Questionnaire on presence and severity of 16 symptoms (shortness of breath, fatigue, dizziness, apprehension, cough, pulsations in neck/abdomen, orthopnea, headache, palpitation, chest pain, choking sensation, confusion, pedal edema, sensation of tachycardia, chest congestion, diaphoresis) scored 0-10. 0=not present, 10=very severe.</P>
</TD>
<TD>
<P>Group mean(SD) for total and individual symptoms.Total symptoms Shortness of breathFatigueDizzinessApprehensionCoughPulsation in neck/abdomenOrthopneaHeadachePalpitationsChest PainChoking SensationConfusionPedal EdemaSensation of TachycardiaChest CongestionDiaphoresis</P>
</TD>
<TD>
<P>VVI29.0 (26.1)3.3 (3.1)4.8 (3.5)2.9 (3.6)3.0 (3.6)1.7 (2.5)2.0 (3.2)1.3 (2.5)1.3 (2.3)1.5 (3.0)1.4 (2.6)1.3 (2.9)0.9 (2.2)0.9 (2.3)1.1 (2.5)1.1 (1.9)0.7 (2.3)</P>
</TD>
<TD>
<P>DDD/DDI7.3 (12.4)0.8 (1.8)1.3 (2.3)0.8 (1.3)0.3 (0.8)0.4 (1.6)0.4 (1.1)0.3 (1.3)0.5 (0.9)0.5 (1.0)0.4 (1.2)0.3 (1.2)0.2 (0.6)0.3 (0.9)0.4 (1.4)0.5 (1.6)0.1 (0.2)</P>
</TD>
<TD>
<P>p&lt;0.001p&lt;0.001p&lt;0.001p&lt;0.001p&lt;0.001p=0.001p=0.002p&lt;0.02p&lt;0.02p&lt;0.04p&lt;0.04p&lt;0.04p&lt;0.05NSNSNSNS</P>
</TD>
<TD>
<P>Lower symptom score in DDD/DDI mode compared to VVI mode for all 16 symptoms. Significant difference for 12 out of 16 symptoms.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kamalvand et al., 1997</P>
</TD>
<TD>
<P>Questionnaire on 11 cardiovascular related symptoms, score 0-84 (score &gt;/= 25 indicative of pacemaker syndrome)</P>
</TD>
<TD>
<P>Group mean (SD) total symptom score</P>
</TD>
<TD>
<P>VVIR26.8 (15.3)</P>
</TD>
<TD>
<P>DDDR22.3 (12.2)MS DDDR21.2 (12.4)</P>
</TD>
<TD>
<P>MS DDDR versus VVIR (p=0.01)</P>
</TD>
<TD>
<P>Higher symptom score in VVIR mode compared to dual modes.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kenny et al., 1996</P>
</TD>
<TD>
<P>Diary card on daily frequency of 3 symptoms (chest pain, dizziness, palpitation);Symptom score for 4 symptoms (chest pain, dizziness, palpitation, syncope) compared to previous crossover period (scale 1-5, 1=much worse, 5=much improved)</P>
</TD>
<TD>
<P>Group mean (SD) for episodes per week PalpitationDizzinessChest PainNumber of patients with specific score: 12345</P>
</TD>
<TD>
<P>VVI019.13 13.00 32302</P>
</TD>
<TD>
<P>DDD(100) DDD(150)0.94 0.604.25 4.967.09 25.750 21 11 34 14 3</P>
</TD>
<TD>
<P>VVI versus DDD (100) and DDD (150) for dizziness p&lt;0.01<BR/>
<BR/>DDD (150) vs DDD (100) for chest pain p&lt;0.01<BR/>
<BR/>VVI versus DDD (100) for chest pain p&lt;0.02</P>
</TD>
<TD>
<P>Highest number of episodes per week in DDD (150) compared to DDD (100) and VVI. Fewer episodes per week for dizziness in dual modes compared to VVI. Similar levels for palpitations (dual modes slightly higher). Number of patients improving on their symptom score compared to previous crossover period is slightly higher in DDD (150) mode compared to VVI mode and highest in DDD (100) mode.</P>
</TD>
<TD>
<P>Group means estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Kristensson et al., 1985</P>
</TD>
<TD>
<P>Questionnaire on frequency and severity of 9 symptoms (palpitation, dizziness, syncope, pulsation in neck, fluttering before eyes, chest pain at rest, chest pain on exercise, dyspnoea at rest, dyspnoea on exercise) based on visual analogue scale (0-10). 0=no symptoms, 10=extreme symptoms.Total number of patients reporting symptoms.</P>
</TD>
<TD>
<P>Group means for individual symptoms PalpitationDizzinessSyncopePulsation in neckEye flutterChest pain at restChest pain on exerciseDyspnoea at restDyspnoea on exerciseTotal number of patients with symptoms in each group:PalpitationDizzinessSyncopePulsation in neckEye flutterChest pain at restChest pain on exerciseDyspnoea at restDyspnoea on exercise</P>
</TD>
<TD>
<P>VVI75.61 29.27 12.20 68.77 18.29 24.39 30.00 20.24 134.15 1712418898933</P>
</TD>
<TD>
<P>VDD26.83 15.85 1.22 30.49 9.76 4.88 23.17 4.88 65.09 107111649125</P>
</TD>
<TD>
<P>p&lt;0.01NSNSp&lt;0.05NS p&lt;0.05NSNSp&lt;0.001</P>
</TD>
<TD>
<P>Lower symptom score in VDD mode compared to VVI mode for 9 symptoms of pacemaker syndrome. Difference is significant for 4 symptoms (palpitation, pulsation in neck, chest pain at rest and dyspnoea on exercise). Fewer patients with symptoms in VDD group (for 8 of the 9 symptoms). One more patient with chest pain on exercise in the VDD group compared to the VVI group.</P>
</TD>
<TD>
<P>Group means estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (1)</P>
</TD>
<TD>
<P>Questionnaire on incidence and frequency of 6 symptoms (dyspnoea, palpitation, dizziness, chest pain, sleep disturbance, neck pulsations) scored 1-5 (1=all of the time, 5=never)</P>
</TD>
<TD>
<P>Group mean for individual symptomsDyspnoeaPalpitationDizzinessChest painSleep disturbanceNeck pulsations</P>
</TD>
<TD>
<P>VVIR3.42 3.00 3.80 4.27 3.96 4.67 AAIR4.00 4.00 3.90 4.67 4.67 5.00</P>
</TD>
<TD>
<P>DDDR3.42 4.30 4.30 4.60 4.25 5.00</P>
</TD>
<TD>
<P>VVIR versus AAIR for palpitation p&lt;0.05<BR/>VVIR versus DDDR for palpitation <BR/>p&lt;0.001</P>
</TD>
<TD>
<P>Lower incidence of symptoms in DDDR and AAIR mode (for 5 out of 6 symptoms) compared to VVIR.</P>
</TD>
<TD>
<P>Data estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (2)</P>
</TD>
<TD>
<P>Physical Malaise Inventory (41 items). Higher numerical score indicates less severe symptoms. Results given for pain, dyspnoea, temperature intolerance, epigastric pain and palpitation only.</P>
</TD>
<TD>
<P>Group mean for individual symptoms<BR/>Pain<BR/>Dyspnoea<BR/>Temperature intolerance<BR/>Epigastric pain<BR/>Palpitation</P>
</TD>
<TD>
<P>VVIR<BR/>
<BR/>1.72<BR/>1.83<BR/>1.63<BR/>1.85<BR/>1.81</P>
</TD>
<TD>
<P>DDD DDDR<BR/>
<BR/>1.55 1.89<BR/>1.85 2.00<BR/>1.63 1.91<BR/>1.93 1.99<BR/>1.84 1.98</P>
</TD>
<TD>
<P>p&lt;0.01 DDD versus DDD for pain; p&lt;0.05 DDDR versus DDD and DDDR versus VVIR for dyspnoea; p&lt;0.01 DDDR versus DDD and DDDR versus VVIR for temperature intolerance; p&lt;0.05 DDDR versus VVIR for epigastric pain; p&lt;0.05 &amp; p&lt; 0.01 DDDR versus VVIR &amp; DDDR versus VVIR for palpitation</P>
</TD>
<TD>
<P>Significantly fewer symptoms in DDDR mode compared to VVIR mode and for DDDR compared to DDD mode for 4 of 5 symptoms.</P>
</TD>
<TD>
<P>Data estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Linde-Edelstam et al., 1992</P>
</TD>
<TD>
<P>Questionnaire on 4 symptoms (breathlessness, dizziness, chest pain, palpitation) on visual analogue scale (increasing no of mm=progressive severity of symptroms)</P>
</TD>
<TD>
<P>Group mean (SD) individual symptom scoreBreathlessnessDizzinessChest painPalpitation</P>
</TD>
<TD>
<P>VVIR18.1 (14.3)15.2 (22.6)6.8 (8.9)6.3 (15.2)</P>
</TD>
<TD>
<P>DDD9.5 (8.5)4.8 (8.5)2.6 (2.5)2.8 (8.1)</P>
</TD>
<TD>
<P>p=0.02 p=0.04p=0.06 p=0.03</P>
</TD>
<TD>
<P>Fewer symptoms of pacemaker syndrome (breathlessness, dizziness, chest pain, palpitation) in DDD mode than VVIR mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Lukl et al., 1994</P>
</TD>
<TD>
<P>Questionnaire consisting of 19 questions, 11 of which relate to cardiovascular symptoms, on 6 point scale (0=optimal state, 6=worst state)</P>
</TD>
<TD>
<P>Group mean (SD) individual symptom scoreSwollen anklesBreathlessness at restBreathlessness during physical exertionOverexertion during household choresFatigueInsomniaDizzy spellsTrouble with memory and concentrationTightness in chestPalpitationSweating</P>
</TD>
<TD>
<P>VVIR0.9 (1.3)0.6 (1.3)3.2 (1.5)2.6 (1.4)2.7 (1.5)1.7 (1.5)1.7 (1.6)0.6 (0.9)0.8 (1.3)3.2 (1.8)2.4 (1.8)</P>
</TD>
<TD>
<P>DDD1.0 (1.3)1.0 (1.3)2.2 (1.6)1.6 (1.3)1.7 (1.6)1.9 (1.7)0.3 (0.8)1.0 (1.2)1.3 (1.7)0.9 (1.2)1.3 (1.3)</P>
</TD>
<TD>
<P>NSNSp&lt;0.02p&lt;0.01p&lt;0.02NS p&lt;0.005NSNSp&lt;0.005 p&lt;0.005</P>
</TD>
<TD>
<P>Significantly lower symptom score in DDD mode compared to VVIR mode for 6 out of 11 symptoms listed.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Menozzi et al., 1990</P>
</TD>
<TD>
<P>Questionnaire on 6 symptoms (palpitation, dizziness, pulsating sensation in neck or abdomen, shortness of breath at rest, shortness of breath on effort, chest pain) scored 1-5 (1=slight and occasional,5=severe and almost persistent)NB: no SD for individual symptoms stated</P>
</TD>
<TD>
<P>Group mean individual symptom scorePalpitationDizzinessPulsating sensationShortness of breath (rest)Shortness of breath (effort)Chest pain</P>
</TD>
<TD>
<P>VVIR199149271</P>
</TD>
<TD>
<P>DDD5201110</P>
</TD>
<TD>
<P>p=0.04NSp=0.05NSp=0.02NS</P>
</TD>
<TD>
<P>Significantly lower scores in DDD compared to VVIR mode for 3 out of 6 symptoms.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mitsuoka et al., 1988</P>
</TD>
<TD>
<P>5 symptoms (general well-being, shortness of breath, chest pain, dizziness, palpitation) scored 1-5 compared to previous month (1=much worse, 5=much improved);weekly attack rates (chest pain, dizziness, palpitation)</P>
</TD>
<TD>
<P>Group mean (SD)General well-beingShortness of breathChest painDizziness PalpitationAttacks/week group mean (SD)Chest painDizzinessPalpitation</P>
</TD>
<TD>
<P>VVI2.061.94 (0.85)3.06 (1.00)2.56 (0.51)2.44 (0.89)1.470.53.66</P>
</TD>
<TD>
<P>DDD3.373.44 (0.73)2.87 (0.62)3.25 (0.45)3.25 (0.77)1.590.340.33</P>
</TD>
<TD>
<P>p&lt;0.01p&lt;0.01NSp&lt;0.01p&lt;0.01NSNSNS</P>
</TD>
<TD>
<P>Significantly higher scores in DDD mode compared to VVI mode for 4/5 symptoms; higher symptom score for chest pain in DDD mode.Differences in attack rates not significant</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Oldroyd et al., 1991</P>
</TD>
<TD>
<P>Questionnaire comprising 3 sets of 8 questions relating to dyspnoea, fatigue and mood disturbance, scored on 100mm visual analogue scale. Maximum score of 800.</P>
</TD>
<TD>
<P>Estimated group means (SD)DyspnoeaFatigueMood disturbance</P>
</TD>
<TD>
<P>VVIR153.12 (119.12)240.62 (196.00)106.94 (57.65)</P>
</TD>
<TD>
<P>DDD133.68 (111.44)170.14 (138.35)85.07 (65.33)</P>
</TD>
<TD>
<P>NSNSNS</P>
</TD>
<TD>
<P>Lower symptom score in DDD mode, although not statistically significant.</P>
</TD>
<TD>
<P>Data estimated from graph</P>
</TD>
</TR>
<TR>
<TD>
<P>Perrins et al., 1983</P>
</TD>
<TD>
<P>Daily diary card of symptoms (cheat pain, dizziness, palpitation, syncope)Subjective symptom score at end of crossover period regarding improvement for chest pain, dizziness, shortness of breath, palpitation and general well-being, scored 1-5 (1=much worse, 5=much improved)</P>
</TD>
<TD>
<P>Group mean (SD) for weekly attack ratesChest painDizzinessPalpitationSyncopeGroup mean (SD) symptom scoreGeneral well-beingShortness of breathSyncopeDizzinessPalpitationChest pain</P>
</TD>
<TD>
<P>VVI1.08 (1.30)2.49 (4.7)1.76 (2.86)01.72 (0.6)2.0 (0.91)3.02.3 (0.91)2.6 (0.69)2.9 (0.31)</P>
</TD>
<TD>
<P>VDD1.16 (2.01)1.45 (2.67)0.35 (1.22)03.54 (0.8)3.45 (0.8)3.03.5 (0.7)3.3 (0.67)3.1 (1.1)</P>
</TD>
<TD>
<P>NSNSp&lt;0.05NSp&lt;0.01p&lt;0.01NSp&lt;0.02p&lt;0.05NS</P>
</TD>
<TD>
<P>Similar weekly attack rates in VVI and VDD mode for 3/4 symptoms; higher rate of attack in VVI mode for palpitation.Improved symptom scores for general well-being, shortness of breath, dizziness and palpitation in VDD mode compared to VVI mode. No difference in symptom score for syncope and chest pain.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rediker et al., 1988</P>
</TD>
<TD>
<P>Questionnaire assessing 5 symptoms (dizziness, weakness, fatigue, shortness of breath, palpitation), scored 1-6 (1=all of the time, 6=none of the time)</P>
</TD>
<TD>
<P>Group mean (SD) symptom scoreFatigueShortness of breathPalpitation</P>
</TD>
<TD>
<P>VVI3.7 (1.2)4.5 (1.1)4.7 (1.5)</P>
</TD>
<TD>
<P>DDD4.3 (1.0)5.2 (0.8)5.8 (0.4)</P>
</TD>
<TD>
<P>p=0.046p=0.01p=0.006</P>
</TD>
<TD>
<P>Significantly fewer symptoms in DDD mode compared to VVI mode.</P>
</TD>
<TD>
<P>No results stated for dizziness or weakness.</P>
</TD>
</TR>
<TR>
<TD>
<P>Saner &amp; Fricker ,1996</P>
</TD>
<TD>
<P>Questionnaire on incidence and frequency of symptoms heart failure and pacemaker syndrome (shortness of breath, palpitation, chest pain, dizziness)</P>
</TD>
<TD>
<P>Group mean (SD) total symptom score</P>
</TD>
<TD>
<P>VVIR5.7 (3.2)</P>
</TD>
<TD>
<P>DDD2.7 (1.6)</P>
</TD>
<TD>
<P>p=0.01</P>
</TD>
<TD>
<P>Significantly fewer symptoms in DDD mode compared to VVIR mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1994</P>
</TD>
<TD>
<P>Questionnaire on 11 cardiovascular related symptoms, scored 0-84 (score&gt;25 indicative of pacemaker syndrome)</P>
</TD>
<TD>
<P>Group mean (SD) total symptom score</P>
</TD>
<TD>
<P>VVIR23.7 (9.8)</P>
</TD>
<TD>
<P>DDDR10.5 (5.5)</P>
</TD>
<TD>
<P>p=0.03</P>
</TD>
<TD>
<P>Significantly fewer symptoms in DDD mode compared to VVIR mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1992</P>
</TD>
<TD>
<P>Questionnaire on 11 cardiovascular related symptoms, scored 0-84 (score&gt;25 indicative of pacemaker syndrome)</P>
</TD>
<TD>
<P>Group mean (SD) total symptom score</P>
</TD>
<TD>
<P>VVI10.45</P>
</TD>
<TD>
<P>DDD DDI4.59 10.22</P>
</TD>
<TD>
<P>p&lt;0.05 for DDD compared to both other modes</P>
</TD>
<TD>
<P>Significantly lower symptom score in DDD mode compared to VVI and DDI modes.</P>
</TD>
<TD>
<P>Data estimated from graph.</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1991</P>
</TD>
<TD>
<P>Questionnaire assessing incidence and frequency of pacemaker syndrome symptoms (including shortness of breath, tiredness, neck flutter and lightheadedness), score 1-5 (1=never, 5=all the time)</P>
</TD>
<TD>
<P>Group mean (SD) total symptom score</P>
</TD>
<TD>
<P>VVIR23.5 (11.5)</P>
</TD>
<TD>
<P>DDD DDDR DDIRmean score only stated: 14.4 (8.1)</P>
</TD>
<TD>
<P>p&lt;0.01 for VVIR compared to mean of all dual modes</P>
</TD>
<TD>
<P>Significantly lower symptom score in dual compared to single mode.</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yee et al., 1984</P>
</TD>
<TD>
<P>Questionnaire assessing functional capacity and presence and frequency of symptoms (including angina, chest pain, dyspnoea, lightheadedness at rest and during exercise), 0=severe limitation in function, 60=absence of symptoms</P>
</TD>
<TD>
<P>Group mean (SD) symptom score</P>
</TD>
<TD>
<P>VVI50.1 (8.4)</P>
</TD>
<TD>
<P>VDD46.9 (8.9)</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Similar symptom scores in VDD and VVI modes</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="4">
<TITLE>Results parallel studies</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Outcome measure</P>
</TH>
<TH>
<P>Single chamber</P>
</TH>
<TH>
<P>Dual chamber</P>
</TH>
<TH>
<P>Stat significance</P>
</TH>
<TH>
<P>Comments</P>
</TH>
</TR>
<TR>
<TD>
<P>CTOPP<BR/>(Connolly et al., 2000, Canada)</P>
</TD>
<TD>
<P>
<BR/>Annual rate of death from all causes (%)<BR/>Annual rate of stroke or death due to cardiovascular causes combined (%)<BR/>Annual rate atrial fibrillation (%)<BR/>Annual rate of stroke (%)<BR/>Annual rate of heart failure (%)</P>
</TD>
<TD>
<P>'Ventricular'<BR/>6.6 (97/1474)<BR/>5.5 (81/1474)<BR/>
<BR/>6.6 (97/1474)<BR/>1.1 (16/1474)<BR/>3.5 (52/1474)</P>
</TD>
<TD>
<P>'Physiologic'<BR/>6.3 (69/1094)<BR/>4.9 (54/1094)<BR/>
<BR/>5.3 (58/1094)<BR/>1.0 (11/1094)<BR/>3.1 (34/1094)</P>
</TD>
<TD>
<P>
<BR/>p=0.34<BR/>p=0.33<BR/>
<BR/>p=0.05<BR/>NS<BR/>p=0.52</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>PASE<BR/>(Lamas et al., 1998, USA)</P>
</TD>
<TD>
<P>
<BR/>n/N cases all-cause mortality (total)<BR/>SSS group<BR/>AV block group<BR/>
<BR/>n/N cases pacemaker syndrome<BR/>n/N cases atrial fibrillation<BR/>SSS group<BR/>AV block group<BR/>
<BR/>n/N cases stroke<BR/>SSS group<BR/>AV block group<BR/>
<BR/>n/N cases heart failure<BR/>SSS group<BR/>AV block group</P>
</TD>
<TD>
<P>VVIR<BR/>34/204<BR/>17/85<BR/>15/102<BR/>
<BR/>53/204<BR/>33/204<BR/>24/85<BR/>11/102<BR/>
<BR/>5/204<BR/>2/85<BR/>3/102<BR/>
<BR/>17/204<BR/>7/85<BR/>9/102</P>
</TD>
<TD>
<P>DDDR<BR/>32/203<BR/>11/90<BR/>17/99<BR/>
<BR/>0/203<BR/>35/203<BR/>17/90<BR/>16/99<BR/>
<BR/>3/203<BR/>1/90<BR/>1/99<BR/>
<BR/>9/203<BR/>6/90<BR/>3/99</P>
</TD>
<TD>
<P>
<BR/>p=0.95<BR/>p=0.09<BR/>p=0.41<BR/>
<BR/>p&lt;0.0001<BR/>p=0.8<BR/>p=0.06<BR/>p=0.26<BR/>
<BR/>NS<BR/>NS<BR/>NS<BR/>
<BR/>NS<BR/>NS<BR/>NS</P>
</TD>
<TD>
<P>Assessment of pacemaker syndrome: 'symptoms of pacemaker syndrome severe enough to warrant reprogramming; multiple symptoms recorded in each patient (fatigue in all, dyspnoea or effort intolerance in 67%, orthopnoea or paroxysmal nocturnal dyspnoea in 24%, presyncope in 33% and a feeling of fullness in 20%); no scores calculated.'</P>
</TD>
</TR>
<TR>
<TD>
<P>MOST<BR/>(Lamas et al., 2002, USA)</P>
</TD>
<TD>
<P>
<BR/>n/N cases all-cause mortality<BR/>n/N cases cardiovascular mortality<BR/>n/N cases atrial fibrillation<BR/>n/N cases pacemaker syndrome<BR/>n/N cases stroke<BR/>n/N cases heart failure</P>
</TD>
<TD>
<P>VVIR<BR/>204/996<BR/>92/996<BR/>270/996<BR/>182/996<BR/>49/996<BR/>123/996</P>
</TD>
<TD>
<P>DDDR<BR/>200/1014<BR/>86/1014<BR/>217/1014<BR/>0/1014<BR/>41/1014<BR/>104/1014</P>
</TD>
<TD>
<P>
<BR/>p=0.95* p=0.64"<BR/>p=0.87 p=0.37<BR/>p=0.008 p=0.004<BR/>NS NS<BR/>p=0.36 p=0.33<BR/>p=0.13 p=0.02<BR/>
<BR/>for *unadjusted "adjusted hazard ratio</P>
</TD>
<TD>
<P>Diagnosis of pacemaker syndrome required signs and symptoms of elevated right-sided or left-sided filling pressures or hypotention with ventricular pacing. Additionally, some patients had symptoms of severe pacemaker syndrome requiring reprogramming (but did not fully meet the strict definition) -these patients have been included in the number of cases with pacemaker syndrome.</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattioli et al., 1998, Italy</P>
</TD>
<TD>
<P>
<BR/>% freedom from atrial fibrillation<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>n/N cases of stroke</P>
</TD>
<TD>
<P>VVI, VVIR<BR/>higher incidence of AF in total population in ventricular mode (no data available)<BR/>
<BR/>higher incidence of AF in SSS population in ventricular modes (7% at 12 months, 20% at 24 months, estimated from graph)<BR/>
<BR/>19/105</P>
</TD>
<TD>
<P>DDD, VDD, AAI<BR/>lower incidence of AF in total population in ventricular mode (no data available)<BR/>
<BR/>lower incidence of AF in SSS population in physiologic modes (0% at 12 months, 3.5% at 24 months, estimated from graph)<BR/>
<BR/>
<BR/>10/105</P>
</TD>
<TD>
<P>
<BR/>p&lt;0.05<BR/>
<BR/>
<BR/>
<BR/>
<BR/>p&lt;0.05<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
<BR/>p&lt;0.05</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wharton et al., 1998, USA</P>
</TD>
<TD>
<P>
<BR/>% mortality<BR/>
<BR/>% of population with pacemaker syndrome</P>
</TD>
<TD>
<P>VVIR<BR/>6.8 (6/98)<BR/>
<BR/>28% (27/98)</P>
</TD>
<TD>
<P>DDDR<BR/>3.2 (3/100)<BR/>
<BR/>0% (0/100)</P>
</TD>
<TD>
<P>
<BR/>p=0.007<BR/>
<BR/>p&lt;0.0001</P>
</TD>
<TD>
<P>Details on assessment of pacemaker syndrome not given.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="5">
<TITLE>Main study characteristics parallel studies</TITLE>
<TABLE COLS="9" ROWS="6">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Pacing indication</P>
</TH>
<TH>
<P>No of patients (m/f)</P>
</TH>
<TH>
<P>Age (mean)</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Comparator</P>
</TH>
<TH>
<P>Randomisation method</P>
</TH>
<TH>
<P>Study duration</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
</TR>
<TR>
<TD>
<P>CTOPP<BR/>(Connolly et al., 2000, Canada)</P>
</TD>
<TD>
<P>SSS or AV block or both</P>
</TD>
<TD>
<P>2568 (60% male, 40% female)</P>
</TD>
<TD>
<P>73 +/-10</P>
</TD>
<TD>
<P>'Physiological' pacemaker (dual or atrial, some rate-adaptive); n=1094</P>
</TD>
<TD>
<P>Ventricular pacemakers, some rate-adaptive; n=1474</P>
</TD>
<TD>
<P>Device</P>
</TD>
<TD>
<P>36 months average (range 24-60 months)</P>
</TD>
<TD>
<P>Atrial fibrillation, stroke, heart failure, mortality, complication rate</P>
</TD>
</TR>
<TR>
<TD>
<P>PASE<BR/>(Lamas et al., 1998, USA)</P>
</TD>
<TD>
<P>SSS or AV block</P>
</TD>
<TD>
<P>407 (60% male, 40% female)</P>
</TD>
<TD>
<P>76 +/-7</P>
</TD>
<TD>
<P>DDDR; n=203</P>
</TD>
<TD>
<P>VVIR; n=204</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>18.3 months average (range 7.2-33.2 months)</P>
</TD>
<TD>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life</P>
</TD>
</TR>
<TR>
<TD>
<P>MOST<BR/>(Lamas et al., 2002, USA)</P>
</TD>
<TD>
<P>SSS (21% also AV block)</P>
</TD>
<TD>
<P>2010 (1045 male, 965 female)</P>
</TD>
<TD>
<P>median 74</P>
</TD>
<TD>
<P>DDDR; n=1014</P>
</TD>
<TD>
<P>VVIR; n=996</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>median 33.1 months</P>
</TD>
<TD>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life, complication rate</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattioli et al., 1998, Italy</P>
</TD>
<TD>
<P>SSS or AV block</P>
</TD>
<TD>
<P>210 (113 male, 97 female)</P>
</TD>
<TD>
<P>79 +/-9</P>
</TD>
<TD>
<P>'Physiological' pacemaker (DDD, VDD, AAI); n=105</P>
</TD>
<TD>
<P>VVI, VVIR; n=105</P>
</TD>
<TD>
<P>Device</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>Atrial fibrillation, stroke</P>
</TD>
</TR>
<TR>
<TD>
<P>Wharton et al., 1998, USA</P>
</TD>
<TD>
<P>SSS (with tachybrady syndrome)</P>
</TD>
<TD>
<P>198 (109 male, 89 female)</P>
</TD>
<TD>
<P>median 72</P>
</TD>
<TD>
<P>DDDR; n=100</P>
</TD>
<TD>
<P>VVIR; n=98</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>23.7 months median</P>
</TD>
<TD>
<P>Pacemaker syndrome, atrial fibrillation, stroke, heart failure, mortality, quality of life</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="6">
<TITLE>Main study characteristics crossover studies</TITLE>
<TABLE COLS="9" ROWS="27">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Pacing indication</P>
</TH>
<TH>
<P>No of patients (m/f)</P>
</TH>
<TH>
<P>Age (mean/range)</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Comparator</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Study duration</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
</TR>
<TR>
<TD>
<P>Avery et al., 1994, UK</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>13 (7 male, 6 female)</P>
</TD>
<TD>
<P>79.4</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Boon et al., 1987, UK</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>15 (13 male, 2 female)</P>
</TD>
<TD>
<P>69 (54-81)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Capucci et al., 1993, Italy</P>
</TD>
<TD>
<P>AV block or SSS or both</P>
</TD>
<TD>
<P>14 (12 male, 2 female)</P>
</TD>
<TD>
<P>66.5 +/-5</P>
</TD>
<TD>
<P>DDD, DDDR</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Channon et al., 1994, UK</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>16 (8 male, 8 female)</P>
</TD>
<TD>
<P>81.25 (77-88)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Davis et al., 1985, Australia</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>14 (10 male, 4 female)</P>
</TD>
<TD>
<P>65 (23-84)</P>
</TD>
<TD>
<P>VDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Deharo et al., 1996, France</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>18 (14 male , 4 female)</P>
</TD>
<TD>
<P>70 +/-6.5</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Hargreaves et al., 1995, UK</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>20 (14 male, 6 female)</P>
</TD>
<TD>
<P>80.5 +/-1</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Heldman et al., 1990, USA</P>
</TD>
<TD>
<P>AV block or SSS or both</P>
</TD>
<TD>
<P>40 (23 male, 17 female)</P>
</TD>
<TD>
<P>68 +/-10 (47-86)</P>
</TD>
<TD>
<P>DDD, DDI</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 week</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Höijer et al., 2002, Sweden</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>19 (13 male, 6 female)</P>
</TD>
<TD>
<P>75.5 +/-7.3</P>
</TD>
<TD>
<P>DDDR, DDIR</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P>Quality of life</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamalvand et al., 1997, UK</P>
</TD>
<TD>
<P>AV block, SSS or both</P>
</TD>
<TD>
<P>48 (28 male, 20 female)</P>
</TD>
<TD>
<P>64 +/-13</P>
</TD>
<TD>
<P>DDDR, DDDR with mode switching</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Kenny et al., 1986, UK</P>
</TD>
<TD>
<P>AV block or SSS or both</P>
</TD>
<TD>
<P>10 (4 male, 6 female)</P>
</TD>
<TD>
<P>69.7 +/-10.4 (52-83)</P>
</TD>
<TD>
<P>DDD(100), DDD(150)</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Kristensson et al., 1985, Sweden</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>44 (22 male, 22 female)</P>
</TD>
<TD>
<P>68 +/-13 (18-84)</P>
</TD>
<TD>
<P>VDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>3 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (1), Hong Kong</P>
</TD>
<TD>
<P>SSS</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>66+/-2</P>
</TD>
<TD>
<P>DDDR</P>
</TD>
<TD>
<P>AAIR, VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, quality of life</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (2), Hong Kong</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>66+/-1</P>
</TD>
<TD>
<P>DDD, DDDR</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, quality of life</P>
</TD>
</TR>
<TR>
<TD>
<P>Linde-Edelstam et al., 1992, Sweden</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>17 (13 male, 4 female)</P>
</TD>
<TD>
<P>64+/-11</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>2 months</P>
</TD>
<TD>
<P>Pacemaker syndrome, quality of life, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Lukl et al., 1994, Czech Republik</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>68 +/-8</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, quality of life</P>
</TD>
</TR>
<TR>
<TD>
<P>Menozzi et al., 1990, Italy</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>14 (4 male, 10 female)</P>
</TD>
<TD>
<P>72 +/-6</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Mitsuoka et al., 1988, UK</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>16 (14 male, 2 female)</P>
</TD>
<TD>
<P>64.1 +/-12.2 (AV block); 63.3 +/- 13.1 (SSS)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Oldroyd et al., 1991, UK</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>10 (7 male, 3 female)</P>
</TD>
<TD>
<P>56 (32-87)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Perrins et al., 1993, UK</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>13 (9 male, 4 female)</P>
</TD>
<TD>
<P>65 (32-87)</P>
</TD>
<TD>
<P>VDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>1 month</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Rediker et al., 1988, USA</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>19 (15 male, 4 female)</P>
</TD>
<TD>
<P>69.5 (35-83)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Saner &amp; Fricker, 1996, Switzerland</P>
</TD>
<TD>
<P>AV block or SSS</P>
</TD>
<TD>
<P>12 (7 male, 5 female)</P>
</TD>
<TD>
<P>68 (36-80)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1994, UK</P>
</TD>
<TD>
<P>AV block or AV block with SSS</P>
</TD>
<TD>
<P>10 (6 male, 4 female)</P>
</TD>
<TD>
<P>53 +/-9.4 (42-67)</P>
</TD>
<TD>
<P>DDDR</P>
</TD>
<TD>
<P>VVIR</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1992, UK</P>
</TD>
<TD>
<P>AV block or AV block with SSS</P>
</TD>
<TD>
<P>16 (11 male, 5 female)</P>
</TD>
<TD>
<P>66.6 (41-84)</P>
</TD>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1991, UK</P>
</TD>
<TD>
<P>AV block or AV block with SSS</P>
</TD>
<TD>
<P>22 (9 male, 13 female)</P>
</TD>
<TD>
<P>51.9 (18-81)</P>
</TD>
<TD>
<P>DDD, DDIR, DDDR</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>4 weeks</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
<TR>
<TD>
<P>Yee et al., 1984, Canada</P>
</TD>
<TD>
<P>AV block</P>
</TD>
<TD>
<P>8 (4 male, 4 female)</P>
</TD>
<TD>
<P>58.9 +/-18.4</P>
</TD>
<TD>
<P>VDD</P>
</TD>
<TD>
<P>VVI</P>
</TD>
<TD>
<P>Mode</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>Pacemaker syndrome, exercise capacity</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="7">
<TITLE>Quality assessment parallel studies</TITLE>
<TABLE COLS="10" ROWS="17">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>A</P>
</TH>
<TH>
<P>B</P>
</TH>
<TH>
<P>C</P>
</TH>
<TH>
<P>D</P>
</TH>
<TH>
<P>E</P>
</TH>
<TH>
<P>F</P>
</TH>
<TH>
<P>G</P>
</TH>
<TH>
<P>H</P>
</TH>
<TH>
<P>I</P>
</TH>
</TR>
<TR>
<TD>
<P>CTOPP<BR/>(Connolly et al., 2000)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Single to dual: 2.1%, 2.7% and 4.3% at 1, 3 and 5 years; dual to single: 10.8%, 12.8% and 17.1% at 1, 3 and 5 years<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>PASE<BR/>(Lamas et al., 1998)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Single to dual: 53/204; dual to single: 4/203</P>
</TD>
</TR>
<TR>
<TD>
<P>MOST<BR/>(Lamas et al., 2002)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Single to dual: 313/996 (an additional 61crossed over from single to dual but crossed back to single); not stated for dual to single</P>
</TD>
</TR>
<TR>
<TD>
<P>Mattioli et al., 1998</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y (n=7)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Crossovers occurred but numbers not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Wharton et al., 1998</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Single to dual: 44%, dual to single 9%</P>
</TD>
</TR>
<TR>
<TD>
<P>A-Trial described as randomised</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>B-Randomisation method stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>C-Adequate concealment described</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D-Trial described as double-blind</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>E-Statement regarding blinding of participants</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>F-Statement regarding blinding of outcome assessors</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>G-Withdrawals stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>H-Intention-to-treat analysis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>I-Crossovers</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Y=criterion met</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>X=criterion not met</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="8">
<TITLE>Quality assessment crossover studies</TITLE>
<TABLE COLS="10" ROWS="40">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>A</P>
</TH>
<TH>
<P>B</P>
</TH>
<TH>
<P>C</P>
</TH>
<TH>
<P>D</P>
</TH>
<TH>
<P>E</P>
</TH>
<TH>
<P>F</P>
</TH>
<TH>
<P>G</P>
</TH>
<TH>
<P>H</P>
</TH>
<TH>
<P>I</P>
</TH>
</TR>
<TR>
<TD>
<P>Avery et al., 1994</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>3/13</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Boon et al., 1987</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>3/18</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Capucci et al., 1993</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>partly</P>
</TD>
<TD>
<P>2/14</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Channon et al., 1994</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>2/16</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>3/16 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Davis et al., 1985</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>partly</P>
</TD>
<TD>
<P>0/13</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Deharo et al., 1996</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/15</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>1/15 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Hargreaves et al., 1995</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/20</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>3/20 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Heldman et al., 1990</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/40</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>17/42 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Höijer et al., 2002</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/19</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>7/19 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Kamalvand et al., 1997</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>partly</P>
</TD>
<TD>
<P>5/48</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>33% single to dual; 22% dual to single</P>
</TD>
</TR>
<TR>
<TD>
<P>Kenny et al., 1986</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/10</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>2/10 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Kristensson et al., 1985</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/44</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (1)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>3/15</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>1/15 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al., 1994 (2)</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/33</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>2/33 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Linde-Edelstam et al., 1992</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y for exercise assessment, X for qol assessment</P>
</TD>
<TD>
<P>2/17 (exercise assessment)</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>1/17 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Lukl et al., 1994</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/21</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Menozzi et al., 1990</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/14</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>5/14 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Mitsuoka et al., 1988</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/8</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>2/16 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Oldroyd et al., 1991</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>partly</P>
</TD>
<TD>
<P>0/10</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>1/10 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Perrins et al., 1983</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/13</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P>Rediker et al., 1993</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>partly</P>
</TD>
<TD>
<P>0/19</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>single to dual unclear; none dual to single</P>
</TD>
</TR>
<TR>
<TD>
<P>Saner &amp; Fricker, 1996</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/12</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>4/12 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1994</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/10</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>3/10 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1992</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/16</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulke et al., 1991</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>0/22</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>5/22 single to dual</P>
</TD>
</TR>
<TR>
<TD>
<P>Yee et al., 1984</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>0/8</P>
</TD>
<TD>
<P>CT</P>
</TD>
<TD>
<P>none</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>A-Study described as randomised</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>B-Randomisation method stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>C-Adequate concealment described</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>D-Trial described as double-blind</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>E-Statement regarding blinding of participants</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>F-Statement regarding blinding of outcome assessors</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>G-Withdrawals</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>H-Intention-to-treat analysis</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>I-Crossover from one mode to another</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Y=criterion met<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>X=criterion not met</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>CT=can't tell</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2008-09-08 22:37:58 +0100" MODIFIED_BY="Karen Hovhannisyan" NO="9">
<TITLE>Quality of life measurements</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Population size</P>
</TH>
<TH>
<P>Improved qol (dual)*</P>
</TH>
<TH>
<P>No difference (d/s)+</P>
</TH>
<TH>
<P>Comment</P>
</TH>
</TR>
<TR>
<TD>
<P>PASE<BR/>(Lamas et al., 1998,<BR/>(parallel)</P>
</TD>
<TD>
<P>n = 407</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-mental health (SF-36) at 9 months<BR/>-cardiovascular functional status at 18 months</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-8/8 SF-36 items at 3 months<BR/>-7/8 SF-36 items at 9 months<BR/>-7/8 SF-36 items at 18 months<BR/>-cardiovascular functional status at 3 and 9 months</P>
</TD>
<TD>
<P>SF-36 (physical and social function, physical and emotional role, energy, pain, health perception, mental health) measured at 3, 9 and 18 months; cardiovascular functional status assessed using Specific Activities Scale at 3, 9 and 18 months</P>
</TD>
</TR>
<TR>
<TD>
<P>MOST<BR/>(Lamas et al., 2002, parallel)</P>
</TD>
<TD>
<P>n = 2010</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>- 6/8 SF-36 subscales at 48 months<BR/>(when last measurement was carried forward in those patients who crossed over)</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-2/8 SF-36 subscales at 48 months<BR/>-cardiovascular functional status at 48 months<BR/>-time-tradeoff utility at 48 months<BR/>(when last measurement was carried forward in those patients who crossed over)</P>
</TD>
<TD>
<P>SF-36 (physical and social function, physical and emotional role, energy, pain, health perception, mental health) measured at 48 months; cardiovascular functional status assessed using Specific Activities Scale at 48 months; time-tradeoff utility measured at 48 months; if health status after crossover was included in the analysis, there were no significant differences between the groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Höijer et al., 2002<BR/>(crossover)</P>
</TD>
<TD>
<P>n = 19</P>
</TD>
<TD>
<P>VVIR versus DDDR/DDIR<BR/>-1/4 items (cardiovascular symptomatology)<BR/>-1/3 items (mood state)<BR/>
</P>
</TD>
<TD>
<P>VVIR versus DDDR/DDIR<BR/>-3/4 items (cardiovascular symptomatology)<BR/>-2/3 items (mood state)<BR/>-2/2 items (sleep disturbance)<BR/>-3/3 items (cognitive ability)<BR/>-2/2 items (physical and social ability)<BR/>-1/1 item (depressive feelings)<BR/>-2/2 self-perceived health<BR/>
</P>
</TD>
<TD>
<P>7 sets of items assessed (cardiovascular symptomatology-visual analogue scales, sleep disturbance-visual analogue scale and sleep quality scale, cognitive functioning-visual analogue scales, physical and social functioning-5 point category scale, depressive feelings-questionnaire, mood states-4 point category scale, self-perceived health status-category scale)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al. ,1994 (1)<BR/>(crossover)<BR/>
<BR/>
</P>
</TD>
<TD>
<P>n = 15</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-1/1 item (general well-being)<BR/>-1/6 items (incidence and frequency of symptoms)<BR/>-1/11 items (psychologist's assessment)<BR/>
<BR/>
</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-5/6 items (incidence and frequency of symptoms)<BR/>-1/1 item (cardiovascular functional status)<BR/>-10/11 items (psychologist's assessment)<BR/>
<BR/>AAIR versus DDDR<BR/>-1/1 item (general well-being)<BR/>-6/6 items (incidence and frequency of symptoms)<BR/>-1/1 item (cardiovascular functional status)<BR/>-11/11 items (psychologist's assessment)</P>
</TD>
<TD>
<P>DDDR, AAIR and VVIR modes compared. 4 sets of items assessed (general well-being on visual analogue scale, incidence and frequency of symptoms, cardiovascular functional status using Specific Activities Scale, psychologist's assessment)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lau et al. ,1994 (2)<BR/>(crossover)</P>
</TD>
<TD>
<P>n = 33</P>
</TD>
<TD>
<P>VVIR versus DDDR<BR/>-4/5 items (physical malaise)<BR/>-3/4 items (quality of life)<BR/>-total sum for quality of life (based on 48 items)<BR/>-4/5 items (illness perception)<BR/>
<BR/>VVIR vs DDD<BR/>-1/4 items quality of life<BR/>-total sum for quality of life<BR/>-1/5 items (illness perception)</P>
</TD>
<TD>
<P>VVIR vs DDDR<BR/>-1/5 items (physical malaise)<BR/>-1/4 items (quality of life)<BR/>-1/5 items (illness perception)<BR/>
<BR/>VVIR vs DDD<BR/>-5/5 items physical malaise<BR/>-3/4 items quality of life<BR/>-4/5 items (illness perception)</P>
</TD>
<TD>
<P>DDDR, DDD and VVIR modes compared. 3 sets of items assessed (physical malaise using Physical Malaise Inventory, 41 items; quality of life based on 48 items; illness perception using Illness Perception Score, 43 items). Results only stated for certain items and overall for quality of life.</P>
</TD>
</TR>
<TR>
<TD>
<P>Linde-Edelstam et al., 1992 <BR/>(crossover)</P>
</TD>
<TD>
<P>n = 17</P>
</TD>
<TD>
<P>VVIR versus DDD<BR/>-4/4 items (cardiovascular symptomatology)<BR/>-1/3 items (cognitive functioning)</P>
</TD>
<TD>
<P>VVIR versus DDD<BR/>-2/2 items (sleep disturbance)<BR/>-2/3 items (cognitive functioning)<BR/>-2/2 items (physical and social functioning)<BR/>-1/1 item (depressive score)<BR/>-3/3 items mood states)<BR/>-2/2 items (self-perceived health status)</P>
</TD>
<TD>
<P>7 sets of items assessed (cardiovascular symptomatology-visual analogue scales, sleep disturbance-visual analogue scale and sleep quality scale, cognitive functioning-visual analogue scales, physical and social functioning-5 point category scale, depressive feelings-questionnaire, mood states-4 point category scale, self-perceived health status-category scale)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lukl et al., 1994<BR/>(crossover)</P>
</TD>
<TD>
<P>n = 21</P>
</TD>
<TD>
<P>VVIR versus DDD<BR/>-12/19 items</P>
</TD>
<TD>
<P>VVIR versus DDD<BR/>-7/19 items</P>
</TD>
<TD>
<P>19 questions on quality of life questionnaire, each question scored 0-5</P>
</TD>
</TR>
<TR>
<TD>
<P>* Statistically significant improvement in qol in a dual mode</P>
</TD>
<TD>
<P>+ No statistically significant difference in qol between dual and single modes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Atrial fibrillation parallel studies</NAME>
<DICH_OUTCOME CHI2="3.2309564815811207" CI_END="0.9305113185263918" CI_START="0.6779266722331401" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7942407957564684" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="447" I2="7.1482386995227625" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.031278339842554154" LOG_CI_START="-0.16881727894525864" LOG_EFFECT_SIZE="-0.1000478093939064" METHOD="MH" NO="1" P_CHI2="0.35736844812549695" P_Q="1.0" P_Z="0.004352550748053428" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2411" TOTAL_2="2772" WEIGHT="100.0" Z="2.8514121807753394">
<NAME>Atrial fibrillation</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.111190981826056" CI_START="0.5684237038803214" EFFECT_SIZE="0.7947498308323051" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="97" LOG_CI_END="0.04578870810836261" LOG_CI_START="-0.24532781981955878" LOG_EFFECT_SIZE="-0.09976955585559809" ORDER="815" O_E="0.0" SE="0.17100328955491523" STUDY_ID="STD-CTOPP" TOTAL_1="1094" TOTAL_2="1474" VAR="0.02924212503860218" WEIGHT="22.63193132193794"/>
<DICH_DATA CI_END="0.8987149578320739" CI_START="0.5963848026373818" EFFECT_SIZE="0.7321065105255821" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="270" LOG_CI_END="-0.046378030035328734" LOG_CI_START="-0.22447343197762404" LOG_EFFECT_SIZE="-0.13542573100647642" ORDER="816" O_E="0.0" SE="0.10461412068736194" STUDY_ID="STD-MOST" TOTAL_1="1014" TOTAL_2="996" VAR="0.01094411424718993" WEIGHT="61.917180870113945"/>
<DICH_DATA CI_END="1.5107307847625828" CI_START="0.5482509955919422" EFFECT_SIZE="0.9100877192982456" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="38" LOG_CI_END="0.179187079091502" LOG_CI_START="-0.2610205709961866" LOG_EFFECT_SIZE="-0.04091674595234228" ORDER="817" O_E="0.0" SE="0.2585801527245197" STUDY_ID="STD-PASE" TOTAL_1="203" TOTAL_2="204" VAR="0.06686369538303591" WEIGHT="9.071594215138633"/>
<DICH_DATA CI_END="2.1553766887919035" CI_START="0.7027972916684605" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="42" LOG_CI_END="0.33352318148861976" LOG_CI_START="-0.15316992079044373" LOG_EFFECT_SIZE="0.09017663034908803" ORDER="818" O_E="0.0" SE="0.28588593744843277" STUDY_ID="STD-Wharton" TOTAL_1="100" TOTAL_2="98" VAR="0.08173076923076922" WEIGHT="6.3792935928094785"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>All cause mortality parallel studies</NAME>
<DICH_OUTCOME CHI2="0.9248170560121061" CI_END="1.1168864508176823" CI_START="0.7962099873995312" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9430143938096883" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="341" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.04800902245313505" LOG_CI_START="-0.09897237906879988" LOG_EFFECT_SIZE="-0.025481678307832423" METHOD="MH" NO="1" P_CHI2="0.8194352714939732" P_Q="1.0" P_Z="0.4967673274344555" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2411" TOTAL_2="2772" WEIGHT="100.0" Z="0.6795849166199953">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3148102769555159" CI_START="0.6945632052555365" EFFECT_SIZE="0.9556248428463666" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="97" LOG_CI_END="0.11886309000011636" LOG_CI_START="-0.15828822732779432" LOG_EFFECT_SIZE="-0.01971256866383896" ORDER="819" O_E="0.0" SE="0.16280005571956158" STUDY_ID="STD-CTOPP" TOTAL_1="1094" TOTAL_2="1474" VAR="0.026503858142292353" WEIGHT="28.124892690399406"/>
<DICH_DATA CI_END="1.1864787844256786" CI_START="0.7669044060933763" EFFECT_SIZE="0.9538950715421304" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="204" LOG_CI_END="0.07425997694928335" LOG_CI_START="-0.11525876707253391" LOG_EFFECT_SIZE="-0.020499395061625285" ORDER="820" O_E="0.0" SE="0.11132424837132841" STUDY_ID="STD-MOST" TOTAL_1="1014" TOTAL_2="996" VAR="0.012393088275441217" WEIGHT="60.14789450105831"/>
<DICH_DATA CI_END="1.585426967709624" CI_START="0.5522064859788878" EFFECT_SIZE="0.935672514619883" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.20014624115892612" LOG_CI_START="-0.2578984966313843" LOG_EFFECT_SIZE="-0.02887612773622908" ORDER="821" O_E="0.0" SE="0.2690577463360479" STUDY_ID="STD-PASE" TOTAL_1="203" TOTAL_2="204" VAR="0.0723920708634331" WEIGHT="10.296958731015787"/>
<DICH_DATA CI_END="1.9520530739411044" CI_START="0.11520745247737772" EFFECT_SIZE="0.4742268041237113" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.29049162142821644" LOG_CI_START="-0.9385194265975579" LOG_EFFECT_SIZE="-0.3240139025846708" ORDER="822" O_E="0.0" SE="0.7219271733131444" STUDY_ID="STD-Wharton" TOTAL_1="100" TOTAL_2="98" VAR="0.5211788435679068" WEIGHT="1.4302540775264931"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Heart failure parallel studies</NAME>
<DICH_OUTCOME CHI2="1.2984962902582453" CI_END="1.001209576434356" CI_START="0.6379010871817261" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7991699927451176" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="192" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="5.249949241070981E-4" LOG_CI_START="-0.19524665767612345" LOG_EFFECT_SIZE="-0.09736083137600815" METHOD="MH" NO="1" P_CHI2="0.5224384585560038" P_Q="1.0" P_Z="0.05124146591149587" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2311" TOTAL_2="2674" WEIGHT="100.00000000000003" Z="1.9494520321746378">
<NAME>Heart failure</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.361298428276671" CI_START="0.5651780230746347" EFFECT_SIZE="0.8771407837445573" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="52" LOG_CI_END="0.13395334309199453" LOG_CI_START="-0.2478147340191281" LOG_EFFECT_SIZE="-0.0569306954635668" ORDER="823" O_E="0.0" SE="0.22425245827753315" STUDY_ID="STD-CTOPP" TOTAL_1="1094" TOTAL_2="1474" VAR="0.05028916504351675" WEIGHT="25.176754918118057"/>
<DICH_DATA CI_END="1.0701596775096265" CI_START="0.6148279118500516" EFFECT_SIZE="0.8111498257839721" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="123" LOG_CI_END="0.029448583187502073" LOG_CI_START="-0.21124642469978502" LOG_EFFECT_SIZE="-0.09089892075614146" ORDER="824" O_E="0.0" SE="0.14138543909249712" STUDY_ID="STD-MOST" TOTAL_1="1014" TOTAL_2="996" VAR="0.019989842387378217" WEIGHT="65.3184708628967"/>
<DICH_DATA CI_END="1.1732908364837555" CI_START="0.22195311807860466" EFFECT_SIZE="0.5103092783505154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.06940567880263729" LOG_CI_START="-0.6537387494679896" LOG_EFFECT_SIZE="-0.29216653533267617" ORDER="825" O_E="0.0" SE="0.4247786167888177" STUDY_ID="STD-PASE" TOTAL_1="203" TOTAL_2="204" VAR="0.18043687328102123" WEIGHT="9.504774218985254"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Stroke parallel studies</NAME>
<DICH_OUTCOME CHI2="1.7036020887158603" CI_END="1.04126623938425" CI_START="0.5396685445789019" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.749625663866736" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="89" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.0175617876393078" LOG_CI_START="-0.2678728947269392" LOG_EFFECT_SIZE="-0.1251555535438157" METHOD="MH" NO="1" P_CHI2="0.6361333551922528" P_Q="1.0" P_Z="0.08565358889702201" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2416" TOTAL_2="2779" WEIGHT="99.99999999999999" Z="1.7187846646911908">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0023498501460266" CI_START="0.4278224595066965" EFFECT_SIZE="0.9255540166204986" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.3015399596137557" LOG_CI_START="-0.36873641989588424" LOG_EFFECT_SIZE="-0.03359823014106427" ORDER="826" O_E="0.0" SE="0.39372366324555186" STUDY_ID="STD-CTOPP" TOTAL_1="1094" TOTAL_2="1474" VAR="0.15501832299949672" WEIGHT="16.25167463147017"/>
<DICH_DATA CI_END="1.081151138535458" CI_START="0.20996943519371053" EFFECT_SIZE="0.47645429362880887" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.03388640999752148" LOG_CI_START="-0.6778439199937395" LOG_EFFECT_SIZE="-0.321978754998109" ORDER="828" O_E="0.0" SE="0.41807391895882035" STUDY_ID="STD-Mattioli" TOTAL_1="105" TOTAL_2="105" VAR="0.1747858017135863" WEIGHT="20.701537923420336"/>
<DICH_DATA CI_END="1.2448856371730306" CI_START="0.5327462170546496" EFFECT_SIZE="0.8143759045241941" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" LOG_CI_END="0.09512945631048444" LOG_CI_START="-0.2734796254581978" LOG_EFFECT_SIZE="-0.08917508457385666" ORDER="827" O_E="0.0" SE="0.21652279927530618" STUDY_ID="STD-MOST" TOTAL_1="1014" TOTAL_2="996" VAR="0.046882122606014535" WEIGHT="57.12912362032811"/>
<DICH_DATA CI_END="2.5317409556623485" CI_START="0.14077625090468904" EFFECT_SIZE="0.597" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4034192671898212" LOG_CI_START="-0.8514706049310831" LOG_EFFECT_SIZE="-0.22402566887063094" ORDER="829" O_E="0.0" SE="0.7371285226888687" STUDY_ID="STD-PASE" TOTAL_1="203" TOTAL_2="204" VAR="0.5433584589614741" WEIGHT="5.917663824781382"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Pacemaker syndrome parallel studies</NAME>
<DICH_OUTCOME CHI2="0.09158831330899542" CI_END="0.1370997547419862" CI_START="0.08223234594296402" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10617925626335181" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="262" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.8629633221200227" LOG_CI_START="-1.084957319912902" LOG_EFFECT_SIZE="-0.9739603210164622" METHOD="PETO" NO="1" P_CHI2="0.955238573073459" P_Q="1.0" P_Z="2.7482324253343707E-66" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1317" TOTAL_2="1298" WEIGHT="99.99999999999997" Z="17.19800688795532">
<NAME>Pacemaker syndrome parallel studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1475969448450464" CI_START="0.08025753330342292" EFFECT_SIZE="0.10883825943290709" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="182" LOG_CI_END="-0.830922632016161" LOG_CI_START="-1.0955141923367233" LOG_EFFECT_SIZE="-0.9632184121764421" ORDER="830" O_E="-91.81492537313433" SE="0.15542239228164528" STUDY_ID="STD-MOST" TOTAL_1="1014" TOTAL_2="996" VAR="41.39737669238704" WEIGHT="70.3931646001999"/>
<DICH_DATA CI_END="0.18059003215754943" CI_START="0.056994486529447524" EFFECT_SIZE="0.10145263010467467" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="53" LOG_CI_END="-0.743306224667262" LOG_CI_START="-1.2441671546020727" LOG_EFFECT_SIZE="-0.9937366896346674" ORDER="831" O_E="-26.434889434889435" SE="0.29420818954529665" STUDY_ID="STD-PASE" TOTAL_1="203" TOTAL_2="204" VAR="11.552885921436289" WEIGHT="19.64482450948521"/>
<DICH_DATA CI_END="0.21918259386689917" CI_START="0.04339724506744592" EFFECT_SIZE="0.09752907638525186" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="27" LOG_CI_END="-0.6591939378140783" LOG_CI_START="-1.362537839381081" LOG_EFFECT_SIZE="-1.0108658885975796" ORDER="832" O_E="-13.636363636363637" SE="0.4131476893889208" STUDY_ID="STD-Wharton" TOTAL_1="100" TOTAL_2="98" VAR="5.858539245710451" WEIGHT="9.962010890314872"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Pacemaker syndrome crossover studies</NAME>
<CONT_OUTCOME CHI2="15.272922934237927" CI_END="-0.5236563787956152" CI_START="-0.946842156565018" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7352492676803166" ESTIMABLE="YES" I2="47.6197186717542" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.05405094794138687" P_Q="1.0" P_Z="9.723227092070323E-12" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="189" UNITS="" WEIGHT="99.99999999999999" Z="6.810541185522146">
<NAME>Pacemaker syndrome crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.26771235037112584" CI_START="-1.937227357097858" EFFECT_SIZE="-1.102469853734492" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="28.0" ORDER="833" SD_1="5.0" SD_2="10.0" SE="0.4259045114848164" STUDY_ID="STD-Avery" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.425123400754246"/>
<CONT_DATA CI_END="-0.16540403002795923" CI_START="-1.6286344924857863" EFFECT_SIZE="-0.8970192612568728" ESTIMABLE="YES" MEAN_1="4.73" MEAN_2="9.4" ORDER="834" SD_1="4.4" SD_2="5.67" SE="0.373279936264034" STUDY_ID="STD-Channon" TOTAL_1="16" TOTAL_2="16" WEIGHT="8.364435940681428"/>
<CONT_DATA CI_END="0.04882246541728996" CI_START="-1.2198898086700636" EFFECT_SIZE="-0.5855336716263868" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="5.2" ORDER="835" SD_1="3.85" SD_2="3.85" SE="0.3236570376024238" STUDY_ID="STD-Hargreaves" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.125917736959572"/>
<CONT_DATA CI_END="-0.5827399764864032" CI_START="-1.520842861187912" EFFECT_SIZE="-1.0517914188371575" ESTIMABLE="YES" MEAN_1="7.3" MEAN_2="29.0" ORDER="836" SD_1="12.4" SD_2="26.1" SE="0.23931635787727337" STUDY_ID="STD-Heldman" TOTAL_1="40" TOTAL_2="40" WEIGHT="20.34984869627882"/>
<CONT_DATA CI_END="0.0801694197934385" CI_START="-0.725391890064256" EFFECT_SIZE="-0.32261123513540874" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="26.8" ORDER="837" SD_1="12.2" SD_2="15.3" SE="0.20550411033362329" STUDY_ID="STD-Kamalvand" TOTAL_1="48" TOTAL_2="48" WEIGHT="27.597194130578888"/>
<CONT_DATA CI_END="-0.2698828552985931" CI_START="-2.020042346892302" EFFECT_SIZE="-1.1449626010954477" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="5.7" ORDER="838" SD_1="1.6" SD_2="3.2" SE="0.4464774621877605" STUDY_ID="STD-Saner-and-Fricker" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.846646982284818"/>
<CONT_DATA CI_END="-0.2756335266707114" CI_START="-1.521311372801172" EFFECT_SIZE="-0.8984724497359418" ESTIMABLE="YES" MEAN_1="14.4" MEAN_2="23.5" ORDER="839" SD_1="8.1" SD_2="11.5" SE="0.31778080004433973" STUDY_ID="STD-Sulke-1991" TOTAL_1="22" TOTAL_2="22" WEIGHT="11.541191464214183"/>
<CONT_DATA CI_END="-0.5560509690391546" CI_START="-2.625837897804461" EFFECT_SIZE="-1.590944433421808" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="23.7" ORDER="840" SD_1="5.5" SD_2="9.8" SE="0.5280165720114047" STUDY_ID="STD-Sulke-1994" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.180332701966681"/>
<CONT_DATA CI_END="1.3394821726809385" CI_START="-0.6402470882987936" EFFECT_SIZE="0.3496175421910725" ESTIMABLE="YES" MEAN_1="-46.9" MEAN_2="-50.1" ORDER="841" SD_1="8.9" SD_2="8.4" SE="0.5050422550096797" STUDY_ID="STD-Yee" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.569308946281355"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Fatigue crossover studies</NAME>
<CONT_OUTCOME CHI2="4.3728960855325" CI_END="-0.48837304645652574" CI_START="-1.0509506658346994" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7696618561456126" ESTIMABLE="YES" I2="8.52743989883975" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="0.35788593076464603" P_Q="1.0" P_Z="8.191931282039567E-8" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="106" UNITS="" WEIGHT="100.0" Z="5.362849378853817">
<NAME>Fatigue crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.12860906943150452" CI_START="-1.290226301560471" EFFECT_SIZE="-0.5808086160644832" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.13" ORDER="842" SD_1="1.42" SD_2="1.69" SE="0.3619544497203948" STUDY_ID="STD-Channon" TOTAL_1="16" TOTAL_2="16" WEIGHT="15.721750087179585"/>
<CONT_DATA CI_END="-0.6943676752355665" CI_START="-1.64656309808444" EFFECT_SIZE="-1.1704653866600032" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="4.8" ORDER="843" SD_1="2.3" SD_2="3.5" SE="0.2429114591797781" STUDY_ID="STD-Heldman" TOTAL_1="40" TOTAL_2="40" WEIGHT="34.90701582338529"/>
<CONT_DATA CI_END="-0.01132806957742849" CI_START="-1.253990638777152" EFFECT_SIZE="-0.6326593541772902" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.7" ORDER="844" SD_1="1.6" SD_2="1.5" SE="0.31701158261113144" STUDY_ID="STD-Lukl" TOTAL_1="21" TOTAL_2="21" WEIGHT="20.4954976560505"/>
<CONT_DATA CI_END="0.48934985339466697" CI_START="-1.2851672435604575" EFFECT_SIZE="-0.3979086950828953" ESTIMABLE="YES" MEAN_1="170.14" MEAN_2="240.62" ORDER="845" SD_1="138.35" SD_2="196.0" SE="0.4526912512046877" STUDY_ID="STD-Oldroyd" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.050890137052528"/>
<CONT_DATA CI_END="0.11649762567284916" CI_START="-1.1801343623961433" EFFECT_SIZE="-0.5318183683616471" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-3.7" ORDER="846" SD_1="1.0" SD_2="1.2" SE="0.33077954449588365" STUDY_ID="STD-Rediker" TOTAL_1="19" TOTAL_2="19" WEIGHT="18.824846296332094"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Dizziness crossover studies</NAME>
<CONT_OUTCOME CHI2="5.63095429913727" CI_END="-0.6391911179025247" CI_START="-1.1338717890409833" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.886531453471754" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.4657725470178876" P_Q="1.0" P_Z="2.140423068531103E-12" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="141" UNITS="" WEIGHT="100.0" Z="7.025015616509697">
<NAME>Dizziness crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.16312755242974364" CI_START="-1.6259414612603238" EFFECT_SIZE="-0.8945345068450337" ESTIMABLE="YES" MEAN_1="0.47" MEAN_2="1.73" ORDER="847" SD_1="0.92" SD_2="1.71" SE="0.37317367063095785" STUDY_ID="STD-Channon" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.43593611315175"/>
<CONT_DATA CI_END="0.15080896331294502" CI_START="-1.1798903726331926" EFFECT_SIZE="-0.5145407046601238" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.53" ORDER="848" SD_1="0.52" SD_2="0.91" SE="0.3394703541602101" STUDY_ID="STD-Deharo" TOTAL_1="18" TOTAL_2="18" WEIGHT="13.81942592597152"/>
<CONT_DATA CI_END="-0.3134772139549699" CI_START="-1.2233880801625834" EFFECT_SIZE="-0.7684326470587767" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="2.9" ORDER="849" SD_1="1.3" SD_2="3.6" SE="0.23212438427054638" STUDY_ID="STD-H_x00f6_ijer" TOTAL_1="40" TOTAL_2="40" WEIGHT="29.556443853171526"/>
<CONT_DATA CI_END="0.09412535752261142" CI_START="-1.2836085094946896" EFFECT_SIZE="-0.594741575986039" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="15.2" ORDER="850" SD_1="8.5" SD_2="22.6" SE="0.3514691795065343" STUDY_ID="STD-Linde_x002d_Edelstam" TOTAL_1="17" TOTAL_2="17" WEIGHT="12.891967862010164"/>
<CONT_DATA CI_END="-0.43371561528687397" CI_START="-1.738112815470277" EFFECT_SIZE="-1.0859142153785755" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.7" ORDER="851" SD_1="0.8" SD_2="1.6" SE="0.3327605023542069" STUDY_ID="STD-Lukl" TOTAL_1="21" TOTAL_2="21" WEIGHT="14.382360381954921"/>
<CONT_DATA CI_END="-0.6149088929036709" CI_START="-2.182154425785769" EFFECT_SIZE="-1.39853165934472" ESTIMABLE="YES" MEAN_1="-3.25" MEAN_2="-2.56" ORDER="852" SD_1="0.45" SD_2="0.51" SE="0.39981488059074827" STUDY_ID="STD-Mitsuoka" TOTAL_1="16" TOTAL_2="16" WEIGHT="9.962671289957083"/>
<CONT_DATA CI_END="-0.5543234292710184" CI_START="-2.3086431714470956" EFFECT_SIZE="-1.431483300359057" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.3" ORDER="853" SD_1="0.7" SD_2="0.91" SE="0.447538770103412" STUDY_ID="STD-Perrins" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.95119457378303"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Breathlessness crossover studies</NAME>
<CONT_OUTCOME CHI2="11.179395165013254" CI_END="-0.6626607100064754" CI_START="-1.1812818528224749" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9219712814144752" ESTIMABLE="YES" I2="46.32983348886848" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.08298786656679069" P_Q="1.0" P_Z="3.201204236266014E-12" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="131" UNITS="" WEIGHT="100.00000000000001" Z="6.9685955977067735">
<NAME>Breathlessness crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05635898021917829" CI_START="-1.3716272011627009" EFFECT_SIZE="-0.6576341104717612" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.0" ORDER="854" SD_1="1.66" SD_2="1.89" SE="0.36428888302174217" STUDY_ID="STD-Channon" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.190231749755466"/>
<CONT_DATA CI_END="-0.5118363978195896" CI_START="-1.441710159181707" EFFECT_SIZE="-0.9767732785006482" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="3.3" ORDER="855" SD_1="1.8" SD_2="3.1" SE="0.23721705314404826" STUDY_ID="STD-Heldman" TOTAL_1="40" TOTAL_2="40" WEIGHT="31.106593167076785"/>
<CONT_DATA CI_END="-0.01777423701587022" CI_START="-1.4098878963310382" EFFECT_SIZE="-0.7138310666734542" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="18.1" ORDER="856" SD_1="8.5" SD_2="14.3" SE="0.35513756127561086" STUDY_ID="STD-Linde_x002d_Edelstam" TOTAL_1="17" TOTAL_2="17" WEIGHT="13.878772156908845"/>
<CONT_DATA CI_END="-1.0009630949031503" CI_START="-2.6901403632260936" EFFECT_SIZE="-1.845551729064622" ESTIMABLE="YES" MEAN_1="-3.44" MEAN_2="-1.94" ORDER="857" SD_1="0.73" SD_2="0.85" SE="0.4309204867147964" STUDY_ID="STD-Mitsuoka" TOTAL_1="16" TOTAL_2="16" WEIGHT="9.42648930011923"/>
<CONT_DATA CI_END="0.7167178832899647" CI_START="-1.0398860848513083" EFFECT_SIZE="-0.16158410078067187" ESTIMABLE="YES" MEAN_1="133.66" MEAN_2="153.12" ORDER="858" SD_1="111.44" SD_2="119.12" SE="0.44812149151646175" STUDY_ID="STD-Oldroyd" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.716712392682062"/>
<CONT_DATA CI_END="-0.7307365010215492" CI_START="-2.5471914116918777" EFFECT_SIZE="-1.6389639563567133" ESTIMABLE="YES" MEAN_1="-3.45" MEAN_2="-2.0" ORDER="859" SD_1="0.8" SD_2="0.91" SE="0.46338986966043577" STUDY_ID="STD-Perrins" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.151756374113527"/>
<CONT_DATA CI_END="-0.05453148759610116" CI_START="-1.370581071877565" EFFECT_SIZE="-0.7125562797368331" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-4.5" ORDER="860" SD_1="0.8" SD_2="1.1" SE="0.3357331039402497" STUDY_ID="STD-Rediker" TOTAL_1="19" TOTAL_2="19" WEIGHT="15.529444859344098"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Palpitation crossover studies</NAME>
<CONT_OUTCOME CHI2="11.013475381406252" CI_END="-0.45153417607048835" CI_START="-0.9339116425750584" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6927229093227734" ESTIMABLE="YES" I2="45.521283770882754" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.08796094547787137" P_Q="1.0" P_Z="1.8099369636549208E-8" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="144" UNITS="" WEIGHT="100.00000000000003" Z="5.62925114797243">
<NAME>Palpitation crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4049740457521585" CI_START="-0.9074439460690893" EFFECT_SIZE="-0.25123495015846536" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.6" ORDER="861" SD_1="0.72" SD_2="1.3" SE="0.3348066602686155" STUDY_ID="STD-Deharo" TOTAL_1="18" TOTAL_2="18" WEIGHT="13.509201312738632"/>
<CONT_DATA CI_END="9.770749167850035E-4" CI_START="-0.8867763508909782" EFFECT_SIZE="-0.4428996379870966" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.5" ORDER="862" SD_1="1.0" SD_2="3.0" SE="0.22647187213904155" STUDY_ID="STD-Heldman" TOTAL_1="40" TOTAL_2="40" WEIGHT="29.524959506755334"/>
<CONT_DATA CI_END="0.39539913133032734" CI_START="-0.9565877126445688" EFFECT_SIZE="-0.2805942906571207" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="6.3" ORDER="863" SD_1="8.1" SD_2="15.2" SE="0.3449009406905422" STUDY_ID="STD-Linde_x002d_Edelstam" TOTAL_1="17" TOTAL_2="17" WEIGHT="12.730020216212804"/>
<CONT_DATA CI_END="-0.7854953985690015" CI_START="-2.1648806721890876" EFFECT_SIZE="-1.4751880353790445" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="3.2" ORDER="864" SD_1="1.2" SD_2="1.8" SE="0.35189046444233185" STUDY_ID="STD-Lukl" TOTAL_1="21" TOTAL_2="21" WEIGHT="12.229335347690153"/>
<CONT_DATA CI_END="-0.21275002900128326" CI_START="-1.6849001401795323" EFFECT_SIZE="-0.9488250845904078" ESTIMABLE="YES" MEAN_1="-3.25" MEAN_2="-2.44" ORDER="865" SD_1="0.77" SD_2="0.89" SE="0.37555539866813403" STUDY_ID="STD-Mitsuoka" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.736675620200906"/>
<CONT_DATA CI_END="-0.17368927213848284" CI_START="-1.8199032189285151" EFFECT_SIZE="-0.996796245533499" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-2.6" ORDER="866" SD_1="0.67" SD_2="0.69" SE="0.41996025431466033" STUDY_ID="STD-Perrins" TOTAL_1="13" TOTAL_2="13" WEIGHT="8.586209304754377"/>
<CONT_DATA CI_END="-0.30382069200299755" CI_START="-1.6582793884400413" EFFECT_SIZE="-0.9810500402215194" ESTIMABLE="YES" MEAN_1="-5.8" MEAN_2="-4.7" ORDER="867" SD_1="0.4" SD_2="1.5" SE="0.34553152688540223" STUDY_ID="STD-Rediker" TOTAL_1="19" TOTAL_2="19" WEIGHT="12.683598691647825"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Exercise capacity crossover studies</NAME>
<CONT_OUTCOME CHI2="2.143899438509153" CI_END="-0.030309174308291387" CI_START="-0.44830646307934774" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23930781869381956" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" NO="1" P_CHI2="0.9889821154005924" P_Q="1.0" P_Z="0.02481955200712108" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="178" UNITS="" WEIGHT="100.00000000000003" Z="2.244199751810472">
<NAME>Exercise capacity crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.30475637744907275" CI_START="-1.2582986440673578" EFFECT_SIZE="-0.4767711333091425" ESTIMABLE="YES" MEAN_1="-360.0" MEAN_2="-327.0" ORDER="868" SD_1="65.0" SD_2="69.0" SE="0.39874585294566867" STUDY_ID="STD-Avery" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.151520661287125"/>
<CONT_DATA CI_END="0.580503828267604" CI_START="-0.8066625335531488" EFFECT_SIZE="-0.11307935264277234" ESTIMABLE="YES" MEAN_1="-18.7" MEAN_2="-16.43" ORDER="869" SD_1="15.8" SD_2="22.72" SE="0.3538754723970808" STUDY_ID="STD-Channon" TOTAL_1="16" TOTAL_2="16" WEIGHT="9.080083286519745"/>
<CONT_DATA CI_END="0.3605293431164867" CI_START="-1.1372283722427006" EFFECT_SIZE="-0.3883495145631069" ESTIMABLE="YES" MEAN_1="-8.4" MEAN_2="-7.2" ORDER="870" SD_1="3.0" SD_2="3.0" SE="0.38208807079449136" STUDY_ID="STD-Davis" TOTAL_1="14" TOTAL_2="14" WEIGHT="7.788678883047108"/>
<CONT_DATA CI_END="0.6533213281800181" CI_START="-0.6533213281800181" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="-10.0" ORDER="871" SD_1="3.6" SD_2="3.8" SE="0.3333333333333333" STUDY_ID="STD-Deharo" TOTAL_1="18" TOTAL_2="18" WEIGHT="10.233713767205277"/>
<CONT_DATA CI_END="0.40258853205559164" CI_START="-0.8411265411522922" EFFECT_SIZE="-0.21926900454835033" ESTIMABLE="YES" MEAN_1="-20.0" MEAN_2="-19.0" ORDER="872" SD_1="4.47" SD_2="4.47" SE="0.3172800834653467" STUDY_ID="STD-Hargreaves" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.295491526366648"/>
<CONT_DATA CI_END="0.23994352244616593" CI_START="-0.5615558111317455" EFFECT_SIZE="-0.16080614434278975" ESTIMABLE="YES" MEAN_1="-7.6" MEAN_2="-7.0" ORDER="873" SD_1="3.6" SD_2="3.8" SE="0.20446787285379625" STUDY_ID="STD-Kamalvand" TOTAL_1="48" TOTAL_2="48" WEIGHT="27.198227274513577"/>
<CONT_DATA CI_END="0.762047561067424" CI_START="-0.9928130968997029" EFFECT_SIZE="-0.11538276791613945" ESTIMABLE="YES" MEAN_1="-8.15" MEAN_2="-7.95" ORDER="874" SD_1="1.68" SD_2="1.64" SE="0.44767676136124024" STUDY_ID="STD-Oldroyd" TOTAL_1="10" TOTAL_2="10" WEIGHT="5.673638413546689"/>
<CONT_DATA CI_END="0.3228307838036638" CI_START="-0.9578714188442995" EFFECT_SIZE="-0.31752031752031784" ESTIMABLE="YES" MEAN_1="-11.3" MEAN_2="-10.1" ORDER="875" SD_1="3.7" SD_2="3.7" SE="0.326715749052018" STUDY_ID="STD-Rediker" TOTAL_1="19" TOTAL_2="19" WEIGHT="10.652477284621426"/>
<CONT_DATA CI_END="0.3003756690265419" CI_START="-1.3314206144560825" EFFECT_SIZE="-0.5155224727147703" ESTIMABLE="YES" MEAN_1="-15.83" MEAN_2="-12.55" ORDER="876" SD_1="6.45" SD_2="5.82" SE="0.4162822113962361" STUDY_ID="STD-Saner-and-Fricker" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.561680052547721"/>
<CONT_DATA CI_END="0.4964445995388016" CI_START="-1.5043696451226278" EFFECT_SIZE="-0.5039625227919131" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-5.3" ORDER="877" SD_1="3.1" SD_2="2.9" SE="0.510421176216399" STUDY_ID="STD-Yee" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.364488850344705"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Chest pain crossover studies</NAME>
<CONT_OUTCOME CHI2="4.182262501560669" CI_END="-0.04991258452151248" CI_START="-0.6004472405444337" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.32517991253297307" ESTIMABLE="YES" I2="4.357988086416273" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.38190095096291343" P_Q="1.0" P_Z="0.02059364461435813" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="104" UNITS="" WEIGHT="100.0" Z="2.3153525762199316">
<NAME>Chest pain crossover studies</NAME>
<GROUP_LABEL_1>Dual chamber</GROUP_LABEL_1>
<GROUP_LABEL_2>Single chamber</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.27195612559658" CI_START="-1.0484363695177796" EFFECT_SIZE="-0.38824012196059987" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.5" ORDER="878" SD_1="0.56" SD_2="0.91" SE="0.33684100971483333" STUDY_ID="STD-Deharo" TOTAL_1="18" TOTAL_2="18" WEIGHT="17.384541111584387"/>
<CONT_DATA CI_END="-0.04400094062270121" CI_START="-0.9342007177955416" EFFECT_SIZE="-0.4891008292091214" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.4" ORDER="879" SD_1="1.2" SD_2="2.6" SE="0.22709595283245573" STUDY_ID="STD-Heldman" TOTAL_1="40" TOTAL_2="40" WEIGHT="38.24673469777165"/>
<CONT_DATA CI_END="0.06337502004414486" CI_START="-1.3180487468814386" EFFECT_SIZE="-0.6273368634186469" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="6.8" ORDER="880" SD_1="2.5" SD_2="8.9" SE="0.35241049780048966" STUDY_ID="STD-Linde_x002d_Edelstam" TOTAL_1="17" TOTAL_2="17" WEIGHT="15.882376191747975"/>
<CONT_DATA CI_END="0.9180073527897296" CI_START="-0.47278308641144895" EFFECT_SIZE="0.22261213318914033" ESTIMABLE="YES" MEAN_1="-2.87" MEAN_2="-3.06" ORDER="881" SD_1="0.62" SD_2="1.0" SE="0.3547999989212955" STUDY_ID="STD-Mitsuoka" TOTAL_1="16" TOTAL_2="16" WEIGHT="15.66916784848892"/>
<CONT_DATA CI_END="0.7231089917258354" CI_START="-0.8146505080477925" EFFECT_SIZE="-0.045770758160978565" ESTIMABLE="YES" MEAN_1="-1.16" MEAN_2="-1.08" ORDER="882" SD_1="2.01" SD_2="1.3" SE="0.39229279514911464" STUDY_ID="STD-Perrins" TOTAL_1="13" TOTAL_2="13" WEIGHT="12.817180150407063"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2013-06-25 16:01:31 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-06-25 16:01:31 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-25 15:46:36 +0100" MODIFIED_BY="[Empty name]">Analyses following recommendations of the Handbook?</TITLE>
<DATE_SUBMITTED>
<DATE DAY="13" MONTH="6" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-06-25 16:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>Are your analyses of crossover studies in line with the recommendations of the Handbook?<BR/>For example, in <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>, it seems to us that you compare the same subjects while on the experimental condition and while on the control condition, as if they were different participants. This seems to be a serious error and your conclusions may be completely unfounded.</P>
<P>Nozomi Takeshima &amp; Toshi A. Furukawa, Kyoto University School of Public Health.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-06-25 15:58:49 +0100" MODIFIED_BY="[Empty name]">
<P>The crossover analysis was based on the data available from the reported trials, and it is possible that this may give rise to a unit of analysis error. However, the Cochrane handbook states that &#8220;nevertheless, this incorrect analysis is conservative, in that studies are underweighted rather than over-weighted.&#8221; Therefore it is unlikely that the consistent trend observed is a completely inaccurate reflection of study findings.</P>
<P>Janine Dretzke, lead author on the review Dual versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block.<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-06-25 16:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>Nozomi Taeshima, Toshi A. Furukawa, and Janine Dretzke.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-06-25 16:10:50 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-06-25 16:10:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-25 16:09:56 +0100" MODIFIED_BY="[Empty name]">
<I>Cochrane Controlled Trials Register (CCTR), search Aug 2002 Issue 3</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-25 16:10:50 +0100" MODIFIED_BY="[Empty name]">
<P>1 Pacemaker-artificial*:ME<BR/>2 Cardiac-Pacing-Artificial*:ME<BR/>3 Pacemaker*<BR/>4 Pacing<BR/>5 #1 or #2 or #3 or #4<BR/>6 Dual and Chamber<BR/>7 Dual and Pac*<BR/>8 Double and Chamber<BR/>9 Physiologic* and Pac*<BR/>10 Atrioventricular and Pac*<BR/>11 Atrioventricular and Sequential<BR/>12 Atrioventricular and Synchron*<BR/>13 DDD<BR/>14 DDDR<BR/>15 DDI<BR/>16 DDIR<BR/>17 VDD<BR/>18 VDDR<BR/>19 VDI<BR/>20 VDIR<BR/>21 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20<BR/>22 Single and Chamber<BR/>23 Single and Pac*<BR/>24 Atrial and Pac*<BR/>25 Ventricular and Pac*<BR/>26 VVI<BR/>27 VVIR<BR/>28 AAI<BR/>29 AAIR<BR/>#22 or #23 or #24 or #25 or #26 or #27 or #28 or #29<BR/>#5 and #21 and #30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-06-25 16:10:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-06-25 16:06:58 +0100" MODIFIED_BY="[Empty name]">
<I>MEDLINE (Ovid) search 1966 to Aug 2002</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-25 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>1 randomized controlled trial.pt.<BR/>2 controlled clinical trial.pt.<BR/>3 randomized controlled trials.sh.<BR/>4 random allocation.sh.<BR/>5 double-blind method.sh.<BR/>6 single-blind method.sh.<BR/>7 or/1-6<BR/>8 (animal not human).sh.<BR/>9 7 not 8<BR/>10 clinical trial.pt.<BR/>11 exp clinical trials/<BR/>12 (clin$ adj25 trial$).ti, ab.<BR/>13 ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).ti, ab.<BR/>14 placebos.sh.<BR/>15 placebo$.ti, ab.<BR/>16 random$.ti, ab.<BR/>17 research design.sh.<BR/>18 or/10-17<BR/>19 18 not 8<BR/>20 19 not 9<BR/>21 comparative study.sh.<BR/>22 exp evaluation studies/<BR/>23 follow up studies.sh.<BR/>24 prospective studies.sh.<BR/>25 (control$ or prospectiv$ or volunteer$).ti, ab.<BR/>26 or/21-25<BR/>27 26 not 8<BR/>28 27 not (9 or 20)<BR/>29 9 or 20 or 28<BR/>30 exp pacemaker, artificial/<BR/>31 exp cardiac pacing, artificial/<BR/>32 pacemaker$.mp.<BR/>33 pacing.mp.<BR/>34 (dual adj chamber).mp.<BR/>35 (dual adj pac$).mp.<BR/>36 double adj chamber.mp.<BR/>37 physiologic$ adj pac$.mp.<BR/>38 (AV adj synchron$).mp.<BR/>39 (atrioventricular adj synchron$).mp.<BR/>40 (AV adj sequential).mp<BR/>41 (atrioventricular adj sequential).mp.<BR/>42 DDD.mp.<BR/>43 DDDR.mp.<BR/>44 DDI.mp.<BR/>45 DDIR.mp.<BR/>46 VDD.mp.<BR/>47 VDDR.mp.<BR/>48 VDI.mp.<BR/>49 VDIR.mp.<BR/>50 (single adj chamber).mp.<BR/>51 (single adj pac$).mp.<BR/>52 (atrial adj pac$).mp.<BR/>53 (ventricular adj pac$).mp.<BR/>54 VVI.mp.<BR/>55 VVIR.mp.<BR/>56 AAI.mp.<BR/>57 AAIR.mp.<BR/>58 or/30-33<BR/>59 or/34-39<BR/>60 or/50-57<BR/>61 29 and 58 and 59 and 60</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-06-25 16:10:02 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-06-25 16:07:58 +0100" MODIFIED_BY="[Empty name]">
<I>EMBASE (Ovid) search, 1980 to Aug 2002</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-25 16:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp controlled trial/<BR/>2 exp randomized controlled trial/<BR/>3 exp clinical trial/<BR/>4 exp controlled study/<BR/>5 exp clinical study/<BR/>6 exp prospective study/<BR/>7 exp double blind procedure/<BR/>8 exp crossover procedure/<BR/>9 exp randomization/<BR/>10 exp major clinical study/<BR/>11 exp pacemaker/<BR/>12 exp heart pacing/<BR/>13 pacemaker$.mp.<BR/>14 pacing.mp.<BR/>15 (dual adj chamber).mp.<BR/>16 (dual adj pac$).mp<BR/>17 (double adj chamber).mp<BR/>18 (physiologic$ adj pac$).mp.<BR/>19 (atrioventricular adj synchron$).mp.<BR/>20 (AV adj synchron$).mp.<BR/>21 (atrioventricular adj sequential).mp.<BR/>22 (AV adj sequential).mp.<BR/>23 DDD.mp.<BR/>24 DDDR.mp.<BR/>25 DDI.mp.<BR/>26 DDIR.mp.<BR/>27 VDD.mp<BR/>28 VDDR.mp.<BR/>29 VDI.mp.<BR/>30 VDIR.mp.<BR/>31 (single adj chamber).mp.<BR/>32 (single adj pac$).mp<BR/>33 VVI.mp.<BR/>34 VVIR.mp.<BR/>35 AAI.mp.<BR/>36 AAIR.mp.<BR/>37 (atrial adj pac$).mp<BR/>38 (ventricular adj pac$).mp.<BR/>39 or/1-10<BR/>40 or/11-14<BR/>41 or/15-30<BR/>42 or/31-38<BR/>43 39 and 40 and 41 and 42</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-06-25 16:09:58 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-06-25 16:08:55 +0100" MODIFIED_BY="[Empty name]">
<I>Science Citation Index (Web of Science), 1980 to Aug 2002</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2013-06-25 16:09:11 +0100" MODIFIED_BY="[Empty name]">
<P>(random* or blind* or comparative or comparison or prospective or controlled or trial or crossover or evaluation) and<BR/>(pacemaker* or pacing) and<BR/>(dual chamber or dual pac* or double chamber or DDD or DDDR or DDI or DDIR or VDD or VDDR or VDI or VDIR or physiologic* pac* or AV synchron* or atrioventricular synchron* or AV sequential or atrioventricualr sequential) and<BR/>(single chamber or single pac* or atrial pac* or ventricular pac* or AAI or AAIR or VVI or VVIR)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>